
<html lang="en"     class="pb-page"  data-request-id="2985710b-2195-402b-8687-e7130daad5c6"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.6b01894;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2017.60.issue-7"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR" /></meta><meta name="dc.Creator" content="Simon  Planken" /></meta><meta name="dc.Creator" content="Douglas C.  Behenna" /></meta><meta name="dc.Creator" content="Sajiv K.  Nair" /></meta><meta name="dc.Creator" content="Theodore O.  Johnson" /></meta><meta name="dc.Creator" content="Asako  Nagata" /></meta><meta name="dc.Creator" content="Chau  Almaden" /></meta><meta name="dc.Creator" content="Simon  Bailey" /></meta><meta name="dc.Creator" content="T. Eric  Ballard" /></meta><meta name="dc.Creator" content="Louise  Bernier" /></meta><meta name="dc.Creator" content="Hengmiao  Cheng" /></meta><meta name="dc.Creator" content="Sujin  Cho-Schultz" /></meta><meta name="dc.Creator" content="Deepak  Dalvie" /></meta><meta name="dc.Creator" content="Judith G.  Deal" /></meta><meta name="dc.Creator" content="Dac M.  Dinh" /></meta><meta name="dc.Creator" content="Martin P.  Edwards" /></meta><meta name="dc.Creator" content="Rose Ann  Ferre" /></meta><meta name="dc.Creator" content="Ketan S.  Gajiwala" /></meta><meta name="dc.Creator" content="Michelle  Hemkens" /></meta><meta name="dc.Creator" content="Robert S.  Kania" /></meta><meta name="dc.Creator" content="John C.  Kath" /></meta><meta name="dc.Creator" content="Jean  Matthews" /></meta><meta name="dc.Creator" content="Brion W.  Murray" /></meta><meta name="dc.Creator" content="Sherry  Niessen" /></meta><meta name="dc.Creator" content="Suvi T. M.  Orr" /></meta><meta name="dc.Creator" content="Mason  Pairish" /></meta><meta name="dc.Creator" content="Neal W.  Sach" /></meta><meta name="dc.Creator" content="Hong  Shen" /></meta><meta name="dc.Creator" content="Manli  Shi" /></meta><meta name="dc.Creator" content="James  Solowiej" /></meta><meta name="dc.Creator" content="Khanh  Tran" /></meta><meta name="dc.Creator" content="Elaine  Tseng" /></meta><meta name="dc.Creator" content="Paolo  Vicini" /></meta><meta name="dc.Creator" content="Yuli  Wang" /></meta><meta name="dc.Creator" content="Scott L.  Weinrich" /></meta><meta name="dc.Creator" content="Ru  Zhou" /></meta><meta name="dc.Creator" content="Michael  Zientek" /></meta><meta name="dc.Creator" content="Longqing  Liu" /></meta><meta name="dc.Creator" content="Yiqin  Luo" /></meta><meta name="dc.Creator" content="Shuibo  Xin" /></meta><meta name="dc.Creator" content="Chengyi  Zhang" /></meta><meta name="dc.Creator" content="Jennifer  Lafontaine" /></meta><meta name="dc.Description" content="Mutant epidermal growth factor receptor (EGFR) is a major driver of non-small-cell lung cancer (NSCLC). Marketed first generation inhibitors, such as erlotinib, effect a transient beneficial respon..." /></meta><meta name="Description" content="Mutant epidermal growth factor receptor (EGFR) is a major driver of non-small-cell lung cancer (NSCLC). Marketed first generation inhibitors, such as erlotinib, effect a transient beneficial respon..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 29, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01894" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01894" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01894" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01894" /></link>
        
    
    

<title>Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01894" /></meta><meta property="og:title" content="Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0022.jpeg" /></meta><meta property="og:description" content="Mutant epidermal growth factor receptor (EGFR) is a major driver of non-small-cell lung cancer (NSCLC). Marketed first generation inhibitors, such as erlotinib, effect a transient beneficial response in EGFR mutant NSCLC patients before resistance mechanisms render these inhibitors ineffective. Secondary oncogenic EGFR mutations account for approximately 50% of relapses, the most common being the gatekeeper T790M substitution that renders existing therapies ineffective. The discovery of PF-06459988 (1), an irreversible pyrrolopyrimidine inhibitor of EGFR T790M mutants, was recently disclosed.1 Herein, we describe our continued efforts to achieve potency across EGFR oncogenic mutations and improved kinome selectivity, resulting in the discovery of clinical candidate PF-06747775 (21), which provides potent EGFR activity against the four common mutants (exon 19 deletion (Del), L858R, and double mutants T790M/L858R and T790M/Del), selectivity over wild-type EGFR, and desirable ADME properties. Compound 21 is currently being evaluated in phase-I clinical trials of mutant EGFR driven NSCLC." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01894"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01894">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01894&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01894&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01894&amp;href=/doi/10.1021/acs.jmedchem.6b01894" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 3002-3019</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01799" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00030" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of <i>N</i>-((3<i>R</i>,4<i>R</i>)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1<i>H</i>-pyrazol-4-yl)amino)-9-methyl-9<i>H</i>-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Simon++Planken">Simon Planken</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-8901-8992" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Douglas+C.++Behenna">Douglas C. Behenna</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sajiv+K.++Nair">Sajiv K. Nair</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Theodore+O.++Johnson">Theodore O. Johnson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Asako++Nagata">Asako Nagata</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chau++Almaden">Chau Almaden</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Simon++Bailey">Simon Bailey</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=T.+Eric++Ballard">T. Eric Ballard</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Louise++Bernier">Louise Bernier</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hengmiao++Cheng">Hengmiao Cheng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sujin++Cho-Schultz">Sujin Cho-Schultz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Deepak++Dalvie">Deepak Dalvie</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Judith+G.++Deal">Judith G. Deal</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dac+M.++Dinh">Dac M. Dinh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin+P.++Edwards">Martin P. Edwards</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rose+Ann++Ferre">Rose Ann Ferre</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ketan+S.++Gajiwala">Ketan S. Gajiwala</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michelle++Hemkens">Michelle Hemkens</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+S.++Kania">Robert S. Kania</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+C.++Kath">John C. Kath</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jean++Matthews">Jean Matthews</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brion+W.++Murray">Brion W. Murray</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sherry++Niessen">Sherry Niessen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Suvi+T.+M.++Orr">Suvi T. M. Orr</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mason++Pairish">Mason Pairish</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Neal+W.++Sach">Neal W. Sach</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Shen">Hong Shen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Manli++Shi">Manli Shi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James++Solowiej">James Solowiej</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Khanh++Tran">Khanh Tran</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Elaine++Tseng">Elaine Tseng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paolo++Vicini">Paolo Vicini</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yuli++Wang">Yuli Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott+L.++Weinrich">Scott L. Weinrich</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ru++Zhou">Ru Zhou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Zientek">Michael Zientek</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Longqing++Liu">Longqing Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yiqin++Luo">Yiqin Luo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shuibo++Xin">Shuibo Xin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chengyi++Zhang">Chengyi Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer++Lafontaine">Jennifer Lafontaine</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>â </sup>Departments of Worldwide Medicinal Chemistry, <sup>Â§</sup>Pharmacokinetics, Dynamics and Metabolism, <sup>â¡</sup>Oncology Research Unit, and <sup>â¥</sup>Drug Safety, La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">â¥</span> <span class="aff-text">Wuxi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#7003191d1f1e5e001c111e1b151e300016190a15025e131f1d"><span class="__cf_email__" data-cfemail="d0a3b9bdbfbefea0bcb1bebbb5be90a0b6b9aab5a2feb3bfbd">[emailÂ protected]</span></a>. Phone: 858-526-4831.</div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#11757e64767d70623f737479747f7f70516177786b74633f727e7c"><span class="__cf_email__" data-cfemail="492d263c2e25283a672b2c212c27272809392f20332c3b672a2624">[emailÂ protected]</span></a>. Phone: 858- 526-4921.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01894&amp;href=/doi/10.1021%2Facs.jmedchem.6b01894" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 3002â3019</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 13, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>11 January 2017</li><li><span class="item_label"><b>Published</b> online</span>29 March 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 April 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01894" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01894</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3002%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DSimon%2BPlanken%252C%2BDouglas%2BC.%2BBehenna%252C%2BSajiv%2BK.%2BNair%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D7%26contentID%3Dacs.jmedchem.6b01894%26title%3DDiscovery%2Bof%2BN-%2528%25283R%252C4R%2529-4-Fluoro-1-%25286-%2528%25283-methoxy-1-methyl-1H-pyrazol-4-yl%2529amino%2529-9-methyl-9H-purin-2-yl%2529pyrrolidine-3-yl%2529acrylamide%2B%2528PF-06747775%2529%2Bthrough%2BStructure-Based%2BDrug%2BDesign%253A%2BA%2BHigh%2BAffinity%2BIrreversible%2BInhibitor%2BTargeting%2BOncogenic%2BEGFR%2BMutants%2Bwith%2BSelectivity%2Bover%2BWild-Type%2BEGFR%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3019%26publicationDate%3DApril%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01894"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4920</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">47</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01894" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;Planken&quot;},{&quot;first_name&quot;:&quot;Douglas&quot;,&quot;last_name&quot;:&quot;C. Behenna&quot;},{&quot;first_name&quot;:&quot;Sajiv&quot;,&quot;last_name&quot;:&quot;K. Nair&quot;},{&quot;first_name&quot;:&quot;Theodore&quot;,&quot;last_name&quot;:&quot;O. Johnson&quot;},{&quot;first_name&quot;:&quot;Asako&quot;,&quot;last_name&quot;:&quot;Nagata&quot;},{&quot;first_name&quot;:&quot;Chau&quot;,&quot;last_name&quot;:&quot;Almaden&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;Bailey&quot;},{&quot;first_name&quot;:&quot;T.&quot;,&quot;last_name&quot;:&quot;Eric Ballard&quot;},{&quot;first_name&quot;:&quot;Louise&quot;,&quot;last_name&quot;:&quot;Bernier&quot;},{&quot;first_name&quot;:&quot;Hengmiao&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Sujin&quot;,&quot;last_name&quot;:&quot;Cho-Schultz&quot;},{&quot;first_name&quot;:&quot;Deepak&quot;,&quot;last_name&quot;:&quot;Dalvie&quot;},{&quot;first_name&quot;:&quot;Judith&quot;,&quot;last_name&quot;:&quot;G. Deal&quot;},{&quot;first_name&quot;:&quot;Dac&quot;,&quot;last_name&quot;:&quot;M. Dinh&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;P. Edwards&quot;},{&quot;first_name&quot;:&quot;Rose&quot;,&quot;last_name&quot;:&quot;Ann Ferre&quot;},{&quot;first_name&quot;:&quot;Ketan&quot;,&quot;last_name&quot;:&quot;S. Gajiwala&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;Hemkens&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;S. Kania&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;C. Kath&quot;},{&quot;first_name&quot;:&quot;Jean&quot;,&quot;last_name&quot;:&quot;Matthews&quot;},{&quot;first_name&quot;:&quot;Brion&quot;,&quot;last_name&quot;:&quot;W. Murray&quot;},{&quot;first_name&quot;:&quot;Sherry&quot;,&quot;last_name&quot;:&quot;Niessen&quot;},{&quot;first_name&quot;:&quot;Suvi&quot;,&quot;last_name&quot;:&quot;T. M. Orr&quot;},{&quot;first_name&quot;:&quot;Mason&quot;,&quot;last_name&quot;:&quot;Pairish&quot;},{&quot;first_name&quot;:&quot;Neal&quot;,&quot;last_name&quot;:&quot;W. Sach&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Manli&quot;,&quot;last_name&quot;:&quot;Shi&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Solowiej&quot;},{&quot;first_name&quot;:&quot;Khanh&quot;,&quot;last_name&quot;:&quot;Tran&quot;},{&quot;first_name&quot;:&quot;Elaine&quot;,&quot;last_name&quot;:&quot;Tseng&quot;},{&quot;first_name&quot;:&quot;Paolo&quot;,&quot;last_name&quot;:&quot;Vicini&quot;},{&quot;first_name&quot;:&quot;Yuli&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;L. Weinrich&quot;},{&quot;first_name&quot;:&quot;Ru&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Zientek&quot;},{&quot;first_name&quot;:&quot;Longqing&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Yiqin&quot;,&quot;last_name&quot;:&quot;Luo&quot;},{&quot;first_name&quot;:&quot;Shuibo&quot;,&quot;last_name&quot;:&quot;Xin&quot;},{&quot;first_name&quot;:&quot;Chengyi&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;Lafontaine&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;29&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;3002-3019&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01894&quot;},&quot;abstract&quot;:&quot;Mutant epidermal growth factor receptor (EGFR) is a major driver of non-small-cell lung cancer (NSCLC). Marketed first generation inhibitors, such as erlotinib, effect a transient beneficial response in EGFR mutant NSCLC patients before resistance mechanisms render these inhibitors ineffective. Secondary oncogenic EGFR mutations account for approximately 50% of relapses, the most common being the gatekeeper T790M substitution that renders existing therapies ineffective. The discovery of PF-06459988 (1), an irreversible pyrrolopyrimidine inhibitor of EGFR T790M mutants, was recently disclosed.1 Herein, we describe our continued efforts to achieve potency across EGFR oncogenic mutations and improved kinome selectivity, resulting in the discovery of clinical candidate PF-06747775 (21), which provides potent EGFR activity against the four common mutants (exon 19 deletion (Del), L858R, and double mutants T790M/L858R and T790M/Del), selectivity over wild-type EGFR, and desirable ADME properties. Compound 21 is curr&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01894&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01894" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01894&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01894" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01894&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01894" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01894&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01894&amp;href=/doi/10.1021/acs.jmedchem.6b01894" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01894" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01894" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (9 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01894%26sid%3Dliteratum%253Aachs%26pmid%3D28287730%26genre%3Darticle%26aulast%3DPlanken%26date%3D2017%26atitle%3DDiscovery%2Bof%2BN-%2528%25283R%252C4R%2529-4-Fluoro-1-%25286-%2528%25283-methoxy-1-methyl-1H-pyrazol-4-yl%2529amino%2529-9-methyl-9H-purin-2-yl%2529pyrrolidine-3-yl%2529acrylamide%2B%2528PF-06747775%2529%2Bthrough%2BStructure-Based%2BDrug%2BDesign%253A%2BA%2BHigh%2BAffinity%2BIrreversible%2BInhibitor%2BTargeting%2BOncogenic%2BEGFR%2BMutants%2Bwith%2BSelectivity%2Bover%2BWild-Type%2BEGFR%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D7%26spage%3D3002%26epage%3D3019%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292395" title="Fluorine">Fluorine</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291452" title="Reactivity">Reactivity</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/jmcmar.2017.60.issue-7/20170413/jmcmar.2017.60.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Mutant epidermal growth factor receptor (EGFR) is a major driver of non-small-cell lung cancer (NSCLC). Marketed first generation inhibitors, such as erlotinib, effect a transient beneficial response in EGFR mutant NSCLC patients before resistance mechanisms render these inhibitors ineffective. Secondary oncogenic EGFR mutations account for approximately 50% of relapses, the most common being the gatekeeper T790M substitution that renders existing therapies ineffective. The discovery of PF-06459988 (<b>1</b>), an irreversible pyrrolopyrimidine inhibitor of EGFR T790M mutants, was recently disclosed.1 Herein, we describe our continued efforts to achieve potency across EGFR oncogenic mutations and improved kinome selectivity, resulting in the discovery of clinical candidate PF-06747775 (<b>21</b>), which provides potent EGFR activity against the four common mutants (exon 19 deletion (Del), L858R, and double mutants T790M/L858R and T790M/Del), selectivity over wild-type EGFR, and desirable ADME properties. Compound <b>21</b> is currently being evaluated in phase-I clinical trials of mutant EGFR driven NSCLC.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76271" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76271" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Activating mutations in the epidermal growth factor receptor (EGFR) are one of the major drivers of non-small-cell lung cancer (NSCLC).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> While reversible first generation EGFR inhibitors are initially an effective treatment, it is well documented that a drug-resistant gatekeeper T790M mutation accounts for â¼50% of disease progression in patients treated with first generation agents.<a onclick="showRef(event, 'cit2a ref3'); return false;" href="javascript:void(0);" class="ref cit2a ref3">(2a, 3)</a> Irreversible second generation EGFR inhibitors, which covalently modify C797 in the ATP binding site of EGFR, are more potent against the T790M mutants.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> These agents, however, are dose limited by their exceptional potency against wild-type (WT) EGFR, which drives mechanism-based toxicity.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Efforts to overcome this limitation led to the emergence of irreversible third generation EGFR inhibitors that provide effective potency against both drug-resistant T790M mutants and the original activating mutants while sparing activity against WT EGFR.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">The recently disclosed third generation EGFR inhibitor PF-06459988 (compound <b>1</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) was discovered by de novo structure-based drug design with a strategic focus on improving inhibitor potency by increasing reversible binding affinity.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Implementation of this strategy enabled the intrinsic reactivity of the inhibitorâs warhead functionality to be minimized in parallel as a means to reduce the probability of any safety risks associated with an irreversible inhibitor mode of action.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Compound <b>1</b> provided low nanomolar biochemical and cellular potency against both EGFR T790M-resistant mutants (T790M/L858R and T790M/Del), excellent selectivity for the drug-resistant mutants over WT EGFR, and in vitro and in vivo ADME characteristics well suited for in vivo efficacy studies.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. <b>1</b> is a previously reported T790M mutant inhibitor that has exceptional selectivity over WT EGFR. The 1.9 Ã cocrystal structure (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG7">5HG7</a>) with EGFR T790M/L858R protein shows the ligand covalently modifying Cys797 of the EGFR protein as designed. The core also forms the classic donorâacceptorâdonor motif to the kinase hinge region. Also highlighted is the gatekeeper residue, Met790. IC<sub>50</sub> data is from cell-based assays.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Furthermore, by virtue of its weakly electrophilic acrylamide warhead, the broad proteome reactivity of <b>1</b> was significantly reduced relative to previous covalent EGFR inhibitors possessing more reactive warhead groups.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> While <b>1</b> possessed characteristics desirable in a clinical candidate, its potency against the two original activating mutants of EGFR (L858R and the exon19_deletion (Del)) was mixed. Recognizing the physicochemical property limitations of the pyrrolopyrimidine series in improving Del potency without compromising the excellent attributes of <b>1</b> (substitution of the halogen with an aromatic ring led to improved Del but with an increase in clearance due to high logD), an alternative chemical series was pursued. Herein we describe our efforts applying the principles of affinity-driven potency and low intrinsic electrophile reactivity to (i) increase Del potency while retaining potency against the T790M mutants and selectivity over the WT EGFR), (ii) improve broad protein kinase selectivity across the kinome, and (iii) maintain excellent ADME properties suitable for once daily oral dosing in patients.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63338" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63338" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To identify suitable chemical leads, a directed screening approach was applied. The lead generation screening strategy was to screen known <i>reversible</i> kinase inhibitors from the Pfizer compound collection, identify hits that were selective for T790M over the WT EGFR, and then append a warhead onto selected scaffolds (as informed by computational modeling using a T790M EGFR cocrystal structure<a onclick="showRef(event, 'cit6d'); return false;" href="javascript:void(0);" class="ref cit6d">(6d)</a>). From screening a diverse kinase targeted library set of approximately 20â¯000 compounds, a purine-containing lead was identified, compound <b>2</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a><b>2</b> exhibited EGFR T790M/L858R double mutant potency with an IC<sub>50</sub> of 78 nM and WT selectivity of 76-fold in a biochemical kinase assay. However, despite acceptable passive permeability (1.9 Ã 10<sup>â6</sup> cm/s), when tested in a cellular context (NSCLC-derived H1975 line expressing T790M/L858R double mutant (DM)), <b>2</b> was inactive even at 10 Î¼M, illustrating the opportunity for covalent inhibitor modality. As in our previous work,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> increasing potency by optimizing noncovalent binding affinity, using an estimated <i>K</i><sub>i</sub> assay (<i>K</i><sub>i</sub><sup>est</sup>) to assess progress, and incorporating <i>weakly</i> reactive aliphatic warheads (as measured using a glutathione assay) were the focus of the optimization program.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Modeled docking of screen hit <b>2</b> into the EGFR T790M/L858R protein (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG7">5HG7</a>). Note coreâhinge interactions including polarized C(8) CâH bond. The close proximity of the C(2) vector to target Cys797 indicated the best vector on which to append an electrophile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To determine how to best incorporate a suitable electrophile, binding of <b>2</b> was modeled using T790M/L858R EGFR crystal structure. The predicted binding mode (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) involved a tridentate hydrogen bonding interaction to the kinase hinge region, consisting of two formal hydrogen bonds (with the core N(7) acting as an acceptor and the aniline NH as a donor), and a polarized CâH bond at the C(8)-position acting as a second hydrogen bond donor (interacting with the carbonyl of hinge residue GLN791). The N(9) isopropyl group was in close proximity to the gatekeeper methionine residue which was predicted to be driving selectivity over WT EGFR, and the C(2) valinol group appeared to be in closest proximity to the target Cys797 residue, offering a vector for warhead incorporation. SBDD suggested a pyrrolidine linker was suitable to place an acrylamide warhead in close proximity to the target cysteine. Key examples are shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Summary Early Purine Examples</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0014.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0015.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>Table a</sup><p class="last"><i>K</i><sub><i>i</i></sub><sup>est</sup> and <i>k</i><sub>obs</sub>/<i>I</i> derived as previously published.</p></div><div class="footnote" id="tbl1-fn2"><sup>Table b</sup><p class="last">Inhibitor concentration at which the <i>k</i><sub>obs</sub>/<i>I</i> is calculated.</p></div><div class="footnote" id="tbl1-fn3"><sup>Table c</sup><p class="last">H1975 and A549 IC<sub>50</sub> represent activities against T790M/L858R and WT EGFR, respectively.</p></div><div class="footnote" id="tbl1-fn4"><sup>Table d</sup><p class="last">Rel GSH <i>T</i><sub>1/2</sub> represents the intrinsic warhead reactivity expressed as the fold-change in half-life of parent compound in a glutathione stability assay relative to that of canertinib (<i>t</i><sub>1/2</sub>, ca. 21 min).</p></div></div><div></div></div><div class="NLM_p">As shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, the pyrrolidine-based linkers contained within <b>3</b> and <b>4</b> showed promising early data with <i>K</i><sub>i</sub><sup>est</sup> values approaching our 10 nM goal. Preference for the 3-acrylamido pyrrolidine warhead was observed, based both on higher affinity (as determined by extrapolated <i>K</i><sub>i</sub><sup>est</sup>) and a significant increase in the rate of covalent modification (measured <i>k</i><sub>obs</sub>/<i>I</i>) observed with <b>4</b> compared to <b>3</b>. An enantiopreference was observed for both pyrrolidine-based linkers, as illustrated when comparing enantiomers of compound <b>3</b> and <b>4</b>. These observations were in agreement with modeling predictions that placed the exocyclic (<i>S</i>)-acrylamide in closer proximity to the target Cys797 (see <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Modeled docking of simplified compounds containing pyrrolidine-linked warheads into the EGFR T790M/L858R protein (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG7">5HG7</a>). Distance of highlighted CYS797 to the acrylamide is shown. (A and B) Linker from <b>4</b> showing âpseudo-axialâ and âpseudo-equatorialâ warhead conformations, respectively. (C) Isomeric pyrroldine linker from <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Together with its very low intrinsic reactivity (relative GSH half-life of 22-fold), high potency in both biochemical and H1975 cell assays (9 nM and 19 nM, respectively), a high <i>k</i><sub>obs</sub>/<i>I</i> value approaching 12â¯000 M<sup>â1</sup> s<sup>â1</sup>, and 15-fold selectivity over WT EGFR, the 3-aminopyrrolidine derivative contained in <b>4</b> represented the best linker motif and formed the basis for further design optimization.</div><div class="NLM_p">Anilines are known potential toxicophores,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and the high molecular weight, high logD, and basic nature of the bis-aniline fragment contained in <b>4</b> (ACD calcd <i>p</i>K<sub>a</sub> 7.9) constrained the moleculeâs physiochemical profile and likely contributed to observed liabilities including ion-channel activity, poor permeability, and poor LipE.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Thus, an early optimization goal was to replace the aniline fragment with a pyrazole moiety (as shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, compounds <b>5</b>, <b>6</b>), leveraging knowledge derived from the program to discover <b>1</b>.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Compound <b>5</b> with a 3-aminopyrrolidine linker afforded activity with a <i>K</i><sub>i</sub><sup>est</sup> of 36 nM and an IC<sub>50</sub> of 52 nM in the H1975 cell assay, while retaining WT selectivity and low reactivity. However, with a relatively low <i>k</i><sub>obs</sub>/<i>I</i> of 4452 M<sup>â1</sup> s<sup>â1</sup>, more potency could be obtained by improving alignment of the warhead to the cysteine.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The bicyclic pyrrolidine linker of <b>6</b> also afforded activity but offered no benefit over the simpler linker of compound <b>5.</b></div><div class="NLM_p">Modeling of lead compound <b>5</b> suggested that the acrylamide would prefer to adopt a less favored, âpseudo-axialâ conformation to place the warhead proximal to Cys797 for facile covalent modification (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>a). As a result of the incurred strain energy penalty (calculated at 1.3 kcal/mol in solution phase), it was hypothesized that a potency gain would be realized if the molecule could be modified to favor this conformation. Replacement of a pyrrolidine hydrogen with a fluorine is known to impart a gauche effect, whereby an adjacent electronegative substituent prefers to be in a gauche orientation.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Addition of fluorine onto the 4-position of the pyrrolidine ring of compound <b>5</b> was calculated to result in a slight preference (by 0.1 kcal/mol) for the 3,4-anti conformation. In fact, fluorine introduction to give <b>7</b> resulted in a significant potency gain from both an affinity and inactivation rate perspective (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>), with the <i>k</i><sub>obs</sub>/<i>I</i> increased to 62â¯982 M<sup>â1</sup> s<sup>â1</sup>. This reflected the less costly accessibility of the anti conformation and the improved orientation and proximity of the warhead relative to the cysteine for <b>7</b> compared to <b>5</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Effect of Fluorine Addition to Linker</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0016.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0017.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup>Table a</sup><p class="last"><i>K</i><sub>i</sub><sup>est</sup> and <i>k</i><sub>obs</sub>/<i>I</i> derived as previously published.</p></div><div class="footnote" id="tbl2-fn2"><sup>Table b</sup><p class="last">Inhibitor concentration at which the <i>k</i><sub>obs</sub>/<i>I</i> is calculated.</p></div><div class="footnote" id="tbl2-fn3"><sup>Table c</sup><p class="last">H1975 and A549 IC<sub>50</sub> represent activities against T790M/L858R and WT EGFR, respectively.</p></div><div class="footnote" id="tbl2-fn4"><sup>Table d</sup><p class="last">LipE calculated from <i>K</i><sub>i</sub><sup>est</sup> and experimental logD.</p></div><div class="footnote" id="tbl2-fn5"><sup>Table e</sup><p class="last">Rel GSH <i>T</i><sub>1/2</sub> represents the intrinsic warhead reactivity expressed as the fold-change in half-life of parent compound in a glutathione stability assay relative to that of canertinib (<i>t</i><sub>1/2</sub>, ca. 21 min).</p></div></div><div></div></div><div class="NLM_p">A 1.5 Ã cocrystal of compound <b>7</b> with EGFR L858R/T790M (with additional surface mutation V948R, distal from the ligand binding site, <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a><a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a>) was obtained which confirmed the predicted anti conformation of the fluorine and the acrylamide. A small molecule X-ray structure also later confirmed the low energy state (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for small molecule crystal structure of <b>21</b>, <a class="ref internalNav" href="#notes-1" aria-label="Figures SF1âSF3">Figures SF1âSF3</a>). In addition, as predicted from docking experiments, the fluoro substituent of <b>7</b> is within 3.6 Ã of the G-loop Phe723 and able to interact via a dipoleâdipole interaction;<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> the cumulative result is a profound 10-fold increase in potency, and a lipE<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> increase of 0.8 relative to the desfluoro analogue. A high enantiomeric preference was observed, as the distomer (compound <b>8</b>) was more than 60-fold less potent against the T790M/L858R double mutant.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. The 1.5 Ã cocrystal structure (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UG8">5UG8</a>) of compound <b>7</b> with EGFR_L858R/T790M mutant (only the ligand binding site is shown). Note <i>anti</i> conformation of fluorine and warhead linker and apparent fluorine interaction with Phe723.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the previously disclosed pyrrolopyrimidine work,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> addition of fluorines into warhead linkers was accompanied by an increase in intrinsic reactivity via lowering of the acrylamide LUMO through the inductive effect of the fluorine, as illustrated in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> when comparing the compound pairs <b>9</b>/<b>10</b> and <b>11</b>/<b>12</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Fluorine Introduction into the Warhead Linker<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0018.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup>Table a</sup><p class="last">Fluorine introduction in pyrrolopyrimidine and early purine examples showed an increase in the relative intrinsic reactivity of the warhead. Rel GSH <i>T</i><sub>1/2</sub> represents the intrinsic warhead reactivity expressed as the fold-change in half-life of parent compound in a glutathione stability assay relative to that of canertinib (<i>t</i><sub>1/2</sub>, ca. 21 min).</p></div></div><div></div></div><div class="NLM_p">Because a minimally reactive warhead was sought, this observed increase in intrinsic reactivity precluded advancement of these compounds. Similar results were seen in the purine series with the same fluorinated pyrrolidine linkers <b>13</b> and <b>14</b> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>) where fluorine introduction led to an increase in reactivity, with the GSH relative half-life dropping from 14- to 9-fold. However, unlike these examples, it was predicted that the anti conformation of the 3-acrylamido-4-fluoropyrrolidine of <b>7</b> would not significantly increase the reactivity of the warhead (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) when the potential for orbital overlap between the CâF bond and the nitrogen of the acrylamide was considered. In examples where an increase in reactivity was observed, it was possible to align the Ï* of the CâF bond with the nitrogen lone pair of the acrylamide, which would lower the LUMO energy and increase the reactivity of the warhead (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>a).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Activating fluorine: Overlap between warhead nitrogen NB-orbital and Ï* orbital of CâF bond of <b>14</b> increases the reactivity of the Michael acceptor. (b) Neutral fluorine: Orthogonal orbitals have minimal interaction which resulted in little effect on intrinsic reactivity of <b>7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the case of compound <b>7</b>, the orthogonal orientation between the warhead nitrogen nonbonding (NB) orbital and the CâF Ï* orbital reduces interaction with the electrons of the LUMO; as a result, the fluorine would not be predicted to adversely impact the intrinsic reactivity (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>b). Upon testing in the glutathione-based reactivity assay, fluorine introduction was found not to exhibit a measurable difference in intrinsic reactivity when comparing the relative GSH reactivity half-lives between <b>5</b> and <b>7</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Thus, fluorine addition was found to have a profound benefit by (i) anti conformational preference, (ii) a dramatic increase in potency, (iii) increased interaction with the protein, and (iv) no negative impact on the intrinsic reactivity. Compound <b>7</b> had moderate clearance with an exceptional EGFR mutant profile, possessing single-digit nanomolar potency against all four mutants and 20-fold selectivity over WT EGFR. Thus, having optimized the warhead linker group, the series was evaluated for selectivity against the kinome.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Kinase Selectivity</h3><div class="NLM_p">The kinome selectivity for the simple pyrrolidine-linker compound <b>5</b> was moderate, with a hit-rate of 25% when assessed against a diverse 38-membered kinome panel (where a hit is defined as >50% inhibition in biochemical screening assay at 1 Î¼M at <i>K</i><sub>m</sub> concentrations of ATP, see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> Table ST2). This is approximately the same for <b>1</b>. While addition of fluorine was beneficial from a potency and efficiency perspective, this change had a deleterious effect on the kinome selectivity with the hit-rate increasing to 43%. One possible explanation for the increase in off-target kinase activity is the observed interaction between the fluorine and Phe723. This Phe is well conserved throughout the kinome (67% of kinases possess a Phe at this location), and specific interaction with it could result in an increase in kinase promiscuity. To improve upon this profile, a selectivity pocket afforded by hinge residue Leu792 (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>) was targeted. In many kinases (59% of the kinome), this hinge residue (H5) is either a larger Phe or Tyr, offering a strategy for selectivity by building a steric clash with those larger residues. Filling this pocket has been shown to achieve kinase selectivity for other kinase programs such as ALK,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> MPS-1,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and LRRK2<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> which both possess a leucine residue at the corresponding hinge position.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Cocrystal structure of <b>16</b> (1.3 Ã, PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UG9">5UG9</a>). The kinase selectivity pocket that is afforded via hinge residue Leu792 is illustrated. Many kinases (59%) have a large Phe or Tyr residue in this position, precluding pyrazole substitution. Filling this pocket with a methoxy group afforded an improved kinase off-target profile without significant detrimental impact on in vitro human microsomal intrinsic clearance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Placing small groups (methyl, methoxy, ethyl) in this region afforded compounds <b>15</b>â<b>17</b> (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Addition of methyl (<b>15</b>), methoxy (<b>16</b>), or ethyl (<b>17</b>) all improved kinase selectivity, with compound <b>16</b> providing the best combined potency and lipE, with minimal impact on the in vitro microsomal intrinsic clearance or potency. Compound <b>16</b> showed activity against only two kinases outside the Tec family both of which possess a leucine residue at the H5 hinge region, thus circumventing the selectivity strategy (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> Table ST2).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro Profiles for Pyrazoles Designed To Improve Kinase Selectivity</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0019.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup>Table a</sup><p class="last"><i>K</i><sub>i</sub><sup>est</sup> and <i>k</i><sub>obs</sub>/<i>I</i> derived as previously published.</p></div><div class="footnote" id="tbl4-fn2"><sup>Table b</sup><p class="last">Inhibitor concentration at which the <i>k</i><sub>obs</sub>/<i>I</i> is calculated.</p></div><div class="footnote" id="tbl4-fn3"><sup>Table c</sup><p class="last">H1975 and A549 IC<sub>50</sub> represent activities against T790M/L858R and WT EGFR, respectively.</p></div><div class="footnote" id="tbl4-fn4"><sup>Table d</sup><p class="last">LipE calculated from <i>K</i><sub>i</sub><sup>est</sup> and experimental logD.</p></div><div class="footnote" id="tbl4-fn5"><sup>Table e</sup><p class="last">hLM: Human liver microsomal intrinsic clearance.</p></div><div class="footnote" id="tbl4-fn6"><sup>Table f</sup><p class="last">Kinase hitrate expressed as % kinases that showed >50% inhibition at 1 Î¼M inhibitor at K<sub>m</sub> levels ATP from a diverse 38 membered panel.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Single Mutant Potency</h3><div class="NLM_p">One of the primary objectives for this work was to improve the potency against the Del mutation. Current clinical T790M inhibitors are least potent against this mutant form compared to other single (L858R) and double T790M mutants, and this was also seen in our previous work using the 5-chloropyrrolopyrimidine scaffold, where <b>1</b> was 11-fold less potent against Del than T790M/L858R (PC9 and H1975 cell lines, respectively).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Plotting double mutant (T790M/L858R, H1975) vs single mutant (Del, PC9) cell potency highlights the differentiation between the pyrrolopyrimidine and the purine scaffolds (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). In general, the purine series (shown in blue) provided equivalent potency or better for Del mutation, in contrast to the pyrrolopyrimidine series (shown in yellow) where a 10-fold loss was generally observed.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Single mutant vs double mutant potency. Plot showing series potencies against the T790M/L858R double mutant (H1975) and the Del (PC9) single mutant highlighting the superior Del mutant coverage of the purine series (blue) over the previous workâs pyrrolopyrimidine series (yellow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">When assessed against the single mutations (L858R and Del) and double mutations (T790M/L858R and T790M/Del), the purine series exhibited higher potency against all key mutant isoforms with more than 15-fold better potency against Del than our previously disclosed compound <b>1</b>. Single-digit nanomolar potencies were observed across each of the four mutant EGFR NSCLC cell lines for <b>16</b> (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. pEGFR Potency Data (IC<sub>50</sub>, nM)<a class="ref internalNav" href="#tbl5-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">H1975 (T790M/L858R)</th><th class="colsep0 rowsep0" align="center">PC9-DRH (T790M/Del)</th><th class="colsep0 rowsep0" align="center">PC9 (Del)</th><th class="colsep0 rowsep0" align="center">H3255 (L858R)</th><th class="colsep0 rowsep0" align="center">A549 (WT)</th><th class="colsep0 rowsep0" align="center">WT ratio<a class="ref internalNav" href="#t5fn1" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">140</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">5110</td><td class="colsep0 rowsep0" align="left">36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">178</td><td class="colsep0 rowsep0" align="left">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">1450</td><td class="colsep0 rowsep0" align="left">56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">160</td><td class="colsep0 rowsep0" align="left">32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">649</td><td class="colsep0 rowsep0" align="left">89</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl5-fn1"><div class="footnote" id="tbl5-fn1"><sup>a</sup><p class="last">The purine series example <b>16</b> displayed a flatter potency profile across the EGFR mutants relative to compound <b>1</b> from previous work where the Del mutation was hardest to cover.</p></div><div class="footnote" id="t5fn1"><sup>b</sup><p class="last">Ratio expressed using lowest EGFR mutant potency. ND not determined.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> N(9) Substituent and EGFR Wild-Type Selectivity</h3><div class="NLM_p">With broad kinase selectivity and the desired EGFR mutant profile in hand, efforts were then focused on investigating the purine N(9) substituent and its impact on WT EGFR selectivity. The N(9) group was considered a driver for WT selectivity because of its close proximity to the gatekeeper residue. Analysis of N(9) <sup>i</sup>Pr purine cocrystal structures showed that to bind in the active site of WT EGFR, rotation of the isopropyl group was necessary to avoid an electrostatic clash between the lipophilic <sup>i</sup>Pr group and the polar threonine gatekeeper. This was confirmed with a cocrystal of reversible acetate analogue <b>18</b> bound in WT EGFR (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. N(9) <sup>i</sup>Pr rotation on binding to WT EGFR. Cocrystal structures of compound <b>18</b> in EGFR L858R/T790M (left, 1.3 Ã resolution, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UGA">5UGA</a>) and WT EGFR (right, 2.1 Ã resolution, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UGB">5UGB</a>) illustrated the orientation of the <sup>i</sup>Pr group relative to the gatekeeper residue: note the rotation of the N(9) <sup>i</sup>Pr when bound in the WT pocket. *Measured <i>K</i><sub>i</sub> in T790M/L858R double mutant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Whereas in the L858R/T790M structure, the two isopropyl methyl groups of the ligand orient themselves toward the gatekeeper residue with productive VDW interactions, Thr790 in the WT structure precludes this both sterically and electrostatically. The <i>tert</i>-butyl (<sup>t</sup>Bu)-substituted analogue was predicted to have increased WT selectivity, as modeling predicted that the larger substitution removes the possibility of the N(9) group to offer a hydrogen toward Thr790. Due to the critical nature of this N(9)âgatekeeper interaction, ethyl and methyl analogues were also synthesized for comparison (see PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UGC">5UGC</a>). Data for key examples are shown in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>, together with selected ADME properties.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Purine N(9) Variation<a class="ref internalNav" href="#tbl6-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0020.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl6-fn1"><div class="footnote" id="tbl6-fn1"><sup>Table a</sup><p class="last">The larger <i>tert</i>-butyl group afforded the highest selectivity margin over WT but at the expense of higher clearance and lower LipE. <i>K</i><sub>i</sub><sup>est</sup> derived as previously published. H1975 and A549 IC<sub>50</sub> represent activities against T790M/L858R and WT EGFR, respectively. LipE calculated from IC<sub>50</sub> and experimental logD. HLM: human liver microsomal clearance. RRCK: permeability as measured using low-efflux MDCK-LE cell line. hHep: human hepatocyte intrinsic clearance.</p></div></div><div></div></div><div class="NLM_p">Introduction of the <sup><i>t</i></sup>Bu N(9) group (<b>19</b>) afforded an incremental increase in the WT/DM ratio, but concomitant increase in clearance driven by the extra lipophilicity prevented progression. Generally across a number of purines, <sup><i>t</i></sup>Bu N(9) <i>did</i> result in the best WT selectivity when compared with other alkyl groups (<sup><i>t</i></sup>Bu > <sup>i</sup>Pr â Me > Et as seen in the pairwise plot, <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>), with <sup>i</sup>Pr and Me N(9) being approximately equal, and Et being the least selective over WT.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0009.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Matched pairwise plot by N(9) substituent. Plot illustrated cellular pEGFR WT selectivity seen by varying N(9) substituent size; the larger <i>tert</i>-butyl group consistently afforded the highest selectivity. The methyl substituent examples go against the trend and in many cases <i>improved</i> WT selectivity relative to the corresponding ethyl or isopropyl analogue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">When considered from a LipE perspective, the <sup>t</sup>Bu N(9) analogue <b>19</b> had a much lower LipE of 2.9 compared to the methyl analogue <b>21</b> (LipE 4.5) vs WT EGFR for reasons discussed above. The ethyl analogue <b>20</b> was able to bind with the ethyl group orthogonal to the core and is buried in a hydrophobic region of the G-loop, making no steric clash with the WT or T790M proteins; hence, WT selectivity is reduced (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Figure SF4). The biochemical and cellular potency of methyl N(9) compound <b>21</b> was within 2-fold of the isopropyl analogue <b>16</b>. However, <b>21</b> (most likely because of the reduction in logD) possessed greatly improved in vitro clearance (hLM 8 Î¼L/min/mg and hHEP 3 Î¼L/min/MM), high permeability (RRCK<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> 9 Ã 10<sup>â6</sup> cm/s), and increased LipE. Additionally, this was accompanied by a loss of CYP450 time-dependent inactivation (TDI) that was observed for examples with higher logD (data not shown). With the improved physiochemical profile (MW 415 g/mol, tPSA 115, <i>p</i>Ka 3.53, logD 2.0) and resultant superior ADME properties, excellent potency, and 26-fold selectivity over the WT, the N(9) methyl analogue <b>21</b> (PF-06747775)<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> was deemed to have the best overall balance of properties and was selected for full characterization.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Preclinical Evaluation Overview of <b>21</b></h3><div class="NLM_p">The covalent inhibitory potency (<i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub> 350â¯000â610â¯000 M<sup>â1</sup> s<sup>â1</sup>) of <b>21</b> was high for both double mutant proteins, significant for single activating mutant proteins (<i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub> 68â¯000â103â¯000 M<sup>â1</sup> s<sup>â1</sup>), and weak for WT EGFR (<i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub> = 12â¯000 M<sup>â1</sup> s<sup>â1</sup>) (full characterization details included in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Table ST5). Cellular potency assessment of <b>21</b> against the EGFR single mutants (Del and L858R) and the double mutants (T790M/Del and T790M/L858R) revealed single digit nanomolar IC<sub>50</sub>s for all but the T790M/L858R isoform which had an IC<sub>50</sub> of 12 nM (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). Selectivity for inhibition of the four activating EGFR mutants vs WT was 26-fold when compared to the least active EGFR mutant (T790M/L858R H1975). Compared to our previously disclosed compound <b>1</b>,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> the mutant EGFR isoform inhibition potency was improved for both single mutants. Other clinical T790M inhibitors Tagrisso (AZD9291,<a onclick="showRef(event, 'cit6f'); return false;" href="javascript:void(0);" class="ref cit6f">(6f)</a><b>23</b>) and rociletinib (CO1686,<a onclick="showRef(event, 'cit6g'); return false;" href="javascript:void(0);" class="ref cit6g">(6g)</a><b>24</b>) (from Astra Zeneca and Clovis, respectively) are included for comparative reference. When the WT selectivity was assessed against the weakest activating mutant activity, <b>21</b> was nearly 10-fold better than <b>23</b> (26- vs 3-fold selective) and slightly better than <b>24</b> (26- vs 20-fold selective). Also shown is first generation quinazoline inhibitor erlotinib<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> (<b>25</b>) which, despite being potent against the single EGFR mutants, lacks potency against the T790M double mutants. Inclusion of a warhead onto a typical quinazoline scaffold (<b>26</b>) rescues the T790M activity, but with no selectivity observed over WT.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. In Vitro Profile Comparison of pEGFR IC<sub>50</sub> (nM) in NSCLC Cell Lines for <b>21</b> and Clinical EGFR_T790M Inhibitors<a class="ref internalNav" href="#tbl7-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0021.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl7-fn1"><div class="footnote" id="tbl7-fn1"><sup>Table a</sup><p class="last">*Cell ratio expressed as WT/least potent target, except for erlotinib which is considered on single mutant data.</p></div></div><div></div></div><div class="NLM_p">Kinase selectivity of <b>21</b> was screened using enzyme assays against a total of 273 kinases constituting approximately 50% of the human catalytic protein kinome (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Table ST3). Under assay conditions of ATP concentration equal to <i>K</i><sub>m</sub> with 1 Î¼M of <b>21</b>, 15 kinases of the 273 tested were inhibited >50% (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Table ST4). These 15 kinases were tested in follow-up enzyme assays where conditions were modified by increasing the ATP concentration to simulate cellular ATP levels. Under these more physiologically relevant conditions, seven kinases showed >50% inhibition (ERBB4, BTK, BMX, TXK, TEC, ROS, and ACK/TNK2). It is notable that of these seven kinases, the first five listed have a cysteine residue in the same position as that of EGFR-Cys797, the residue that is targeted for covalent modification by <b>21</b>, and hence these kinases are subject to time-dependent irreversible inhibition. Only two of the six tested non-cysteine kinases (FER and ACK/TNK2) were inhibited with moderate potency, albeit with a selectivity margin of >9-fold as compared to EGFR mutant target cellular potencies of <b>21</b>.</div><div class="NLM_p last">To extend this selectivity analysis to the more physiologically relevant setting of intact cells, selected kinases were tested for inhibition by <b>21</b> in the cellular context (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Table ST4). Four tested kinases (BTK, JAK3, ROS, and BLK) showed weak inhibition in the cellular context. Collectively, the kinase selectivity analysis of <b>21</b> using standard enzymatic and cellular formats identified 7 kinases of the 273 tested (ERBB4, ERBB2, BMX, TXK, TEC, FER, and ACK/TNK2) with the potential for inhibition by <b>21,</b> yielding a high selectivity index of 97%.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Proteome Reactivity Assessment</h3><div class="NLM_p">To assess the total cellular proteome reactivity of <b>21</b> (and to compare relative to <b>1</b>), an alkynylated variant was synthesized (at a position that produced a minimal change in terms of target protein reactivity and specificity, designated here <b>P_21</b>, <a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The physiochemical properties of this chemical probe including its cellular IC<sub>50</sub> against WT and double mutant EGFR, <i>k</i><sub>obs</sub>/<i>I</i>, and GSH reactivity closely matched that of the corresponding parent molecule, making this probe an adequate surrogate of its parent inhibitor (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Table ST6). The generation and characterization of the chemical probe for <b>1</b>, called here <b>P_1</b>, has been previously described.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The reactivity of these two probes was compared to that of a chemical probe based on <b>26</b> (<b>P_AQ</b>, see <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>), a quinazoline-based covalent second generation pan-ERBB2 inhibitor, which contains a similar Michael acceptor acrylamide. Initial experiments were performed in the biologically relevant H1975 lung cancer cells, as this line expresses the double mutant L858R T790M form of EGFR. The in situ reactivity of these three probes was assessed in a competitive mode by gel-based analysis (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>). We were gratified by the lack of proteome-wide reactivity observed with the chemical probe <b>P_21</b> and <b>P_1</b> compared to <b>P_AQ</b> in both the particulate and soluble proteomes. In fact, for <b>P_21</b> the only protein that reacts and competes with parent inhibitor <b>21</b> would be predicted to be EGFR (marked with *). Finally, <b>P_21</b> displays proteome reactivity even less than that of <b>P_1</b> under these conditions, highlighting the exquisite selectivity and reactivity of this third-generation T790M inhibitor.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0010.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Competitive in situ labeling profiles of 1 Î¼M of each chemical probe, P_1 and P_21, vs a representative aminoquinazoline probe, P_AQ. H1975 cells were treated 1 Î¼M parent inhibitor (<b>26</b>, <b>1</b>, <b>21</b>) or an equal amount of DMSO for 2 h. Next, 1 Î¼M of the corresponding chemical probe was added during 3 h. Representative proteome labeling profiles were also generated with 100 nM of each chemical probe for 3 h. After labeling, cells were harvested, lysed, and separated into particulate (left) and soluble (right) proteomes. Equal amounts of protein lysate were reacted with azide-rhodamine, and covalently labeled proteins were revealed by gel-based fluorescence (gels are shown in grayscale). *Highlights a protein in the particulate proteome predicted to be EGFR by molecular weight that fully competes with parent inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Microsomal and hepatic in vitro clearance was species dependent, with mouse and rat showing high clearance and dog and human showing low clearance (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>), with little or no inhibition of cytochrome P450 isoforms. Blood stability was high across all species, and <b>21</b> was found to distribute preferentially into plasma relative to whole blood in all species except dog (blood to plasma ratio ranged from 0.5 to 1.2). Plasma protein binding was relatively low. Metabolite identification using hepatocytes and microsomes revealed that no active metabolites were observed. Glutathione adducts and demethylation were the major observed pathways (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Figure SF5 and Table ST8).</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Additional Key in Vitro and Single-Dose PK Summary for <b>21</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">mouse</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">dog</th><th class="colsep0 rowsep0" align="center">human</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">microsomal Cl<sub>int,app</sub> (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">74</td><td class="colsep0 rowsep0" align="left">141</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left"><6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hepatic Cl<sub>int,app</sub> (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">196</td><td class="colsep0 rowsep0" align="left">183</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">blood half-life (min)</td><td class="colsep0 rowsep0" align="left">306</td><td class="colsep0 rowsep0" align="left">237</td><td class="colsep0 rowsep0" align="left">279</td><td class="colsep0 rowsep0" align="left">348</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein binding (<i>f</i><sub>u</sub>)</td><td class="colsep0 rowsep0" align="left">0.20â0.49<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">0.22</td><td class="colsep0 rowsep0" align="left">0.75</td><td class="colsep0 rowsep0" align="left">0.27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human cytochrome P450 inhibition (3A4, 2D6, 2C8, 2C9, 1A2)</td><td class="colsep0 rowsep0" colspan="4" align="left"><30%Â @Â 10Â Î¼M</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL<sub>p</sub> (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">53</td><td class="colsep0 rowsep0" align="left">49</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">-</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>dss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">1.48</td><td class="colsep0 rowsep0" align="left">0.66</td><td class="colsep0 rowsep0" align="left">0.94</td><td class="colsep0 rowsep0" align="left">-</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.56</td><td class="colsep0 rowsep0" align="left">0.28</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">-</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i>Â %</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="left">-</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last"><i>f</i><sub>u</sub> in mice was found to be strain dependent. Intravenous clearance, <i>V</i><sub>dss</sub>, and <i>T</i><sub>1/2</sub> data assessed for mouse (female Nu/Nu), rat (male Wistar-Han), and dog (male beagle) using a 1 mg/kg solution. Bioavailability (<i>F</i> %) determined via dosing a 1 mg/kg crystalline suspension in mouse, 30 mg/kg in rat, and 3 mg/kg in dog. Half-life based on the terminal Î²-phase.</p></div></div></div><div class="NLM_p">Following iv administration at 1 mg/kg to mice, rats, and dogs, <b>21</b> exhibited a moderate to high plasma clearance, and low steady-state volume of distribution (<i>V</i><sub>dss</sub>), resulting in a short plasma half-life (CL<sub>p</sub>, <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>). After oral dosing in preclinical species, <b>21</b> was rapidly absorbed with low to moderate oral bioavailability, which is believed to be driven by first-pass metabolism (based on rat portal vein studies). In preclinical species, hepatic clearance was predominant when compared to nonhepatic clearance. The route of clearance was discerned by scaling the hepatic blood clearance utilizing the CL<sub>int</sub> obtained from nonclinical species hepatocytes, the blood-to-plasma ratio, and the free fraction in plasma as opposed to the clearance observed in intravenous studies. In all nonclinical species tested, the clearance scaling method from hepatocytes predicted approximately 2-fold or less than what had been observed in vivo for <b>21</b>. Hence, in vitro human hepatocyte scaling was deemed sufficient for the human clearance prediction. In humans, the major route of clearance of <b>21</b> is likely to be the hepatic metabolic clearance, which includes oxidative metabolism and glutathione conjugation via glutathione S-transferase.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The human clearance was predicted to be approximately 1/20th to 1/30th of hepatic blood flow, and the predicted terminal half-life range was 12 to 13 h. Oral bioavailability was predicted to be moderate (â¼80%) with a <i>T</i><sub>max</sub> of â¼4 h. Details of the full evaluation of <b>21</b> in vivo using pharmacokinetic/pharmacodynamic (PK/PD) and tumor growth inhibition (TGI) studies will be disclosed in a separate publication.</div><div class="NLM_p last">Nonclinical safety profiling of <b>21</b> was also conducted. An off-target assessment was performed in vitro at 10 Î¼M against a broad panel of receptors, enzymes, and ion channels (Cerep, Poitiers, France) where <b>21</b> exhibited less than 50% effect or inhibition against all nonkinase targets (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Table ST7). Assessment of the effects of <b>21</b> on the hERG<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> current showed IC<sub>50</sub> > 100 Î¼M, and the Ames mutagenicity evaluation was negative. Cardiovascular (i.e., blood pressure, heart rate, and electrocardiogram measurements), pulmonary, and central nervous systems functions were all assessed in vivo in a battery of single and repeat-dose safety pharmacology studies in rats and dogs with no effects (data not shown). Collectively, these results suggest minimal potential for secondary (off target) pharmacology. The in vivo toxicity profile of <b>21</b> was characterized in repeat-dose studies in rats and dogs (91 days duration). Compound <b>21</b> was well tolerated with no body weight loss. Compound-related effects at higher exposures were of an epithelial origin in the expected target organs (e.g., skin and gastrointestinal tract) at concentrations shown to inhibit WT EGFR, which reversed with cessation of dosing.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Synthetic Chemistry</h3><div class="NLM_p">In support of lead optimization, our initial goal was to achieve a modular and flexible route that allowed us to vary substitution at N(9), C(6), and C(2) of the purine scaffold. The synthesis of compound <b>4</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) is representative of our initial efforts in this series. Both Mitsunobu and alkylation methods favored N(9) substitution but provided significant amounts of N(7)-alkylated material that required chromatographic separation. In the case of anilinopiperazine <b>29</b>, S<sub>N</sub>Ar displacement at the C(6) position could be achieved with high selectivity under acidic conditions, but for other fragments (e.g., amino pyrazoles), S<sub>N</sub>Ar under basic conditions (DIPEA, DMSO) proved optimal. Compound <b>30</b> was typical of 6-amino-substituted purines in this series in that it was not sufficiently electrophilic to undergo S<sub>N</sub>Ar displacement at C(2) in good yield. As a result, BuchwaldâHartwig-type aminations were investigated, and after significant reaction optimization, it was found that the palladium precatalyst SK-CC02-A provided excellent reactivity across a range of amine nucleophiles. The doubly amine-substituted intermediates, such as compound <b>32</b>, were then readily deprotected. Acylation to form acrylamide <b>4</b> using acryloyl chloride under SchottenâBaumann conditions provided only moderate yields. Similar yields were typically observed using activating reagents and acrylic acid. Our observations of these reactions suggest that at least two factors contribute to the difficult acryloylation: (a) poor solubility of the intermediate free-based amine and (b) covalent reaction of the free-based amine with the desired acrylamide product.</div><figure id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0011.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Initial Route Exemplified by the Synthesis of Compound <b>4</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The challenges encountered during our initial synthetic efforts led us to optimize the route to provide quicker and more robust access to diverse analogues (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Specifically, our goals were to eliminate the demanding palladium-catalyzed coupling and to improve the acrylamide formation. To obviate the need for palladium-catalyzed amination at C(2), a 2-fluoro substituent was utilized, which provided increased electrophilicity. The incorporation of a Î²-sulfone-containing propionate fragment in pyrrolidine <b>36</b> both increased convergency and provided a masked acrylamide group that was well-behaved in amide formation. These two innovations made possible the telescoped three-step one-pot synthesis shown. The 2-fluoro substituent engendered sufficient electrophilicity in the system to allow sequential S<sub>N</sub>Ar reactions but retained sufficient difference in the C(2) and C(6) reactivity to allow for complete positional fidelity in the reactions. Subsequent addition of potassium <i>tert</i>-butoxide revealed the desired acrylamide <b>5</b> in good yield.</div><figure id="sch2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0012.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Optimized Analoguing Route Exemplified by the Synthesis of Compound <b>5</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further refinements focused on improving the scalability of the route to compound <b>21</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The challenge of selective N(9) alkylation was overcome by first introducing the C(6) amine substituent and then alkylating the aminopurine intermediate. In the case of pyrazole-substituted purine <b>39</b>, no N(7) alkylation could be detected. Thus, 2-fluoropurine derivative <b>40</b> underwent S<sub>N</sub>Ar displacement with pyrrolidine <b>41</b> in high yield. Treatment of sulfone <b>42</b> with potassium <i>tert</i>-butoxide revealed acrylamide <b>21</b>. This route was executed without any chromatographic purification steps and was robust enough to produce a 100 g batch of clinical candidate <b>21</b> in support of exploratory toxicology studies.</div><figure id="sch3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0013.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Scalable Route to Purine Compounds Exemplified by Clinical Candidate <b>21</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Conclusion</h3><div class="NLM_p last">Development of a series of irreversible purine inhibitors from an initial screening hit to clinical candidate has been described. The medicinal chemistry program focused on deriving potency from binding affinity rather than the inactivation rate of covalent modification. This approach culminated in the discovery of <b>21</b>, a compound possessing low intrinsic reactivity, which in-turn provided reduced off-target labeling when compared to other known clinical T790M inhibitors in a cellular context. <b>21</b> has potency against both common T790M EGFR double mutants and the single-point activating mutants Del and L858R while retaining selectivity over EGFR wild-type to mitigate the side effects seen with generation two EGFR irreversible inhibitors. <b>21</b> possesses an optimal balance of potency in combination with good ADME, kinase selectivity, and in vitro and in vivo toxicity profiles. <b>21</b> has progressed into human clinical studies as an EGFR_T790M inhibitor for NSCLC. Further details of in vivo efficacy, PK/PD, and early clinical readouts will be published in due course.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35477" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35477" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General</h3><div class="NLM_p last">Starting materials and reagents were purchased from commercial suppliers and were used without further purification unless otherwise indicated. <b>23</b>, <b>24</b>, and dacomitinib were synthesized via Pfizer Worldwide Research and Development (La Jolla, CA) using published methods. Erlotinib was purchased from LC Laboratories (Woburn, MA). Compound <b>21</b> (catalog no. PZ0302) and compound <b>1</b> (catalog no. PZ0296) are commercially available via MilliporeSigma. All reactions were performed under a positive pressure of nitrogen or argon or with a drying tube at ambient temperature (unless otherwise stated) in anhydrous solvents (unless otherwise indicated). Reactions were assayed by high-performance liquid chromatography (HPLC) or thin-layer chromatography (TLC) and terminated as judged by the consumption of starting material. Analytical thin-layer chromatography was performed on glass-backed silica gel 60_F 254 plates (Analtech (0.25 mm)) and eluted with the appropriate solvent ratios (v/v). TLC plates were visualized by UV fluorescence, phosphomolybdic acid stain, anisaldehyde stain, or iodine stain. Microwave-assisted reactions were run in a Biotage initiator. <sup>1</sup>H NMR spectra were recorded on a Bruker instrument operating at 400 MHz unless otherwise indicated. <sup>1</sup>H NMR spectra were obtained as DMSO-<i>d</i><sub>6</sub> or CDCl<sub>3</sub> solutions as indicated (reported in parts per million) using chloroform as the reference standard (7.27 ppm) or DMSO-<i>d</i><sub>6</sub> (2.50 ppm) at 30 Â°C unless otherwise noted. <sup>13</sup>C NMR spectra are referenced internally to solvent. <sup>19</sup>F spectra are externally referenced to CFCl<sub>3</sub> (0.0 ppm). Other NMR solvents were used as needed. When peak multiplicities are reported, the following abbreviations are used: s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, m = multiplet, br = broad, dd = doublet of doublets, dt = doublet of triplets. Coupling constants, when given, are reported in hertz. Mass spectra were obtained using liquid chromatographyâmass spectrometry (LCâMS) on an Agilent 1260 LC with MSD Agilent model 6120 single-quadrupole mass spectrometry detectors using atmospheric pressure chemical ionization (APCI) or electrospray ionization (ESI). High-resolution mass measurements were carried out on an Agilent TOF 6200 series with ESI. All test compounds showed >95% purity as determined by combustion analysis or by HPLC. HPLC conditions were as follows: WatersAcquityBEH C18, 2.1 Ã 30 mm, 1.7 Î¼m particle size, 5â95%B in 2.5 min, 95%B 2.5â3.0 min; flow rate 1.2 mL/min (solvent A: water (0.1% formic acid + 0.05% ammonium formate) and solvent B: acetonitrile (5% H<sub>2</sub>O + 0.1% formic acid + 0.05% ammonium formate)); UV detection (Î» = 254, 224 nm). Combustion analyses were performed by Atlantic Microlab, Inc. (Norcross, GA).</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Synthesis of <b>21</b></h3><div id="sec3_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 2-Fluoro-<i>N</i>-(3-methoxy-1-methyl-1<i>H</i>-pyrazol-4-yl)-9<i>H</i>-purin-6-amine (<b>39</b>)</h4><div class="NLM_p last">A suspension of 6-chloro-2-fluoro-9<i>H</i>-purine (5.49 g, 31.8 mmol, 1.00 equiv), 3-methoxy-1-methyl-1<i>H</i>-pyrazol-4-amine hydrochloride (6.60 g, 40.34 mmol, 1.26 equiv), and <i>N</i>,<i>N</i>-diisopropylethylamine (16.6 mL, 95.5 mmol, 3.00 equiv) in DMSO (31.8 mL) was stirred at ambient temperature for 19 h. The reaction mixture was concentrated under reduced pressure at 50 Â°C, poured into water (250 mL), and stirred vigorously at 0 Â°C for 1 h. The resulting solids were filtered off, washed with ice cold water (20 mL), and dried for 16 h at 50 Â°C to give the title compound (<b>39</b>) (7.26 g, 87% yield, 96% purity) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 13.03 (br s, 1H), 9.21 (br s, 1H), 8.18 (br s, 1H), 7.74 (br s, 1H), 3.81 (br s, 3H), 3.71 (s, 3H). <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm â51.53 (br s, 1F). <i>m</i>/<i>z</i> (APCI+) for C<sub>10</sub>H<sub>11</sub>FN<sub>7</sub>O 264.2 (M + H)<sup>+</sup>.</div></div><div id="sec3_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 2-Fluoro-<i>N</i>-(3-methoxy-1-methyl-1<i>H</i>-pyrazol-4-yl)-9-methyl-9<i>H</i>-purin-6-amine (<b>40</b>)</h4><div class="NLM_p last">To a vigorously stirred suspension of 2-fluoro-<i>N</i>-(3-methoxy-1-methyl-1<i>H</i>-pyrazol-4-yl)-9<i>H</i>-purin-6-amine (7.25 g, 27.5 mmol, 1.00 equiv) and potassium carbonate (7.61 g, 55.1 mmol, 2.00 equiv) in 1,4-dioxane (92.0 mL) was added dimethyl sulfate (2.90 mL, 30.3 mmol, 1.10 equiv) in a dropwise manner over 3 min. After 4 h, additional portions of 1,4-dioxane (50.0 mL), potassium carbonate (3.80 g, 27.5 mmol, 1.00 equiv), and dimethyl sulfate (1.00 mL, 10.4 mmol, 0.30 equiv) were added to the reaction mixture. After a further 16 h, the reaction mixture was concentrated under reduced pressure, diluted with water (120 mL), and stirred at ambient temperature for 1 h. The resulting solids were filtered, washed with water (20 mL), and dried at 60 Â°C for 16 h to give the title compound (<b>40</b>) (6.42 g, 84% yield, >95% purity) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 9.23 (br s, 1H), 8.13 (br s, 1H), 7.67 (s, 1H), 3.78 (s, 3H), 3.70 (s, 3H), 3.69 (br s, 3H). <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm â51.25 (br s, 1F). <i>m</i>/<i>z</i> (APCI+) for C<sub>11</sub>H<sub>13</sub>FN<sub>7</sub>O 278.2 (M + H)<sup>+</sup>.</div></div><div id="sec3_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>N</i>-((3<i>R</i>,4<i>R</i>)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1<i>H</i>-pyrazol-4-yl)amino)-9-methyl-9<i>H</i>-purin-2-yl)pyrrolidin-3-yl)acrylamide (<b>21</b>)</h4><div class="NLM_p last">To a stirred suspension of 2-fluoro-<i>N</i>-(3-methoxy-1-methyl-1<i>H</i>-pyrazol-4-yl)-9-methyl-9<i>H</i>-purin-6-amine (554 mg, 2.00 mmol, 1.00 equiv) and <i>N</i>-((3<i>R</i>,4<i>R</i>)-4-fluoropyrrolidin-3-yl)-3-(methylsulfonyl)propanamide (500 mg, 2.10 mmol, 1.05 equiv) in DMSO (4.2 mL) was added <i>N</i>,<i>N</i>-diisopropylethylamine (0.83 mL, 5.00 mmol, 2.50 equiv). The reaction mixture was heated at 100 Â°C for 16 h, cooled to ambient temperature, diluted with THF (4 mL), and treated with potassium <i>tert</i>-butoxide (4.00 mL, 1 M in THF, 2.00 equiv). After 1 h, an additional portion of potassium <i>tert</i>-butoxide (0.50 mL, 1 M in THF, 0.25 equiv) was added to the reaction mixture. After a further 1 h, the reaction mixture was poured into phosphate buffer (50 mL, pH 7) and water (50 mL) and extracted with ethyl acetate (5 Ã 40 mL). The combined organic layers were combined, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure. This crude product was dissolved in ethyl acetate (40 mL) at 60 Â°C and treated with heptanes (20 mL), at which point the solution became cloudy and was allowed to cool to ambient temperature and cooled to 0 Â°C. After 16 h at 0 Â°C, the resulting solids were filtered and dried at ambient temperature to give the title compound (<b>21</b>) (620.5 mg, 75% yield, 98% purity) as a white powder. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 8.44 (d, <i>J</i> = 6.5 Hz, 1H), 7.97 (s, 1H), 7.82 (s, 1H), 7.78 (s, 1H), 6.23 (dd, <i>J</i> = 10.0, 17.0 Hz, 1H), 6.14 (dd, <i>J</i> = 2.8, 17.0 Hz, 1H), 5.62 (dd, <i>J</i> = 2.8, 10.0 Hz, 1H), 5.12 (d, <i>J</i> = 51.0 Hz, 1H), 4.46 (td, <i>J</i> = 6.0, 11.9 Hz, 1H), 3.88â3.6 (m, 4H), 3.82 (s, 3H), 3.71 (s, 3H), 3.62 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 164.6, 157.3, 154.8 (br s, 1C), 151.7 (br s, 1C), 151.6 (br s, 1C), 138.7, 131.1, 125.9, 125.5 (br s, 1C), 113.2, 105.4, 94.3 (d, <i>J</i><sub>CâF</sub> = 179.0 Hz, 1C), 55.9, 53.1 (d, <i>J</i><sub>CâF</sub> = 29.0 Hz, 1C), 51.0 (d, <i>J</i><sub>CâF</sub> = 21.0 Hz, 1C), 49.6 (br s, 1C), 38.7, 28.9. <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm â177.76 (br s, 1F). <i>m</i>/<i>z</i> (APCI+) for C<sub>18</sub>H<sub>23</sub>FN<sub>9</sub>O<sub>2</sub> 416.3 (M + H)<sup>+</sup>. [Î±]<sup>D</sup><sub>22</sub>= +41.1Â° (<i>c</i> = 0.5 EtOH). Calcd for C<sub>18</sub>H<sub>23</sub>FN<sub>9</sub>O<sub>2</sub> C, 52.04; H, 5.34; N, 30.34; Found: C, 52.20; H, 5.32, N, 30.46. mp 260 Â°C.</div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Biochemical Kinase Assays</h3><div class="NLM_p last">EGFR kinase activity assays were reported previously.<a onclick="showRef(event, 'ref1 ref27'); return false;" href="javascript:void(0);" class="ref ref1 ref27">(1, 27)</a></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Cell Lines and Culture Conditions</h3><div class="NLM_p last">H1975 and A549 cancer cell lines were purchased from ATCC and were cultured according to ATCC recommendations. PC9 cells were purchased from RIKEN Cell Bank (Tsukuba, Ibaraki Prefecture, Japan) and were cultured in Gibco RPMI 1640 (Life Technologies, Carlsbad, CA) medium with 10% FBS (Sigma, St. Louis, MO). H3255 cells were from Dr. Bruce E. Johnson at the National Cancer Institute (Bethesda, MD) and were cultured in RPMI 1640, 10% FBS, and ACL-4 supplement (Mediatech Inc., Manassas, VA). PC9-DRH, harboring both the single mutant (Del) and double mutant (Del/T790M) alleles, is a pool of cells derived from PC9 parental line that was selected after treatment with gradually increasing concentrations of dacomitinib up to 2 Î¼M. PC9-DRH EGFR alleles consist of 70% Del/T790M and 30% Del. PC9-DRH cells were cultured in Gibco RPMI 1640 medium with 10% FBS and maintained in dacomitinib (2 Î¼M).</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> EGFR Cellular Autophosphorylation ELISA</h3><div class="NLM_p last">Cells were plated (25â¯000â50â¯000 cells/well) in a final volume of 100 Î¼L of complete media in 96-well microtiter plates and cultured overnight (37 Â°C, 5% CO<sub>2</sub>). Inhibitors were solubilized in DMSO and tested in duplicate utilizing 11-point serial dilutions with the highest concentration at 1 or 10 Î¼M (0.3% v/v final DMSO). Inhibitors were incubated with cells for 2 h at 37 Â°C, 5% CO<sub>2</sub>. For EGFR wild-type assays, cells were plated in full-serum (10%) media for 24 h prior to compound treatment; cells were treated in full serum media as described and then stimulated for 10 min with EGF (Life Technologies) in serum-free media (50 ng/mL for A549). For all cells postinhibitor treatment (Â±EGF), media was removed and 100 Î¼L of ice-cold lysis buffer was added: 1x cell lysis buffer (Cell Signaling Technology, Danvers, MA), 1 mM phenylmethanesulfonyl fluoride (Calbiochem/EMD Chemicals, Billerica, MA), 1 mM sodium orthovanadate (New England Biolabs Inc., Ipswich, MA), complete Mini EDTA-free Protease Inhibitor Cocktail Tablets (Roche Applied Science, Indianapolis, IN), and PhosSTOP (Roche Applied Science). Plates were shaken (20â30 min, 4 Â°C) to lyse the cells, and 100 Î¼L of lysate was added to an ELISA plate. PathScan Phospho-EGF Receptor (Try1068) Sandwich ELISA (Cell Signaling Technology) was used to quantify EGFR autophosphorylation per the manufacturerâs protocol. IC<sub>50</sub> values were determined by nonlinear regression analysis with a four-parameter fit by utilizing a Microsoft Excel-based macro.</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Intrinsic Chemical Reactivity Assay</h3><div class="NLM_p">The intrinsic chemical reactivity was accessed by evaluating the rate of electrophilic attack of the test compound to a strong nucleophile, glutathione (GSH). This was achieved by monitoring test compound loss during the reaction via LC-MS/MS detection. The experiment was initiated with an aliquot (100 Î¼L) of the test compound to a reaction buffer consisting of 100 Î¼M phosphate buffer pH 7.4, in the presence or absence of 5 mM GSH. The reaction which did not contain GSH was used as a control for chemical instability. Each compound was tested experimentally in duplicate. The final test compound concentration was 1 Î¼M. The 37 Â°C reaction temperature was maintained throughout the entire experiment. Aliquots of the reaction volume (100 Î¼L) were taken at 0, 5, 15, 30, 45, 60, 90, and 120 min and quenched 1:1 (v:v) with 40 mM <i>N</i>-ethylmaleimide (NEM) in acetonitrile containing internal standard. CI-1033 served as the positive control in all experiments.</div><div class="NLM_p last">A linear regression analysis using the natural log of the peak area ratio, based on the internal standard, versus time provided the elimination constant (<i>k</i><sub>el</sub>). Half-life was calculated as ln 2/â(<i>k</i><sub>el</sub>). The intrinsic reactivity of each test compound was reported as the ratio of the compound half-life compared to the half-life of canertinib.</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Computational Calculations</h3><div class="NLM_p last">The conformation search was performed using the mixed torsional/low-mode sampling method in MacroModel (Schrodinger Inc.). Conformations with energies less than 5 kcal/mol relative energy were clustered, and representative conformations of each cluster were used as initial structures for the ab initio calculations. Geometry optimization was carried out at the B3LYP/6-31G(d,p) level using Jaguar (Schrodinger Inc.) v8.0. The lowest ab initio energy minima were used to calculate the relative ab initio energy for each geometry-optimized conformation.</div></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Cocrystal Visualizations and ProteinâLigand Modeling Methods</h3><div class="NLM_p last">Pfizer in-house software was used for visualization and modeling studies. Authors will release the atomic coordinates and experimental data upon article publication. PDB codes used in main article: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG7">5HG7</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UG8">5UG8</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UG9">5UG9</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UGA">5UGA</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UGB">5UGB</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UGC">5UGC</a> (for <b>21</b> as shown in TOC graphic).</div></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> In Vivo Work</h3><div class="NLM_p last">All studies involving animals were performed in accordance with institutional guidelines as defined by Institutional Animal Care and Use Committee for U.S. institutions.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01894">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66814" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66814" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b01894" class="ext-link">10.1021/acs.jmedchem.6b01894</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">SMILES data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01894/suppl_file/jm6b01894_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Focused kinase activity data for select compounds within, full kinase profiling for <b>21</b>, off-target in vitro assessment of <b>21</b> in a safety panel, EGFR kinetic parameters for <b>21</b>, small molecule X-ray data for <b>21</b>, proteomic compound probes (their key activity and physiochemical data and commassie gels), <b>21</b> metabolite ID and profiling, details of ADME assays, synthetic experimental details, and molecular formula strings for key compounds contained within (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01894/suppl_file/jm6b01894_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01894/suppl_file/jm6b01894_si_001.csv">jm6b01894_si_001.csv (1.89 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01894/suppl_file/jm6b01894_si_002.pdf">jm6b01894_si_002.pdf (1.9 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b01894" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80453" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80453" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon Planken</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8901-8992" title="Orcid link">http://orcid.org/0000-0001-8901-8992</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#97e4fefaf8f9b9e7fbf6f9fcf2f9d7e7f1feedf2e5b9f4f8fa"><span class="__cf_email__" data-cfemail="c8bba1a5a7a6e6b8a4a9a6a3ada688b8aea1b2adbae6aba7a5">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Douglas C. Behenna</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#096d667c6e65687a276b6c616c67676849796f60736c7b276a6664"><span class="__cf_email__" data-cfemail="b5d1dac0d2d9d4c69bd7d0ddd0dbdbd4f5c5d3dccfd0c79bd6dad8">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sajiv K. Nair</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Theodore O. Johnson</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Asako Nagata</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chau Almaden</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon Bailey</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">T. Eric Ballard</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Louise Bernier</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hengmiao Cheng</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sujin Cho-Schultz</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deepak Dalvie</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Judith G. Deal</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dac M. Dinh</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin P. Edwards</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rose Ann Ferre</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ketan S. Gajiwala</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle Hemkens</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert S. Kania</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John C. Kath</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jean Matthews</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brion W. Murray</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sherry Niessen</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Suvi T. M. Orr</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mason Pairish</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neal W. Sach</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Shen</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Manli Shi</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Solowiej</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Khanh Tran</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elaine Tseng</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paolo Vicini</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuli Wang</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott L. Weinrich</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ru Zhou</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Zientek</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Longqing Liu</span> - <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yiqin Luo</span> - <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuibo Xin</span> - <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chengyi Zhang</span> - <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer Lafontaine</span> - <span class="hlFld-Affiliation affiliation">â Departments
of Worldwide Medicinal Chemistry, Â§Pharmacokinetics, Dynamics and Metabolism, â¡Oncology Research
Unit, and â¥Drug Safety, La Jolla Laboratories, Pfizer
Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e2934-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24307" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24307" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to Patrick Bingham and Dawn Nowlin for HTS screening, Jun Li Feng and Kevin Ryan for protein production, Klaus Dress for data management and visualization help, Jeff Elleraas and Loanne Chung for synthetic purification work, and Greg Stevens for preclinical safety discussions and considerations. Also, thanks to Dan Widlicka, Brian Samas, and Alex Yanovsky for small molecule X-ray generation.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i36" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i36"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i37" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i37"> Abbreviations Used</h2><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorptionâdistributionâmetabolismâexcretion</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild-type</p></td></tr><tr><td class="NLM_term">DM</td><td class="NLM_def"><p class="first last">double mutant (L858R/T790M or Del/T790M)</p></td></tr><tr><td class="NLM_term">TM</td><td class="NLM_def"><p class="first last">triple mutant (L858R/T790M/V948R)</p></td></tr><tr><td class="NLM_term">Del</td><td class="NLM_def"><p class="first last">exon 19 E746-A750 deletion oncogenic mutation</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structureâactivity relationship</p></td></tr><tr><td class="NLM_term">SBDD</td><td class="NLM_def"><p class="first last">structure-based drug design</p></td></tr><tr><td class="NLM_term">LUMO</td><td class="NLM_def"><p class="first last">lowest unoccupied molecular orbital</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">hLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">hHEP</td><td class="NLM_def"><p class="first last">human hepatocytes</p></td></tr><tr><td class="NLM_term">DOF</td><td class="NLM_def"><p class="first last">dofetilide</p></td></tr><tr><td class="NLM_term">sol</td><td class="NLM_def"><p class="first last">solubility</p></td></tr><tr><td class="NLM_term">PSA</td><td class="NLM_def"><p class="first last">polar surface area</p></td></tr><tr><td class="NLM_term">RRCK</td><td class="NLM_def"><p class="first last">permeability measured with low-efflux MDCKII cell</p></td></tr><tr><td class="NLM_term">LipE</td><td class="NLM_def"><p class="first last">lipophilic efficiency</p></td></tr><tr><td class="NLM_term">TDI</td><td class="NLM_def"><p class="first last">time-dependent inactivation</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81611" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81611" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 27 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almaden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behenna, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho-Schultz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferre, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemkens, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson-Fisher, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalaie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kephart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafontaine, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunney, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niessen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ornelas, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planken, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walls, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinrich, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zientek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span> </span><span class="NLM_article-title">Discovery of 1-{(3<i>R</i>,4<i>R</i>)-3-[({5-Chloro-2-[(1-methyl-1<i>H</i>-pyrazol-4-yl)amino]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a potent, WT sparing, irreversible inhibitor of T790M-containing EGFR mutants</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">2005</span><span class="NLM_x">â</span> <span class="NLM_lpage">2024</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01633</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01633" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2005-2024&issue=5&author=H.+Chengauthor=S.+K.+Nairauthor=B.+W.+Murrayauthor=C.+Almadenauthor=S.+Baileyauthor=S.+Baxiauthor=D.+Behennaauthor=S.+Cho-Schultzauthor=D.+Dalvieauthor=D.+M.+Dinhauthor=M.+P.+Edwardsauthor=J.+L.+Fengauthor=R.+A.+Ferreauthor=K.+S.+Gajiwalaauthor=M.+D.+Hemkensauthor=A.+Jackson-Fisherauthor=M.+Jalaieauthor=T.+O.+Johnsonauthor=R.+S.+Kaniaauthor=S.+Kephartauthor=J.+Lafontaineauthor=B.+Lunneyauthor=K.+K.+Liuauthor=Z.+Liuauthor=J.+Matthewsauthor=A.+Nagataauthor=S.+Niessenauthor=M.+A.+Ornelasauthor=S.+T.+Orrauthor=M.+Pairishauthor=S.+Plankenauthor=S.+Renauthor=D.+Richterauthor=K.+Ryanauthor=N.+Sachauthor=H.+Shenauthor=T.+Smealauthor=J.+Solowiejauthor=S.+Suttonauthor=K.+Tranauthor=E.+Tsengauthor=W.+Vernierauthor=M.+Wallsauthor=S.+Wangauthor=S.+L.+Weinrichauthor=S.+Xinauthor=H.+Xuauthor=M.+J.+Yinauthor=M.+Zientekauthor=R.+Zhouauthor=J.+C.+Kath&title=Discovery+of+1-%7B%283R%2C4R%29-3-%5B%28%7B5-Chloro-2-%5B%281-methyl-1H-pyrazol-4-yl%29amino%5D-7H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%7Doxy%29methyl%5D-4-methoxypyrrolidin-1-yl%7Dprop-2-en-1-one+%28PF-06459988%29%2C+a+potent%2C+WT+sparing%2C+irreversible+inhibitor+of+T790M-containing+EGFR+mutants&doi=10.1021%2Facs.jmedchem.5b01633"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01633%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DNair%26aufirst%3DS.%2BK.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBaxi%26aufirst%3DS.%26aulast%3DBehenna%26aufirst%3DD.%26aulast%3DCho-Schultz%26aufirst%3DS.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DFeng%26aufirst%3DJ.%2BL.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DHemkens%26aufirst%3DM.%2BD.%26aulast%3DJackson-Fisher%26aufirst%3DA.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKephart%26aufirst%3DS.%26aulast%3DLafontaine%26aufirst%3DJ.%26aulast%3DLunney%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMatthews%26aufirst%3DJ.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DOrnelas%26aufirst%3DM.%2BA.%26aulast%3DOrr%26aufirst%3DS.%2BT.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DPlanken%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DRichter%26aufirst%3DD.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DSach%26aufirst%3DN.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DSutton%26aufirst%3DS.%26aulast%3DTran%26aufirst%3DK.%26aulast%3DTseng%26aufirst%3DE.%26aulast%3DVernier%26aufirst%3DW.%26aulast%3DWalls%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWeinrich%26aufirst%3DS.%2BL.%26aulast%3DXin%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DM.%2BJ.%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%25201-%257B%25283R%252C4R%2529-3-%255B%2528%257B5-Chloro-2-%255B%25281-methyl-1H-pyrazol-4-yl%2529amino%255D-7H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%257Doxy%2529methyl%255D-4-methoxypyrrolidin-1-yl%257Dprop-2-en-1-one%2520%2528PF-06459988%2529%252C%2520a%2520potent%252C%2520WT%2520sparing%252C%2520irreversible%2520inhibitor%2520of%2520T790M-containing%2520EGFR%2520mutants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D5%26spage%3D2005%26epage%3D2024%26doi%3D10.1021%2Facs.jmedchem.5b01633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">169</span><span class="NLM_x">â</span> <span class="NLM_lpage">181</span><span class="refDoi">Â DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&issue=3&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lini16OFcBv9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26issue%3D3%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bonanno, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jirillo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favaretto, A.</span><span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">922</span><span class="NLM_x">â</span> <span class="NLM_lpage">933</span><span class="refDoi">Â DOI: 10.2174/138945011795528958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.2174%2F138945011795528958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=21443472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlOmsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=922-933&issue=6&author=L.+Bonannoauthor=A.+Jirilloauthor=A.+Favaretto&title=Mechanisms+of+acquired+resistance+to+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+and+new+therapeutic+perspectives+in+non+small+cell+lung+cancer&doi=10.2174%2F138945011795528958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer</span></div><div class="casAuthors">Bonanno, Laura; Jirillo, Antonio; Favaretto, Adolfo</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">922-933</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  EGFR somatic mutations define a subset of NSCLCs that are most likely to benefit from EGFR tyrosine kinase inhibitors (TKIs).  These tumors are dependent on EGFR-signaling for survival.  Recently, tyrosine kinase domain somatic mutations were approved as criterion to decide 1st-line therapy in this group of advanced NSCLCs.  Anyway, all patients ultimately develop resistance to these drugs.  Acquired resistance is linked to a secondary EGFR mutation in about a half of patients.  Uncontrolled activation of MET, another tyrosine kinase receptor, was implicated in neoplastic invasive growth.  MET is overexpressed, activated and sometimes mutated in NSCLC cell lines and tumor tissues.  MET increased gene copy no. was also documented in NSCLC and was studied as neg. prognostic factor.  It was also found in about 20% of patients developing acquired resistance to TKIs inhibitors.  In this group, it seems to display a new mechanism, which is able to mark tumor independence from EGFR signaling.  The study of delayed resistance mechanisms could lead to the development of new therapeutic strategies.  Different mol. alterations could be specifically targeted to extend disease control in this group of NSCLCs with distinct clin. and mol. features.  EGFR irreversible inhibitors, MET inhibitors and dual EGFR/VEGFR inhibitors represent one of the most challenging issues in current clin. research.  Ongoing clin. trials and future perspectives are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1PSQ8xqQ2mbVg90H21EOLACvtfcHk0lini16OFcBv9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlOmsrg%253D&md5=25b1b08011e4aee60673d8dbb8cca222</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.2174%2F138945011795528958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945011795528958%26sid%3Dliteratum%253Aachs%26aulast%3DBonanno%26aufirst%3DL.%26aulast%3DJirillo%26aufirst%3DA.%26aulast%3DFavaretto%26aufirst%3DA.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520and%2520new%2520therapeutic%2520perspectives%2520in%2520non%2520small%2520cell%2520lung%2520cancer%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2011%26volume%3D12%26issue%3D6%26spage%3D922%26epage%3D933%26doi%3D10.2174%2F138945011795528958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruvka, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1070</span><span class="NLM_x">â</span> <span class="NLM_lpage">1080</span><span class="refDoi">Â DOI: 10.1200/JCO.2012.43.3912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1200%2FJCO.2012.43.3912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=23401451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltl2mtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1070-1080&issue=8&author=K.+Ohashiauthor=Y.+E.+Maruvkaauthor=F.+Michorauthor=W.+Pao&title=Epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor-resistant+disease&doi=10.1200%2FJCO.2012.43.3912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease</span></div><div class="casAuthors">Ohashi, Kadoaki; Maruvka, Yosef E.; Michor, Franziska; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1070-1080</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Purpose EGFR-mutant lung cancer was first described as a new clin. entity in 2004.  Here, we present an update on new controversies and conclusions regarding the disease.  Methods This article reviews the clin. implications of EGFR mutations in lung cancer with a focus on epidermal growth factor receptor tyrosine kinase inhibitor resistance.  Results The discovery of EGFR mutations has altered the ways in which we consider and treat non-small-cell lung cancer (NSCLC).  Patients whose metastatic tumors harbor EGFR mutations are expected to live longer than 2 years, more than double the previous survival rates for lung cancer.  Conclusion The information presented in this review can guide practitioners and help them inform their patients about EGFR mutations and their impact on the treatment of NSCLC.  Efforts should now conc. on making EGFR-mutant lung cancer a chronic rather than fatal disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3FJbVyt6ydLVg90H21EOLACvtfcHk0lj3d3TjjFBt1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltl2mtb0%253D&md5=dfda1563a90ce24bc51e55ebbf47d981</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.43.3912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.43.3912%26sid%3Dliteratum%253Aachs%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DMaruvka%26aufirst%3DY.%2BE.%26aulast%3DMichor%26aufirst%3DF.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor-resistant%2520disease%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26issue%3D8%26spage%3D1070%26epage%3D1080%26doi%3D10.1200%2FJCO.2012.43.3912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Chang, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, J. Y.</span><span> </span><span class="NLM_article-title">The role of epidermal growth factor receptor mutations and epidermal growth factor receptor-tyrosine kinase inhibitors in the treatment of lung cancer</span> <span class="citation_source-journal">Cancers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">2667</span><span class="NLM_x">â</span> <span class="NLM_lpage">2678</span><span class="refDoi">Â DOI: 10.3390/cancers3022667</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.3390%2Fcancers3022667" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=2667-2678&issue=2&author=S.+C.+Changauthor=C.+Y.+Changauthor=J.+Y.+Shih&title=The+role+of+epidermal+growth+factor+receptor+mutations+and+epidermal+growth+factor+receptor-tyrosine+kinase+inhibitors+in+the+treatment+of+lung+cancer&doi=10.3390%2Fcancers3022667"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.3390%2Fcancers3022667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers3022667%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%2BC.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DShih%26aufirst%3DJ.%2BY.%26atitle%3DThe%2520role%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520mutations%2520and%2520epidermal%2520growth%2520factor%2520receptor-tyrosine%2520kinase%2520inhibitors%2520in%2520the%2520treatment%2520of%2520lung%2520cancer%26jtitle%3DCancers%26date%3D2011%26volume%3D3%26issue%3D2%26spage%3D2667%26epage%3D2678%26doi%3D10.3390%2Fcancers3022667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abolhoda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span> </span><span class="NLM_article-title">The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">784</span><span class="NLM_x">â</span> <span class="NLM_lpage">791</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-11-0750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1158%2F1535-7163.MCT-11-0750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=22228822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKitr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=784-791&issue=3&author=Y.+Kimauthor=J.+Koauthor=Z.+Cuiauthor=A.+Abolhodaauthor=J.+S.+Ahnauthor=S.+H.+Ouauthor=M.+J.+Ahnauthor=K.+Park&title=The+EGFR+T790M+mutation+in+acquired+resistance+to+an+irreversible+second-generation+EGFR+inhibitor&doi=10.1158%2F1535-7163.MCT-11-0750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor</span></div><div class="casAuthors">Kim, Youngwook; Ko, Jeonghun; Cui, ZhengYun; Abolhoda, Amir; Ahn, Jin Seok; Ou, Sai-Hong; Ahn, Myung-Ju; Park, Keunchil</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">784-791</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mol. target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCLC) who harbor activating mutations in EGFR.  However, these patients eventually develop resistance to the reversible TKIs, and this has led to the development of second-generation, irreversible EGFR inhibitors.  Currently, the mechanism of acquired resistance to irreversible EGFR inhibitors is not clear.  Using an in vitro cell culture system, we modeled the acquired resistance to first-line treatment with second-generation EGFR-TKIs using an EGFR-mutant NSCLC cell line.  Here, we report a mechanism of resistance involving T790M secondary mutation as well as a corresponding clin. case.  The results of these findings suggest that inhibition of EGFR by currently available second-generation EGFR-TKIs may not be sufficient to physiol. prevent the emergence of cells that are still dependent on EGFR signaling.  This finding bears important implications on the limitations of currently available second-generation EGFR-TKIs.  Mol Cancer Ther; 11(3); 784-91.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDhUxzW64OFLVg90H21EOLACvtfcHk0lj3d3TjjFBt1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKitr4%253D&md5=3cd09bb1dd73f8045b93b054c79480d3</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0750%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%26aulast%3DKo%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DZ.%26aulast%3DAbolhoda%26aufirst%3DA.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DPark%26aufirst%3DK.%26atitle%3DThe%2520EGFR%2520T790M%2520mutation%2520in%2520acquired%2520resistance%2520to%2520an%2520irreversible%2520second-generation%2520EGFR%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D3%26spage%3D784%26epage%3D791%26doi%3D10.1158%2F1535-7163.MCT-11-0750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wheeler, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harari, P. M.</span><span> </span><span class="NLM_article-title">Understanding resistance to EGFR inhibitors-impact on future treatment strategies</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">493</span><span class="NLM_x">â</span> <span class="NLM_lpage">507</span><span class="refDoi">Â DOI: 10.1038/nrclinonc.2010.97</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1038%2Fnrclinonc.2010.97" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=20551942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyjsr7L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=493-507&issue=9&author=D.+L.+Wheelerauthor=E.+F.+Dunnauthor=P.+M.+Harari&title=Understanding+resistance+to+EGFR+inhibitors-impact+on+future+treatment+strategies&doi=10.1038%2Fnrclinonc.2010.97"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding resistance to EGFR inhibitors-impact on future treatment strategies</span></div><div class="casAuthors">Wheeler, Deric L.; Dunn, Emily F.; Harari, Paul M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">493-507</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  EGFR is one of the most studied targets in oncol., and several inhibitors have shown promising results in selected patient populations.  However, intrinsic and acquired resistance to these targeted therapies is increasingly recognized.  The authors of this Review describe the successful translation of EGFR inhibitors to the clinic, and highlight the mechanisms of resistance to these agents that limit their long-term efficacy.  Understanding these processes will allow researchers to develop therapies that overcome resistance and ultimately lead to more successful outcomes.  EGFR is a tyrosine kinase that participates in the regulation of cellular homeostasis.  Following ligand binding, EGFR stimulates downstream cell signaling cascades that influence cell proliferation, apoptosis, migration, survival and complex processes, including angiogenesis and tumorigenesis.  EGFR has been strongly implicated in the biol. of human epithelial malignancies, with therapeutic applications in cancers of the colon, head and neck, lung, and pancreas.  Accordingly, targeting EGFR has been intensely pursued, with the development of a series of promising mol. inhibitors for use in clin. oncol.  As is common in cancer therapy, challenges with respect to treatment resistance emerge over time.  This situation is certainly true of EGFR inhibitor therapies, where intrinsic and acquired resistance is now well recognized.  In this Review, we provide a brief overview regarding the biol. of EGFR, preclin. and clin. development of EGFR inhibitors, and mol. mechanisms that underlie the development of treatment resistance.  A greater understanding of the mechanisms that lead to EGFR resistance may provide valuable insights to help design new strategies that will enhance the impact of this promising class of inhibitors for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw7LepfpXQa7Vg90H21EOLACvtfcHk0lj3d3TjjFBt1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyjsr7L&md5=2f043ede90d7206e45ec80642302a766</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2010.97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2010.97%26sid%3Dliteratum%253Aachs%26aulast%3DWheeler%26aufirst%3DD.%2BL.%26aulast%3DDunn%26aufirst%3DE.%2BF.%26aulast%3DHarari%26aufirst%3DP.%2BM.%26atitle%3DUnderstanding%2520resistance%2520to%2520EGFR%2520inhibitors-impact%2520on%2520future%2520treatment%2520strategies%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D7%26issue%3D9%26spage%3D493%26epage%3D507%26doi%3D10.1038%2Fnrclinonc.2010.97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span> </span><span class="NLM_article-title">Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Proteins Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1804</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">559</span><span class="NLM_x">â</span> <span class="NLM_lpage">566</span><span class="refDoi">Â DOI: 10.1016/j.bbapap.2009.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1016%2Fj.bbapap.2009.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=20026433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1ymsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1804&publication_year=2010&pages=559-566&issue=3&author=M.+J.+Eckauthor=C.+H.+Yun&title=Structural+and+mechanistic+underpinnings+of+the+differential+drug+sensitivity+of+EGFR+mutations+in+non-small+cell+lung+cancer&doi=10.1016%2Fj.bbapap.2009.12.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer</span></div><div class="casAuthors">Eck, Michael J.; Yun, Cai-Hong</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1804</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">559-566</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  EGFR and other ErbB-family tyrosine kinases are overexpressed in many human tumors, and their aberrant expression and mutational activation is assocd. with the development, progression and aggressiveness of a no. of malignancies.  Thus the EGFR kinase has long been recognized as a potential drug target in oncol., and small-mol. inhibitors have been under development for more than two decades.  As a result of their effectiveness in treating non-small cell lung cancers (NSCLCs) driven by somatic mutations in the EGFR kinase, gefitinib and erlotinib were the first EGFR tyrosine kinase inhibitors (TKIs) approved for clin. use.  Ironically, these drugs found their target against mutant forms of the EGFR kinase, which have altered enzyme active sites, and not against the wild type (WT) kinase against which their potency and selectivity was carefully honed.  Here we review recent structural and enzymol. studies that explore the exquisite sensitivity of a subset of these lung cancer mutants to gefitinib and erlotinib.  We discuss available structural evidence for the mechanisms of activation of the EGFR kinase by these mutants, and compare it to physiol. activation of the kinase by ligand-induced dimerization.  Finally, we consider the mechanisms by which the secondary T790M "gatekeeper" mutation confers resistance to gefitinib and erlotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0KpzCSm4-TbVg90H21EOLACvtfcHk0lis2C0CzAj6JA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1ymsrs%253D&md5=7717d659eacc3dea0cdb6ae4c85d865c</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2009.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2009.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DYun%26aufirst%3DC.%2BH.%26atitle%3DStructural%2520and%2520mechanistic%2520underpinnings%2520of%2520the%2520differential%2520drug%2520sensitivity%2520of%2520EGFR%2520mutations%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2010%26volume%3D1804%26issue%3D3%26spage%3D559%26epage%3D566%26doi%3D10.1016%2Fj.bbapap.2009.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">307</span><span class="NLM_x">â</span> <span class="NLM_lpage">317</span><span class="refDoi">Â DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&issue=4&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0lis2C0CzAj6JA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26issue%3D4%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluge, A. F.</span><span> </span><span class="NLM_article-title">Targeted covalent drugs of the kinase family</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">475</span><span class="NLM_x">â</span> <span class="NLM_lpage">480</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2010.06.168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1016%2Fj.cbpa.2010.06.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=20609616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=475-480&issue=4&author=J.+Singhauthor=R.+C.+Petterauthor=A.+F.+Kluge&title=Targeted+covalent+drugs+of+the+kinase+family&doi=10.1016%2Fj.cbpa.2010.06.168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted covalent drugs of the kinase family</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Kluge, Arthur F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">475-480</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In the past decade tremendous progress has been made toward a new class of therapeutics termed 'targeted covalent drugs', in which structure-based approaches are employed to create small mols. that inactivate their protein target through targeted covalent attachment to a specific cysteine.  In the kinase field, this approach is demonstrating promise in overcoming the potency, selectivity, and efficacy challenges currently faced by reversible kinase inhibitors, with several advancing into late stage clin. testing.  This design paradigm has been successfully applied to making drug candidates for epidermal growth factor receptor (EGFR), Her2, and Bruton's tyrosine kinase (Btk).  Here we review recent pre-clin. and clin. advances with targeted covalent kinase inhibitors, and the potential for broader application of the approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPQb40Eok-vbVg90H21EOLACvtfcHk0lis2C0CzAj6JA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtr8%253D&md5=ee3b8b9e0c6ec317f975a426cf08428f</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.06.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.06.168%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DKluge%26aufirst%3DA.%2BF.%26atitle%3DTargeted%2520covalent%2520drugs%2520of%2520the%2520kinase%2520family%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26issue%3D4%26spage%3D475%26epage%3D480%26doi%3D10.1016%2Fj.cbpa.2010.06.168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span> </span><span class="NLM_article-title">Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers</span> <span class="citation_source-journal">J. Natl. Compr. Cancer Network</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">â</span> <span class="NLM_lpage">169</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=23411383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFehurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=161-169&author=H.+A.+Yuauthor=G.+J.+Riely&title=Second-generation+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+in+lung+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4dR"><div class="casContent"><span class="casTitleNuber">4d</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers</span></div><div class="casAuthors">Yu, Helena A.; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Comprehensive Cancer Network</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-169</span>CODEN:
                <span class="NLM_cas:coden">JNCCA4</span>;
        ISSN:<span class="NLM_cas:issn">1540-1405</span>.
    
            (<span class="NLM_cas:orgname">Harborside Press</span>)
        </div><div class="casAbstract">A review.  EGFR mutations identify patients who are more likely to respond to treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) than cytotoxic chemotherapy.  The distinct success of the first-generation EGFR TKIs erlotinib and gefitinib has been accompanied by the observation that acquired resistance to these treatments develops after a median of 1 yr of treatment.  Newer, second-generation EGFR TKIs have been developed with the intent to delay or overcome acquired resistance by the broader inhibition of kinases (eg, HER2 and vascular endothelial growth factor receptor) and/or altering the interactions with EGFR through irreversibly binding to the kinase domain.  This article discusses many of these agents (including afatinib, dacomitinib, XL647, AP26113, and CO-1686) which have the potential for greater efficacy compared with first-generation EGFR TKIs, and may also have clin. activity against other oncogenic mutations within the EGFR family, including HER2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7jw642CNY4LVg90H21EOLACvtfcHk0liW2yKKihsWHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFehurk%253D&md5=b6c03450a9e9f5835de035a1620875bb</span></div><a href="/servlet/linkout?suffix=cit4d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DSecond-generation%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520lung%2520cancers%26jtitle%3DJ.%2520Natl.%2520Compr.%2520Cancer%2520Network%26date%3D2013%26volume%3D11%26spage%3D161%26epage%3D169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naumov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">PF-00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">11924</span><span class="NLM_x">â</span> <span class="NLM_lpage">11932</span><span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-07-1885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1158%2F0008-5472.CAN-07-1885" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11924-11932&issue=24&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=C.+M.+Galeauthor=E.+Lifshitsauthor=A.+J.+Gonzalesauthor=T.+Shimamuraauthor=F.+Zhaoauthor=P.+W.+Vincentauthor=G.+N.+Naumovauthor=J.+E.+Bradnerauthor=I.+W.+Althausauthor=L.+Gandhiauthor=G.+I.+Shapiroauthor=J.+M.+Nelsonauthor=J.+V.+Heymachauthor=M.+Meyersonauthor=K.+K.+Wongauthor=P.+A.+Janne&title=PF-00299804%2C+an+irreversible+pan-ERBB+inhibitor%2C+is+effective+in+lung+cancer+models+with+EGFR+and+ERBB2+mutations+that+are+resistant+to+gefitinib&doi=10.1158%2F0008-5472.CAN-07-1885"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1885%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DGale%26aufirst%3DC.%2BM.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DNaumov%26aufirst%3DG.%2BN.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DPF-00299804%252C%2520an%2520irreversible%2520pan-ERBB%2520inhibitor%252C%2520is%2520effective%2520in%2520lung%2520cancer%2520models%2520with%2520EGFR%2520and%2520ERBB2%2520mutations%2520that%2520are%2520resistant%2520to%2520gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26issue%3D24%26spage%3D11924%26epage%3D11932%26doi%3D10.1158%2F0008-5472.CAN-07-1885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicer, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fakhoury, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, F. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivault, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlosser, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trachet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tecle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 20. Optimization of substituted quinazoline and pyrido[3,4-<i>d</i>]pyrimidine derivatives as orally active, irreversible inhibitors of the epidermal growth factor receptor family</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">8103</span><span class="NLM_x">â</span> <span class="NLM_lpage">8124</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00883</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00883" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8103-8124&issue=17&author=J.+B.+Smaillauthor=A.+J.+Gonzalesauthor=J.+A.+Spicerauthor=H.+Leeauthor=J.+E.+Reedauthor=K.+Sextonauthor=I.+W.+Althausauthor=T.+Zhuauthor=S.+L.+Blackauthor=A.+Blaserauthor=W.+A.+Dennyauthor=P.+A.+Ellisauthor=S.+Fakhouryauthor=P.+J.+Harveyauthor=K.+Hookauthor=F.+O.+McCarthyauthor=B.+D.+Palmerauthor=F.+Rivaultauthor=K.+Schlosserauthor=T.+Ellisauthor=A.+M.+Thompsonauthor=E.+Trachetauthor=R.+T.+Wintersauthor=H.+Tecleauthor=A.+Bridges&title=Tyrosine+kinase+inhibitors.+20.+Optimization+of+substituted+quinazoline+and+pyrido%5B3%2C4-d%5Dpyrimidine+derivatives+as+orally+active%2C+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor+family&doi=10.1021%2Facs.jmedchem.6b00883"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00883%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DSpicer%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DReed%26aufirst%3DJ.%2BE.%26aulast%3DSexton%26aufirst%3DK.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBlack%26aufirst%3DS.%2BL.%26aulast%3DBlaser%26aufirst%3DA.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DFakhoury%26aufirst%3DS.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DHook%26aufirst%3DK.%26aulast%3DMcCarthy%26aufirst%3DF.%2BO.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DRivault%26aufirst%3DF.%26aulast%3DSchlosser%26aufirst%3DK.%26aulast%3DEllis%26aufirst%3DT.%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DTrachet%26aufirst%3DE.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DBridges%26aufirst%3DA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252020.%2520Optimization%2520of%2520substituted%2520quinazoline%2520and%2520pyrido%255B3%252C4-d%255Dpyrimidine%2520derivatives%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520family%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D17%26spage%3D8103%26epage%3D8124%26doi%3D10.1021%2Facs.jmedchem.6b00883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lelais, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epple, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsilje, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, Y. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNeill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anumolu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badiger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiDonato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juarez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manuia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groessl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasibhatla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isbell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spraggon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P. Y.</span><span> </span><span class="NLM_article-title">Discovery of (<i>R</i>,<i>E</i>)-<i>N</i>-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1<i>H</i>-benzo[<i>d</i>]imid azol-2-yl)-2-methylisonicotinamide (EGF816), a novel, potent, and WT sparing covalent inhibitor of oncogenic (L858R, ex19del) and resistant (T790M) EGFR mutants for the treatment of EGFR mutant non-small-cell lung cancers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">6671</span><span class="NLM_x">â</span> <span class="NLM_lpage">6689</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01985</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01985" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOgu77P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6671-6689&issue=14&author=G.+Lelaisauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=Y.+O.+Longauthor=M.+McNeillauthor=B.+Chenauthor=W.+Luauthor=J.+Anumoluauthor=S.+Badigerauthor=B.+Bursulayaauthor=M.+DiDonatoauthor=R.+Fongauthor=J.+Juarezauthor=J.+Liauthor=M.+Manuiaauthor=D.+E.+Masonauthor=P.+Gordonauthor=T.+Groesslauthor=K.+Johnsonauthor=Y.+Jiaauthor=S.+Kasibhatlaauthor=C.+Liauthor=J.+Isbellauthor=G.+Spraggonauthor=S.+Benderauthor=P.+Y.+Michellys&title=Discovery+of+%28R%2CE%29-N-%287-Chloro-1-%281-%5B4-%28dimethylamino%29but-2-enoyl%5Dazepan-3-yl%29-1H-benzo%5Bd%5Dimid+azol-2-yl%29-2-methylisonicotinamide+%28EGF816%29%2C+a+novel%2C+potent%2C+and+WT+sparing+covalent+inhibitor+of+oncogenic+%28L858R%2C+ex19del%29+and+resistant+%28T790M%29+EGFR+mutants+for+the+treatment+of+EGFR+mutant+non-small-cell+lung+cancers&doi=10.1021%2Facs.jmedchem.5b01985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers</span></div><div class="casAuthors">Lelais, Gerald; Epple, Robert; Marsilje, Thomas H.; Long, Yun O.; McNeill, Matthew; Chen, Bei; Lu, Wenshuo; Anumolu, Jaganmohan; Badiger, Sangamesh; Bursulaya, Badry; DiDonato, Michael; Fong, Rina; Juarez, Jose; Li, Jie; Manuia, Mari; Mason, Daniel E.; Gordon, Perry; Groessl, Todd; Johnson, Kevin; Jia, Yong; Kasibhatla, Shailaja; Li, Chun; Isbell, John; Spraggon, Glen; Bender, Steven; Michellys, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6671-6689</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Over the past decade, first and second generation EGFR inhibitors have significantly improved outcomes for lung cancer patients with activating mutations in EGFR.  However, both resistance through a secondary T790M mutation at the gatekeeper residue and dose-limiting toxicities from wild-type (WT) EGFR inhibition ultimately limit the full potential of these therapies to control mutant EGFR-driven tumors and new therapies are urgently needed.  Herein, we describe our approach toward the discovery of 47 (EGF816, nazartinib), a novel, covalent mutant-selective EGFR inhibitor with equipotent activity on both oncogenic and T790M-resistant EGFR mutations.  Through mol. docking studies we converted a mutant-selective high-throughput screening hit (7) into a no. of targeted covalent EGFR inhibitors with equipotent activity across mutants EGFR and good WT-EGFR selectivity.  We used an abbreviated in vivo efficacy study for prioritizing compds. with good tolerability and efficacy that ultimately led to the selection of 47 as the clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpcKsqbwkyp7Vg90H21EOLACvtfcHk0liW2yKKihsWHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOgu77P&md5=c106545d878ab3d675644b47099668a0</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01985%26sid%3Dliteratum%253Aachs%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DLong%26aufirst%3DY.%2BO.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DAnumolu%26aufirst%3DJ.%26aulast%3DBadiger%26aufirst%3DS.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DFong%26aufirst%3DR.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DMason%26aufirst%3DD.%2BE.%26aulast%3DGordon%26aufirst%3DP.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DIsbell%26aufirst%3DJ.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26atitle%3DDiscovery%2520of%2520%2528R%252CE%2529-N-%25287-Chloro-1-%25281-%255B4-%2528dimethylamino%2529but-2-enoyl%255Dazepan-3-yl%2529-1H-benzo%255Bd%255Dimid%2520azol-2-yl%2529-2-methylisonicotinamide%2520%2528EGF816%2529%252C%2520a%2520novel%252C%2520potent%252C%2520and%2520WT%2520sparing%2520covalent%2520inhibitor%2520of%2520oncogenic%2520%2528L858R%252C%2520ex19del%2529%2520and%2520resistant%2520%2528T790M%2529%2520EGFR%2520mutants%2520for%2520the%2520treatment%2520of%2520EGFR%2520mutant%2520non-small-cell%2520lung%2520cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D14%26spage%3D6671%26epage%3D6689%26doi%3D10.1021%2Facs.jmedchem.5b01985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine(790) --> methionine(790) mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">2711</span><span class="NLM_x">â</span> <span class="NLM_lpage">2723</span><span class="refDoi">Â DOI: 10.1021/jm201591k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2711-2723&issue=6&author=S.+Changauthor=L.+Zhangauthor=S.+Xuauthor=J.+Luoauthor=X.+Luauthor=Z.+Zhangauthor=T.+Xuauthor=Y.+Liuauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=M.+Gengauthor=J.+Dingauthor=D.+Peiauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+conformationally+constrained+inhibitors+targeting+epidermal+growth+factor+receptor+threonine%28790%29+%2D%2D%3E+methionine%28790%29+mutant&doi=10.1021%2Fjm201591k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1021%2Fjm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520conformationally%2520constrained%2520inhibitors%2520targeting%2520epidermal%2520growth%2520factor%2520receptor%2520threonine%2528790%2529%2520--%253E%2520methionine%2528790%2529%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D6%26spage%3D2711%26epage%3D2723%26doi%3D10.1021%2Fjm201591k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Sogabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cary, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span> </span><span class="NLM_article-title">Structure-based approach for the discovery of pyrrolo[3,2-<i>d</i>]pyrimidine-based EGFR T790M/L858R mutant inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">201</span><span class="NLM_x">â</span> <span class="NLM_lpage">205</span><span class="refDoi">Â DOI: 10.1021/ml300327z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300327z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=201-205&issue=2&author=S.+Sogabeauthor=Y.+Kawakitaauthor=S.+Igakiauthor=H.+Iwataauthor=H.+Mikiauthor=D.+R.+Caryauthor=T.+Takagiauthor=S.+Takagiauthor=Y.+Ohtaauthor=T.+Ishikawa&title=Structure-based+approach+for+the+discovery+of+pyrrolo%5B3%2C2-d%5Dpyrimidine-based+EGFR+T790M%2FL858R+mutant+inhibitors&doi=10.1021%2Fml300327z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1021%2Fml300327z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300327z%26sid%3Dliteratum%253Aachs%26aulast%3DSogabe%26aufirst%3DS.%26aulast%3DKawakita%26aufirst%3DY.%26aulast%3DIgaki%26aufirst%3DS.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DCary%26aufirst%3DD.%2BR.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DTakagi%26aufirst%3DS.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DStructure-based%2520approach%2520for%2520the%2520discovery%2520of%2520pyrrolo%255B3%252C2-d%255Dpyrimidine-based%2520EGFR%2520T790M%252FL858R%2520mutant%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26issue%3D2%26spage%3D201%26epage%3D205%26doi%3D10.1021%2Fml300327z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x"> (</span><span class="NLM_issue">7276</span><span class="NLM_x">) </span> <span class="NLM_fpage">1070</span><span class="NLM_x">â</span> <span class="NLM_lpage">1074</span><span class="refDoi">Â DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&issue=7276&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6dR"><div class="casContent"><span class="casTitleNuber">6d</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0liJ-FP2CiFf4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26issue%3D7276%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for EGFR-T790M</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">638</span><span class="NLM_x">â</span> <span class="NLM_lpage">643</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2010.12.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1016%2Fj.bmcl.2010.12.036" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=638-643&issue=2&author=W.+Zhouauthor=D.+Ercanauthor=P.+A.+Janneauthor=N.+S.+Gray&title=Discovery+of+selective+irreversible+inhibitors+for+EGFR-T790M&doi=10.1016%2Fj.bmcl.2010.12.036"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.036%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520EGFR-T790M%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D2%26spage%3D638%26epage%3D643%26doi%3D10.1016%2Fj.bmcl.2010.12.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Finlay, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethel, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grist, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassall, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemmitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waring, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrigley, G. L.</span><span> </span><span class="NLM_article-title">Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">20</span><span class="NLM_x">) </span> <span class="NLM_fpage">8249</span><span class="NLM_x">â</span> <span class="NLM_lpage">8267</span><span class="refDoi">Â DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&issue=20&author=M.+R.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+potent+and+selective+EGFR+inhibitor+%28AZD9291%29+of+both+sensitizing+and+T790M+resistance+mutations+that+spares+the+wild+type+form+of+the+receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6fR"><div class="casContent"><span class="casTitleNuber">6f</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0lh1WtwNKHCAKw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit6f&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520EGFR%2520inhibitor%2520%2528AZD9291%2529%2520of%2520both%2520sensitizing%2520and%2520T790M%2520resistance%2520mutations%2520that%2520spares%2520the%2520wild%2520type%2520form%2520of%2520the%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D20%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjin, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.,  St</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kalken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1404</span><span class="NLM_x">â</span> <span class="NLM_lpage">1415</span><span class="refDoi">Â DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&issue=12&author=A.+O.+Walterauthor=R.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St.+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M-mediated+resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6gR"><div class="casContent"><span class="casTitleNuber">6g</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lh1WtwNKHCAKw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit6g&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt.%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M-mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26issue%3D12%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Barf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptein, A.</span><span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors: balancing the benefits and risks</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">6243</span><span class="NLM_x">â</span> <span class="NLM_lpage">6262</span><span class="refDoi">Â DOI: 10.1021/jm3003203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&issue=14&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+protein+kinase+inhibitors%3A+balancing+the+benefits+and+risks&doi=10.1021%2Fjm3003203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0lh1WtwNKHCAKw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%253A%2520balancing%2520the%2520benefits%2520and%2520risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D14%26spage%3D6243%26epage%3D6262%26doi%3D10.1021%2Fjm3003203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Mah, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafer, C. M.</span><span> </span><span class="NLM_article-title">Drug discovery considerations in the development of covalent inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">33</span><span class="NLM_x">â</span> <span class="NLM_lpage">39</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2013.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1016%2Fj.bmcl.2013.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=24314671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOlsr3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=33-39&issue=1&author=R.+Mahauthor=J.+R.+Thomasauthor=C.+M.+Shafer&title=Drug+discovery+considerations+in+the+development+of+covalent+inhibitors&doi=10.1016%2Fj.bmcl.2013.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery considerations in the development of covalent inhibitors</span></div><div class="casAuthors">Mah, Robert; Thomas, Jason R.; Shafer, Cynthia M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-39</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In recent years, the no. of drug candidates with a covalent mechanism of action progressing through clin. trials or being approved by the FDA has increased significantly.  And as interest in covalent inhibitors has increased, the tech. challenges for characterizing and optimizing these inhibitors have become evident.  A no. of new tools have been developed to aid this process, but these have not gained wide-spread use.  This review will highlight a no. of methods and tools useful for prosecuting covalent inhibitor drug discovery programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7dY63LHbEhLVg90H21EOLACvtfcHk0lizF8YNe4hS8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOlsr3O&md5=9407bcb76e83065f5a56a97b63547ede</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DMah%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DJ.%2BR.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26atitle%3DDrug%2520discovery%2520considerations%2520in%2520the%2520development%2520of%2520covalent%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D1%26spage%3D33%26epage%3D39%26doi%3D10.1016%2Fj.bmcl.2013.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><div class="note"><p class="first last">For a discussion of a purine-derived reversible EGFR inhibitor, see:</p></div><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, X.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.-Y.</span><span> </span><span class="NLM_article-title">Structural optimization and structureâactivity relationships of <i>N</i><sup>2</sup>-(4-(4-Methylpiperazin-1-yl)phenyl)-<i>N</i><sup>8</sup>-phenyl-9<i>H</i>-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">10685</span><span class="NLM_x">â</span> <span class="NLM_lpage">10699</span><span class="refDoi">Â DOI: 10.1021/jm301365e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301365e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10685-10699&issue=23&author=J.+Yangauthor=L.-J.+Wangauthor=J.-J.+Liuauthor=L.+Zhongauthor=R.-L.+Zhengauthor=Y.+Xuauthor=P.+Jiauthor=C.-H.+Zhangauthor=W.-J.+Wangauthor=X.-D.+Linauthor=L.-L.+Liauthor=Y.-Q.+Weiauthor=S.-Y.+Yang&title=Structural+optimization+and+structure%E2%80%93activity+relationships+of+N2-%284-%284-Methylpiperazin-1-yl%29phenyl%29-N8-phenyl-9H-purine-2%2C8-diamine+derivatives%2C+a+new+class+of+reversible+kinase+inhibitors+targeting+both+EGFR-activating+and+resistance+mutations&doi=10.1021%2Fjm301365e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm301365e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301365e%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.-J.%26aulast%3DLiu%26aufirst%3DJ.-J.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DR.-L.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DC.-H.%26aulast%3DWang%26aufirst%3DW.-J.%26aulast%3DLin%26aufirst%3DX.-D.%26aulast%3DLi%26aufirst%3DL.-L.%26aulast%3DWei%26aufirst%3DY.-Q.%26aulast%3DYang%26aufirst%3DS.-Y.%26atitle%3DStructural%2520optimization%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520N2-%25284-%25284-Methylpiperazin-1-yl%2529phenyl%2529-N8-phenyl-9H-purine-2%252C8-diamine%2520derivatives%252C%2520a%2520new%2520class%2520of%2520reversible%2520kinase%2520inhibitors%2520targeting%2520both%2520EGFR-activating%2520and%2520resistance%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D23%26spage%3D10685%26epage%3D10699%26doi%3D10.1021%2Fjm301365e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Schwartz, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzmic, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergqvist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolanos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almaden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">173</span><span class="NLM_x">â</span> <span class="NLM_lpage">178</span><span class="refDoi">Â DOI: 10.1073/pnas.1313733111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1073%2Fpnas.1313733111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=24347635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=173-178&issue=1&author=P.+A.+Schwartzauthor=P.+Kuzmicauthor=J.+Solowiejauthor=S.+Bergqvistauthor=B.+Bolanosauthor=C.+Almadenauthor=A.+Nagataauthor=K.+Ryanauthor=J.+Fengauthor=D.+Dalvieauthor=J.+C.+Kathauthor=M.+Xuauthor=R.+Waniauthor=B.+W.+Murray&title=Covalent+EGFR+inhibitor+analysis+reveals+importance+of+reversible+interactions+to+potency+and+mechanisms+of+drug+resistance&doi=10.1073%2Fpnas.1313733111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span></div><div class="casAuthors">Schwartz, Phillip A.; Kuzmic, Petr; Solowiej, James; Bergqvist, Simon; Bolanos, Ben; Almaden, Chau; Nagata, Asako; Ryan, Kevin; Feng, Junli; Dalvie, Deepak; Kath, John C.; Xu, Meirong; Wani, Revati; Murray, Brion William</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">173-178</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Covalent inhibition is a reemerging paradigm in kinase drug design, but the roles of inhibitor binding affinity and chem. reactivity in overall potency are not well-understood.  To characterize the underlying mol. processes at a microscopic level and det. the appropriate kinetic consts., specialized exptl. design and advanced numerical integration of differential equations are developed.  Previously uncharacterized investigational covalent drugs reported here are shown to be extremely effective epidermal growth factor receptor (EGFR) inhibitors (kinact/Ki in the range 105-107 M-1s-1), despite their low specific reactivity (kinact â¤ 2.1 Ã 10-3 s-1), which is compensated for by high binding affinities (Ki < 1 nM).  For inhibitors relying on reactivity to achieve potency, noncovalent enzyme-inhibitor complex partitioning between inhibitor dissocn. and bond formation is central.  Interestingly, reversible binding affinity of EGFR covalent inhibitors is highly correlated with antitumor cell potency.  Furthermore, cellular potency for a subset of covalent inhibitors can be accounted for solely through reversible interactions.  One reversible interaction is between EGFR-Cys797 nucleophile and the inhibitor's reactive group, which may also contribute to drug resistance.  Because covalent inhibitors target a cysteine residue, the effects of its oxidn. on enzyme catalysis and inhibitor pharmacol. are characterized.  Oxidn. of the EGFR cysteine nucleophile does not alter catalysis but has widely varied effects on inhibitor potency depending on the EGFR context (e.g., oncogenic mutations), type of oxidn. (sulfinylation or glutathiolation), and inhibitor architecture.  These methods, parameters, and insights provide a rational framework for assessing and designing effective covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTpPuRq8MwCLVg90H21EOLACvtfcHk0lizF8YNe4hS8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D&md5=47197c5e7876a238eefb2e8e7de305ea</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1313733111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1313733111%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DP.%2BA.%26aulast%3DKuzmic%26aufirst%3DP.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBolanos%26aufirst%3DB.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWani%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DCovalent%2520EGFR%2520inhibitor%2520analysis%2520reveals%2520importance%2520of%2520reversible%2520interactions%2520to%2520potency%2520and%2520mechanisms%2520of%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26issue%3D1%26spage%3D173%26epage%3D178%26doi%3D10.1073%2Fpnas.1313733111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span> </span><span class="NLM_article-title">Should the incorporation of structural alerts be restricted in drug design? An analysis of structure-toxicity trends with aniline-based drugs</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">438</span><span class="NLM_x">â</span> <span class="NLM_lpage">464</span><span class="refDoi">Â DOI: 10.2174/0929867321666141112122118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.2174%2F0929867321666141112122118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=25388012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSrtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=438-464&issue=4&author=A.+S.+Kalgutkar&title=Should+the+incorporation+of+structural+alerts+be+restricted+in+drug+design%3F+An+analysis+of+structure-toxicity+trends+with+aniline-based+drugs&doi=10.2174%2F0929867321666141112122118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Should the Incorporation of Structural Alerts be Restricted in Drug Design? An Analysis of Structure-Toxicity Trends with Aniline-Based Drugs</span></div><div class="casAuthors">Kalgutkar, A. S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">438-464</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Certain idiosyncratic adverse drug reactions (IADRs) can be triggered by electrophilic protein-reactive metabolites that are formed in the process of drug metab.  While methodologies (e.g., structural alert concept in drug design, glutathione (GSH) trapping, and protein covalent binding) for examg. reactive metabolite (RM) formation are available, predicting the IADR potential applying these parameters remains a significant challenge.  The present work examines toxicity trends assocd. with the aniline structural alert in the top 200 prescribed drugs of 2011 and recently approved (2009-2013) small mol. drugs, in relation with 30 aniline-based drugs withdrawn from com. use or assocd. with a black box warning for IADRs.  The aniline sub-structure was found in several drugs from the toxic, mostprescribed, and recently approved category.  RMs resulting from the bioactivation of the aniline alert was also noted in the three categories chosen for comparison.  A major discriminator between the toxic drugs and the majority of drugs in the most-prescribed list, however, was the daily dose - drugs most frequented assocd. with IADRs were the ones with higher daily doses (exceeding hundreds of milligrams).  A greater tolerance for IADRs was also noted with certain drugs intended to treat rare, unmet medical needs (e.g., cancer).  Overall, the anal. suggests that optimization of pharmacol. potency and pharmacokinetics that would lead to a lower daily dose, and therefore, a lower body burden of parent drug/metabolites, should be taken into consideration in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfHSM4D4TO37Vg90H21EOLACvtfcHk0ljPwSYAvbRSDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSrtbY%253D&md5=c60bd0b64f0020b87e32c07b1dc8a052</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F0929867321666141112122118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867321666141112122118%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DShould%2520the%2520incorporation%2520of%2520structural%2520alerts%2520be%2520restricted%2520in%2520drug%2520design%253F%2520An%2520analysis%2520of%2520structure-toxicity%2520trends%2520with%2520aniline-based%2520drugs%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26issue%3D4%26spage%3D438%26epage%3D464%26doi%3D10.2174%2F0929867321666141112122118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span> </span><span class="NLM_article-title">Role of physiochemical properties and ligand lipophilicity efficiency in addressing drug safety risks</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">380</span><span class="NLM_x">â</span> <span class="NLM_lpage">391</span><span class="refDoi">Â DOI: 10.1016/S0065-7743(10)45023-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1016%2FS0065-7743%2810%2945023-X" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=380-391&author=M.+P.+Edwardsauthor=D.+A.+Price&title=Role+of+physiochemical+properties+and+ligand+lipophilicity+efficiency+in+addressing+drug+safety+risks&doi=10.1016%2FS0065-7743%2810%2945023-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2810%2945023-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-7743%252810%252945023-X%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26atitle%3DRole%2520of%2520physiochemical%2520properties%2520and%2520ligand%2520lipophilicity%2520efficiency%2520in%2520addressing%2520drug%2520safety%2520risks%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D380%26epage%3D391%26doi%3D10.1016%2FS0065-7743%2810%2945023-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Krenske, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houk, K. N.</span><span> </span><span class="NLM_article-title">Transition states and energetics of nucleophilic additions of thiols to substituted alpha,beta-unsaturated ketones: substituent effects involve enone stabilization, product branching, and solvation</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">5074</span><span class="NLM_x">â</span> <span class="NLM_lpage">5081</span><span class="refDoi">Â DOI: 10.1021/jo200761w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo200761w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2011&pages=5074-5081&issue=12&author=E.+H.+Krenskeauthor=R.+C.+Petterauthor=Z.+Zhuauthor=K.+N.+Houk&title=Transition+states+and+energetics+of+nucleophilic+additions+of+thiols+to+substituted+alpha%2Cbeta-unsaturated+ketones%3A+substituent+effects+involve+enone+stabilization%2C+product+branching%2C+and+solvation&doi=10.1021%2Fjo200761w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjo200761w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo200761w%26sid%3Dliteratum%253Aachs%26aulast%3DKrenske%26aufirst%3DE.%2BH.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DHouk%26aufirst%3DK.%2BN.%26atitle%3DTransition%2520states%2520and%2520energetics%2520of%2520nucleophilic%2520additions%2520of%2520thiols%2520to%2520substituted%2520alpha%252Cbeta-unsaturated%2520ketones%253A%2520substituent%2520effects%2520involve%2520enone%2520stabilization%252C%2520product%2520branching%252C%2520and%2520solvation%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2011%26volume%3D76%26issue%3D12%26spage%3D5074%26epage%3D5081%26doi%3D10.1021%2Fjo200761w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hunter, L.</span><span> </span><span class="NLM_article-title">The C-F bond as a conformational tool in organic and biological chemistry</span>.  <span class="citation_source-journal">Beilstein J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span>, No. 38. doi: <span class="refDoi">Â DOI: 10.3762/bjoc.6.38</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.3762%2Fbjoc.6.38" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=20502650" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&author=L.+Hunter&title=The+C-F+bond+as+a+conformational+tool+in+organic+and+biological+chemistry&doi=10.3762%2Fbjoc.6.38"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.3762%2Fbjoc.6.38&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3762%252Fbjoc.6.38%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DL.%26atitle%3DThe%2520C-F%2520bond%2520as%2520a%2520conformational%2520tool%2520in%2520organic%2520and%2520biological%2520chemistry%26jtitle%3DBeilstein%2520J.%2520Org.%2520Chem.%26date%3D2010%26volume%3D6%26doi%3D10.3762%2Fbjoc.6.38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rablen, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hrovat, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borden, W. T.</span><span> </span><span class="NLM_article-title">Is hyperconjugation responsible for the gauche effect in 1-fluoropropane and other 2-substituted-1-fluoroethanes?</span> <span class="citation_source-journal">J. Chem. Soc., Perkin Trans. 2</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_fpage">1719</span><span class="NLM_x">â</span> <span class="NLM_lpage">1726</span><span class="refDoi">Â DOI: 10.1039/A901974J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1039%2FA901974J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADyaK1MXks1GgtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&pages=1719-1726&author=P.+R.+Rablenauthor=R.+W.+Hoffmannauthor=D.+A.+Hrovatauthor=W.+T.+Borden&title=Is+hyperconjugation+responsible+for+the+gauche+effect+in+1-fluoropropane+and+other+2-substituted-1-fluoroethanes%3F&doi=10.1039%2FA901974J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Is hyperconjugation responsible for the "gauche effect" in 1-fluoropropane and other 2-substituted-1-fluoroethanes?</span></div><div class="casAuthors">Rablen, Paul R.; Hoffmann, Reinhard W.; Hrovat, David A.; Borden, Weston Thatcher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1719-1726</span>CODEN:
                <span class="NLM_cas:coden">JCPKBH</span>;
        ISSN:<span class="NLM_cas:issn">0300-9580</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The energies and geometries of a series of 2-substituted-1-fluoroethanes were computed at the MP2/6-311++G**(6D)//MP2/6-31+G* level of theory for both the maxima and min. of the rotation about the C-C bond.  The results did not support the predictions of a hyperconjugative model, that both 1,2-difluoroethane and 1-chloro-2-fluoroethane would strongly prefer a gauche conformation, and that 1-fluoro-2-silylethane would strongly prefer an anti conformation.  The existence of competing electrostatic interactions between the fluorine and the substituents at C-2 was indicated by the detailed geometries of the gauche conformers and by the calcd. sensitivity of the gauche-anti energy differences to the presence of a polar solvent.  However, Fourier analyses of the torsional potential energies were wholly consistent with hyperconjugative electron donation into the C-F Ï* orbital contributing to the conformational preferences of these 1-fluoroethanes.  Fourier analyses also showed that hyperconjugation contributes to the small variations in C-C and C-F bond lengths and in fluorine at. charges that were computed.  The torsional potential energies, variations in geometry and at. charge, and sensitivity to solvent were all in accord with the expected ranking of hyperconjugative electron donating ability of bonds to carbon, C-Si > C-H > C-C > C-Cl > C-F.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ6jY2idjLdbVg90H21EOLACvtfcHk0ljPwSYAvbRSDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXks1GgtbY%253D&md5=35c634a19b21a591229978e51125ff11</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1039%2FA901974J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FA901974J%26sid%3Dliteratum%253Aachs%26aulast%3DRablen%26aufirst%3DP.%2BR.%26aulast%3DHoffmann%26aufirst%3DR.%2BW.%26aulast%3DHrovat%26aufirst%3DD.%2BA.%26aulast%3DBorden%26aufirst%3DW.%2BT.%26atitle%3DIs%2520hyperconjugation%2520responsible%2520for%2520the%2520gauche%2520effect%2520in%25201-fluoropropane%2520and%2520other%25202-substituted-1-fluoroethanes%253F%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25202%26date%3D1999%26spage%3D1719%26epage%3D1726%26doi%3D10.1039%2FA901974J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">OâHagan, D.</span><span> </span><span class="NLM_article-title">Understanding organofluorine chemistry. An introduction to the C-F bond</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">308</span><span class="NLM_x">â</span> <span class="NLM_lpage">319</span><span class="refDoi">Â DOI: 10.1039/B711844A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1039%2FB711844A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=18197347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVGnsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2008&pages=308-319&author=D.+O%E2%80%99Hagan&title=Understanding+organofluorine+chemistry.+An+introduction+to+the+C-F+bond&doi=10.1039%2FB711844A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14cR"><div class="casContent"><span class="casTitleNuber">14c</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding organofluorine chemistry. An introduction to the C-F bond</span></div><div class="casAuthors">O'Hagan, David</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">308-319</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Fluorine is the most electroneg. element in the periodic table.  When bound to carbon it forms the strongest bonds in org. chem. and this makes fluorine substitution attractive for the development of pharmaceuticals and a wide range of specialty materials.  Although highly polarized, the C-F bond gains stability from the resultant electrostatic attraction between the polarized CÎ´+ and FÎ´- atoms.  This polarity suppresses lone pair donation from fluorine and in general fluorine is a weak coordinator.  However, the C-F bond has interesting properties which can be understood either in terms of electrostatic/dipole interactions or by considering stereoelectronic interactions with neighboring bonds or lone pairs.  In this tutorial review these fundamental aspects of the C-F bond are explored to rationalize the geometry, conformation and reactivity of individual organofluorine compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKbJH2EG40obVg90H21EOLACvtfcHk0liP_pCX4O79Ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVGnsw%253D%253D&md5=7d4111d3b05c22c8e6df282cf051fccb</span></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1039%2FB711844A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB711844A%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hagan%26aufirst%3DD.%26atitle%3DUnderstanding%2520organofluorine%2520chemistry.%2520An%2520introduction%2520to%2520the%2520C-F%2520bond%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2008%26volume%3D37%26spage%3D308%26epage%3D319%26doi%3D10.1039%2FB711844A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferre, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodsky, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinrich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A.</span><span> </span><span class="NLM_article-title">Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">209</span><span class="NLM_x">â</span> <span class="NLM_lpage">219</span><span class="refDoi">Â DOI: 10.1016/j.str.2012.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1016%2Fj.str.2012.11.014" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=209-219&issue=2&author=K.+S.+Gajiwalaauthor=J.+Fengauthor=R.+Ferreauthor=K.+Ryanauthor=O.+Brodskyauthor=S.+Weinrichauthor=J.+C.+Kathauthor=A.+Stewart&title=Insights+into+the+aberrant+activity+of+mutant+EGFR+kinase+domain+and+drug+recognition&doi=10.1016%2Fj.str.2012.11.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2012.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2012.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DFerre%26aufirst%3DR.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DBrodsky%26aufirst%3DO.%26aulast%3DWeinrich%26aufirst%3DS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DStewart%26aufirst%3DA.%26atitle%3DInsights%2520into%2520the%2520aberrant%2520activity%2520of%2520mutant%2520EGFR%2520kinase%2520domain%2520and%2520drug%2520recognition%26jtitle%3DStructure%26date%3D2013%26volume%3D21%26issue%3D2%26spage%3D209%26epage%3D219%26doi%3D10.1016%2Fj.str.2012.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bissantz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, M.</span><span> </span><span class="NLM_article-title">A medicinal chemistâs guide to molecular interactions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">5061</span><span class="NLM_x">â</span> <span class="NLM_lpage">5084</span><span class="refDoi">Â DOI: 10.1021/jm100112j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100112j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKjtbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5061-5084&issue=14&author=C.+Bissantzauthor=B.+Kuhnauthor=M.+Stahl&title=A+medicinal+chemist%E2%80%99s+guide+to+molecular+interactions&doi=10.1021%2Fjm100112j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">A Medicinal Chemist's Guide to Molecular Interactions</span></div><div class="casAuthors">Bissantz, Caterina; Kuhn, Bernd; Stahl, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5061-5084</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraV8HPbwsihbVg90H21EOLACvtfcHk0liP_pCX4O79Ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKjtbs%253D&md5=f39cf8700267cdc311c73de4d433bab0</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1021%2Fjm100112j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100112j%26sid%3Dliteratum%253Aachs%26aulast%3DBissantz%26aufirst%3DC.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DA%2520medicinal%2520chemist%25E2%2580%2599s%2520guide%2520to%2520molecular%2520interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D14%26spage%3D5061%26epage%3D5084%26doi%3D10.1021%2Fjm100112j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhou, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang, Z.</span><span> </span><span class="NLM_article-title">Fluorine bonding--how does it work in protein-ligand interactions?</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">2344</span><span class="NLM_x">â</span> <span class="NLM_lpage">2355</span><span class="refDoi">Â DOI: 10.1021/ci9002393</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci9002393" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2lur7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=2344-2355&issue=10&author=P.+Zhouauthor=J.+Zouauthor=F.+Tianauthor=Z.+Shang&title=Fluorine+bonding%2D%2Dhow+does+it+work+in+protein-ligand+interactions%3F&doi=10.1021%2Fci9002393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine Bonding - How Does It Work In Protein-Ligand Interactions?</span></div><div class="casAuthors">Zhou, Peng; Zou, Jianwei; Tian, Feifei; Shang, Zhicai</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2344-2355</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although fluorination of pharmacol. active compds. has long been a common strategy to increase their metabolic stability and membrane permeation, the functionality of protein-ligand interactions involving fluorine atoms (fluorine bonding) was only recently recognized in the chem. and biol. communities.  In this study, the geometric characteristics and the energetic behaviors of fluorine bonding were systematically investigated by combining two quite disparate but complementary approaches: X-ray structural anal. and theor. calcns.  We found that the short contacts involving fluorine atoms (generalized fluorine bonding) between proteins and fluorinated ligands are very frequent, and these contacts, compared to those routine hydrogen/halogen bonding, are more similar to sulfur-involved hydrogen bonding obsd. in proteins.  ONIOM-based quantum mechanics/mol. mechanics anal. further revealed that fluorine bonding does play an essential role in protein-ligand binding, albeit the strength of isolated fluorine bonding is quite modest.  Furthermore, 14 quantum mechanics (QM) and mol. mechanics (MM) methods were performed to reproduce fluorine bonding energies obtained at the rigorous MP2/aug-cc-pVDZ level of theory, and the results showed that most QM and very few MM methods perform well in the reproducibility; the MPWLYP functional and MMFF94 force field are recommended to study moderate and large fluorine bonding systems, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsf6h3MdRaPLVg90H21EOLACvtfcHk0liP_pCX4O79Ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2lur7E&md5=3c4539b546dcf207f4bf44a500be1d71</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1021%2Fci9002393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci9002393%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DZou%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DF.%26aulast%3DShang%26aufirst%3DZ.%26atitle%3DFluorine%2520bonding--how%2520does%2520it%2520work%2520in%2520protein-ligand%2520interactions%253F%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26issue%3D10%26spage%3D2344%26epage%3D2355%26doi%3D10.1021%2Fci9002393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Ryckmans, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correia, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, T.</span><span> </span><span class="NLM_article-title">Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A lipophilic efficiency (LipE) analysis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">4406</span><span class="NLM_x">â</span> <span class="NLM_lpage">4409</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.05.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1016%2Fj.bmcl.2009.05.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=19500981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4406-4409&issue=15&author=T.+Ryckmansauthor=M.+P.+Edwardsauthor=V.+A.+Horneauthor=A.+M.+Correiaauthor=D.+R.+Owenauthor=L.+R.+Thompsonauthor=I.+Tranauthor=M.+F.+Tuttauthor=T.+Young&title=Rapid+assessment+of+a+novel+series+of+selective+CB%282%29+agonists+using+parallel+synthesis+protocols%3A+A+lipophilic+efficiency+%28LipE%29+analysis&doi=10.1016%2Fj.bmcl.2009.05.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis</span></div><div class="casAuthors">Ryckmans, Thomas; Edwards, Martin P.; Horne, Val A.; Correia, Ana Monica; Owen, Dafydd R.; Thompson, Lisa R.; Tran, Isabelle; Tutt, Michelle F.; Young, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4406-4409</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of libraries were designed using the 1-(cyclopropylmethyl)-2-alkyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-5-ium templates 2a-b, and Sulfonamide derivs. 11a-n proved to be potent agonists of the CB2 receptor.  Anal. of the Lipophilic Efficiency (LipE) of potent compds. provided new insight for the design of potent, metabolically stable CB2 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1cihq9YHuO7Vg90H21EOLACvtfcHk0lgkgJLN3R9sgw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D&md5=b62d97e5f52a594cfdd510f32d2e566f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.05.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.05.062%26sid%3Dliteratum%253Aachs%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DHorne%26aufirst%3DV.%2BA.%26aulast%3DCorreia%26aufirst%3DA.%2BM.%26aulast%3DOwen%26aufirst%3DD.%2BR.%26aulast%3DThompson%26aufirst%3DL.%2BR.%26aulast%3DTran%26aufirst%3DI.%26aulast%3DTutt%26aufirst%3DM.%2BF.%26aulast%3DYoung%26aufirst%3DT.%26atitle%3DRapid%2520assessment%2520of%2520a%2520novel%2520series%2520of%2520selective%2520CB%25282%2529%2520agonists%2520using%2520parallel%2520synthesis%2520protocols%253A%2520A%2520lipophilic%2520efficiency%2520%2528LipE%2529%2520analysis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D15%26spage%3D4406%26epage%3D4409%26doi%3D10.1016%2Fj.bmcl.2009.05.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deal, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lingardo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Discovery of (10<i>R</i>)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2<i>H</i>-8,4-(metheno)pyrazolo[4,3-<i>h</i>][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">4720</span><span class="NLM_x">â</span> <span class="NLM_lpage">4744</span><span class="refDoi">Â DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&issue=11&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.+L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28metheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+macrocyclic+inhibitor+of+anaplastic+lymphoma+kinase+%28ALK%29+and+c-ros+oncogene+1+%28ROS1%29+with+preclinical+brain+exposure+and+broad-spectrum+potency+against+ALK-resistant+mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0lgkgJLN3R9sgw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-2H-8%252C4-%2528metheno%2529pyrazolo%255B4%252C3-h%255D%255B2%252C5%252C11%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520macrocyclic%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520and%2520c-ros%2520oncogene%25201%2520%2528ROS1%2529%2520with%2520preclinical%2520brain%2520exposure%2520and%2520broad-spectrum%2520potency%2520against%2520ALK-resistant%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D11%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Innocenti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodward, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solanki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwood, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faisal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Haven Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâFee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saville, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matijssen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Montfort, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linardopoulos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoelder, S.</span><span> </span><span class="NLM_article-title">Rapid discovery of pyrido[3,4-<i>d</i>]pyrimidine inhibitors of monopolar spindle kinase 1 (MPS1) using a structure-based hybridization approach</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">3671</span><span class="NLM_x">â</span> <span class="NLM_lpage">3688</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01811</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01811" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3671-3688&issue=8&author=P.+Innocentiauthor=H.+L.+Woodwardauthor=S.+Solankiauthor=S.+Naudauthor=I.+M.+Westwoodauthor=N.+Croninauthor=A.+Hayesauthor=J.+Robertsauthor=A.+T.+Henleyauthor=R.+Bakerauthor=A.+Faisalauthor=G.+W.+Makauthor=G.+Boxauthor=M.+Valentiauthor=A.+De+Haven+Brandonauthor=L.+O%E2%80%99Feeauthor=H.+Savilleauthor=J.+Schmittauthor=B.+Matijssenauthor=R.+Burkeauthor=R.+L.+van+Montfortauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=S.+Linardopoulosauthor=J.+Blaggauthor=S.+Hoelder&title=Rapid+discovery+of+pyrido%5B3%2C4-d%5Dpyrimidine+inhibitors+of+monopolar+spindle+kinase+1+%28MPS1%29+using+a+structure-based+hybridization+approach&doi=10.1021%2Facs.jmedchem.5b01811"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01811%26sid%3Dliteratum%253Aachs%26aulast%3DInnocenti%26aufirst%3DP.%26aulast%3DWoodward%26aufirst%3DH.%2BL.%26aulast%3DSolanki%26aufirst%3DS.%26aulast%3DNaud%26aufirst%3DS.%26aulast%3DWestwood%26aufirst%3DI.%2BM.%26aulast%3DCronin%26aufirst%3DN.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DRoberts%26aufirst%3DJ.%26aulast%3DHenley%26aufirst%3DA.%2BT.%26aulast%3DBaker%26aufirst%3DR.%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3DMak%26aufirst%3DG.%2BW.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DDe%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Fee%26aufirst%3DL.%26aulast%3DSaville%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DJ.%26aulast%3DMatijssen%26aufirst%3DB.%26aulast%3DBurke%26aufirst%3DR.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DLinardopoulos%26aufirst%3DS.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DHoelder%26aufirst%3DS.%26atitle%3DRapid%2520discovery%2520of%2520pyrido%255B3%252C4-d%255Dpyrimidine%2520inhibitors%2520of%2520monopolar%2520spindle%2520kinase%25201%2520%2528MPS1%2529%2520using%2520a%2520structure-based%2520hybridization%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D8%26spage%3D3671%26epage%3D3688%26doi%3D10.1021%2Facs.jmedchem.5b01811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Greshock, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanders, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drolet, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajapakse, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rada, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiscia, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sur, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilodeau, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renger, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kern, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span> </span><span class="NLM_article-title">Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">2631</span><span class="NLM_x">â</span> <span class="NLM_lpage">2635</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.04.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1016%2Fj.bmcl.2016.04.021" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2631-2635&issue=11&author=T.+J.+Greshockauthor=J.+M.+Sandersauthor=R.+E.+Droletauthor=H.+A.+Rajapakseauthor=R.+K.+Changauthor=B.+Kimauthor=V.+L.+Radaauthor=H.+E.+Tisciaauthor=H.+Suauthor=M.+T.+Laiauthor=S.+M.+Surauthor=R.+I.+Sanchezauthor=M.+T.+Bilodeauauthor=J.+J.+Rengerauthor=J.+T.+Kernauthor=J.+A.+McCauley&title=Potent%2C+selective+and+orally+bioavailable+leucine-rich+repeat+kinase+2+%28LRRK2%29+inhibitors&doi=10.1016%2Fj.bmcl.2016.04.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.04.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.04.021%26sid%3Dliteratum%253Aachs%26aulast%3DGreshock%26aufirst%3DT.%2BJ.%26aulast%3DSanders%26aufirst%3DJ.%2BM.%26aulast%3DDrolet%26aufirst%3DR.%2BE.%26aulast%3DRajapakse%26aufirst%3DH.%2BA.%26aulast%3DChang%26aufirst%3DR.%2BK.%26aulast%3DKim%26aufirst%3DB.%26aulast%3DRada%26aufirst%3DV.%2BL.%26aulast%3DTiscia%26aufirst%3DH.%2BE.%26aulast%3DSu%26aufirst%3DH.%26aulast%3DLai%26aufirst%3DM.%2BT.%26aulast%3DSur%26aufirst%3DS.%2BM.%26aulast%3DSanchez%26aufirst%3DR.%2BI.%26aulast%3DBilodeau%26aufirst%3DM.%2BT.%26aulast%3DRenger%26aufirst%3DJ.%2BJ.%26aulast%3DKern%26aufirst%3DJ.%2BT.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26atitle%3DPotent%252C%2520selective%2520and%2520orally%2520bioavailable%2520leucine-rich%2520repeat%2520kinase%25202%2520%2528LRRK2%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D11%26spage%3D2631%26epage%3D2635%26doi%3D10.1016%2Fj.bmcl.2016.04.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Estrada, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker-Glenn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beresford, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominguez, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drummond, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuji, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinheinz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Pichon, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyssikatos, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medhurst, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scearce-Levie, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shore, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, Z. K.</span><span> </span><span class="NLM_article-title">Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">921</span><span class="NLM_x">â</span> <span class="NLM_lpage">936</span><span class="refDoi">Â DOI: 10.1021/jm401654j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401654j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=921-936&issue=3&author=A.+A.+Estradaauthor=B.+K.+Chanauthor=C.+Baker-Glennauthor=A.+Beresfordauthor=D.+J.+Burdickauthor=M.+Chambersauthor=H.+Chenauthor=S.+L.+Dominguezauthor=J.+Dotsonauthor=J.+Drummondauthor=M.+Flagellaauthor=R.+Fujiauthor=A.+Gillauthor=J.+Halladayauthor=S.+F.+Harrisauthor=T.+P.+Heffronauthor=T.+Kleinheinzauthor=D.+W.+Leeauthor=C.+E.+Le+Pichonauthor=X.+Liuauthor=J.+P.+Lyssikatosauthor=A.+D.+Medhurstauthor=J.+G.+Moffatauthor=K.+Nashauthor=K.+Scearce-Levieauthor=Z.+Shengauthor=D.+G.+Shoreauthor=S.+Wongauthor=S.+Zhangauthor=X.+Zhangauthor=H.+Zhuauthor=Z.+K.+Sweeney&title=Discovery+of+highly+potent%2C+selective%2C+and+brain-penetrant+aminopyrazole+leucine-rich+repeat+kinase+2+%28LRRK2%29+small+molecule+inhibitors&doi=10.1021%2Fjm401654j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1021%2Fjm401654j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401654j%26sid%3Dliteratum%253Aachs%26aulast%3DEstrada%26aufirst%3DA.%2BA.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DBaker-Glenn%26aufirst%3DC.%26aulast%3DBeresford%26aufirst%3DA.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DChambers%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DDominguez%26aufirst%3DS.%2BL.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DDrummond%26aufirst%3DJ.%26aulast%3DFlagella%26aufirst%3DM.%26aulast%3DFuji%26aufirst%3DR.%26aulast%3DGill%26aufirst%3DA.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DHarris%26aufirst%3DS.%2BF.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DD.%2BW.%26aulast%3DLe%2BPichon%26aufirst%3DC.%2BE.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26aulast%3DMedhurst%26aufirst%3DA.%2BD.%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26aulast%3DNash%26aufirst%3DK.%26aulast%3DScearce-Levie%26aufirst%3DK.%26aulast%3DSheng%26aufirst%3DZ.%26aulast%3DShore%26aufirst%3DD.%2BG.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26atitle%3DDiscovery%2520of%2520highly%2520potent%252C%2520selective%252C%2520and%2520brain-penetrant%2520aminopyrazole%2520leucine-rich%2520repeat%2520kinase%25202%2520%2528LRRK2%2529%2520small%2520molecule%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D3%26spage%3D921%26epage%3D936%26doi%3D10.1021%2Fjm401654j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney-Pickett, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umland, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gebhard, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Federico, J. J.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varma, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kempshall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Kattan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liston, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troutman, M. D.</span><span> </span><span class="NLM_article-title">Development of a new permeability assay using low-efflux MDCKII cells</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">4974</span><span class="NLM_x">â</span> <span class="NLM_lpage">4985</span><span class="refDoi">Â DOI: 10.1002/jps.22674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1002%2Fjps.22674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=21766308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=4974-4985&issue=11&author=L.+Diauthor=C.+Whitney-Pickettauthor=J.+P.+Umlandauthor=H.+Zhangauthor=X.+Zhangauthor=D.+F.+Gebhardauthor=Y.+Laiauthor=J.+J.+Federicoauthor=R.+E.+Davidsonauthor=R.+Smithauthor=E.+L.+Reynerauthor=C.+Leeauthor=B.+Fengauthor=C.+Rotterauthor=M.+V.+Varmaauthor=S.+Kempshallauthor=K.+Fennerauthor=A.+F.+El-Kattanauthor=T.+E.+Listonauthor=M.+D.+Troutman&title=Development+of+a+new+permeability+assay+using+low-efflux+MDCKII+cells&doi=10.1002%2Fjps.22674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a new permeability assay using low-efflux MDCKII cells</span></div><div class="casAuthors">Di, Li; Whitney-Pickett, Carrie; Umland, John P.; Zhang, Hui; Zhang, Xun; Gebhard, David F.; Lai, Yurong; Federico, James J.; Davidson, Ralph E.; Smith, Russ; Reyner, Eric L.; Lee, Caroline; Feng, Bo; Rotter, Charles; Varma, Manthena V.; Kempshall, Sarah; Fenner, Katherine; El-kattan, Ayman F.; Liston, Theodore E.; Troutman, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4974-4985</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Permeability is an important property of drug candidates.  The Madin-Darby canine kidney cell line (MDCK) permeability assay is widely used and the primary concern of using MDCK cells is the presence of endogenous transporters of nonhuman origin.  The canine P-glycoprotein (Pgp) can interfere with permeability and transporter studies, leading to less reliable data.  A new cell line, MDCKII-LE (low efflux), has been developed by selecting a subpopulation of low-efflux cells from MDCKII-WT using an iterative fluorescence-activated cell sorting technique with calcein-AM as a Pgp and efflux substrate.  MDCKII-LE cells are a subpopulation of MDCKII cells with over 200-fold lower canine Pgp mRNA level and fivefold lower protein level than MDCKII-WT.  MDCKII-LE cells showed less functional efflux activity than MDCKII-WT based on efflux ratios.  Notably, MDCKII-MDR1 showed about 1.5-fold decreased expression of endogenous canine Pgp, suggesting that using the net flux ratio might not completely cancel out the background endogenous transporter activities.  MDCKII-LE cells offer clear advantages over the MDCKII-WT by providing less efflux transporter background signals and minimizing interference from canine Pgp.  The MDCKII-LE apparent permeability values well differentiates compds. from high to medium/low human intestinal absorption and can be used for Biopharmaceutical Classification System.  The MDCKII-LE permeability assay (4-in-1 cassette dosing) is high throughput with good precision, reproducibility, robustness, and cost-effective. Â© 2011 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTVtRmYnbF17Vg90H21EOLACvtfcHk0lj1B7b0LOlsBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D&md5=97f647fc215ea6d04882351ffc912a1e</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1002%2Fjps.22674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22674%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DUmland%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGebhard%26aufirst%3DD.%2BF.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DFederico%26aufirst%3DJ.%2BJ.%26aulast%3DDavidson%26aufirst%3DR.%2BE.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DRotter%26aufirst%3DC.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26atitle%3DDevelopment%2520of%2520a%2520new%2520permeability%2520assay%2520using%2520low-efflux%2520MDCKII%2520cells%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26issue%3D11%26spage%3D4974%26epage%3D4985%26doi%3D10.1002%2Fjps.22674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Varma, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyn, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nkansah, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotter, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney-Pickett, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenner, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Kattan, A. F.</span><span> </span><span class="NLM_article-title">pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1199</span><span class="NLM_x">â</span> <span class="NLM_lpage">1212</span><span class="refDoi">Â DOI: 10.1021/mp2004912</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp2004912" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=1199-1212&issue=5&author=M.+V.+Varmaauthor=I.+Gardnerauthor=S.+J.+Steynauthor=P.+Nkansahauthor=C.+J.+Rotterauthor=C.+Whitney-Pickettauthor=H.+Zhangauthor=L.+Diauthor=M.+Cramauthor=K.+S.+Fennerauthor=A.+F.+El-Kattan&title=pH-Dependent+solubility+and+permeability+criteria+for+provisional+biopharmaceutics+classification+%28BCS+and+BDDCS%29+in+early+drug+discovery&doi=10.1021%2Fmp2004912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery</span></div><div class="casAuthors">Varma, Manthena V.; Gardner, Iain; Steyn, Stefanus J.; Nkansah, Paul; Rotter, Charles J.; Whitney-Pickett, Carrie; Zhang, Hui; Di, Li; Cram, Michael; Fenner, Katherine S.; El-Kattan, Ayman F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1199-1212</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Biopharmaceutics Classification System (BCS) is a scientific framework that provides a basis for predicting the oral absorption of drugs.  These concepts have been extended in the Biopharmaceutics Drug Disposition Classification System (BDDCS) to explain the potential mechanism of drug clearance and understand the effects of uptake and efflux transporters on absorption, distribution, metab., and elimination.  The objective of present work is to establish criteria for provisional biopharmaceutics classification using pH-dependent passive permeability and aq. soly. data generated from high throughput screening methodologies in drug discovery settings.  The apparent permeability across monolayers of clonal cell line of Madin-Darby canine kidney cells, selected for low endogenous efflux transporter expression, was measured for a set of 105 drugs, with known BCS and BDDCS class.  The permeability at apical pH 6.5 for acidic drugs and at pH 7.4 for nonacidic drugs showed a good correlation with the fraction absorbed in human (Fa).  Receiver operating characteristic (ROC) curve anal. was utilized to define the permeability class boundary.  At permeability â¥5 Ã 10-6 cm/s, the accuracy of predicting Fa of â¥0.90 was 87%.  Also, this cutoff showed more than 80% sensitivity and specificity in predicting the literature permeability classes (BCS), and the metab. classes (BDDCS).  The equil. soly. of a subset of 49 drugs was measured in pH 1.2 medium, pH 6.5 phosphate buffer, and in FaSSIF medium (pH 6.5).  Although dose was not considered, good concordance of the measured soly. with BCS and BDDCS soly. class was achieved, when soly. at pH 1.2 was used for acidic compds. and FaSSIF soly. was used for basic, neutral, and zwitterionic compds.  Using a cutoff of 200 Î¼g/mL, the data set suggested a 93% sensitivity and 86% specificity in predicting both the BCS and BDDCS soly. classes.  In conclusion, this study identified pH-dependent permeability and soly. criteria that can be used to assign provisional biopharmaceutics class at early stage of the drug discovery process.  Addnl., such a classification system will enable discovery scientists to assess the potential limiting factors to oral absorption, as well as help predict the drug disposition mechanisms and potential drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr84irw4TD15rVg90H21EOLACvtfcHk0lg0Frb9fVHGtw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D&md5=2bcb29ea512d2e0665973292e4a4a0a3</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1021%2Fmp2004912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp2004912%26sid%3Dliteratum%253Aachs%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DNkansah%26aufirst%3DP.%26aulast%3DRotter%26aufirst%3DC.%2BJ.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DCram%26aufirst%3DM.%26aulast%3DFenner%26aufirst%3DK.%2BS.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26atitle%3DpH-Dependent%2520solubility%2520and%2520permeability%2520criteria%2520for%2520provisional%2520biopharmaceutics%2520classification%2520%2528BCS%2520and%2520BDDCS%2529%2520in%2520early%2520drug%2520discovery%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26issue%3D5%26spage%3D1199%26epage%3D1212%26doi%3D10.1021%2Fmp2004912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Behenna, D. C.; Cheng, H.; Cho-Schultz, S.; Johnson, T. O.; Kath, J. C.; Nagata, A.; Nair, S. K.; Planken, S.</span><span> </span><span class="NLM_article-title">Purine derivatives</span>. Pfizer Patent US 2015/0141402,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=D.+C.+Behenna&author=H.+Cheng&author=S.+Cho-Schultz&author=T.+O.+Johnson&author=J.+C.+Kath&author=A.+Nagata&author=S.+K.+Nair&author=S.+Planken&title=Purine+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBehenna%26aufirst%3DD.%2BC.%26atitle%3DPurine%2520derivatives%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Perez-Soler, R.</span><span> </span><span class="NLM_article-title">The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">12-2</span><span class="NLM_x">) </span> <span class="NLM_fpage">4238s</span><span class="NLM_x">â</span> <span class="NLM_lpage">4240s</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-040017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1158%2F1078-0432.CCR-040017" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=4238s-4240s&issue=12-2&author=R.+Perez-Soler&title=The+role+of+erlotinib+%28Tarceva%2C+OSI+774%29+in+the+treatment+of+non-small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-040017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-040017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-040017%26sid%3Dliteratum%253Aachs%26aulast%3DPerez-Soler%26aufirst%3DR.%26atitle%3DThe%2520role%2520of%2520erlotinib%2520%2528Tarceva%252C%2520OSI%2520774%2529%2520in%2520the%2520treatment%2520of%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26issue%3D12-2%26spage%3D4238s%26epage%3D4240s%26doi%3D10.1158%2F1078-0432.CCR-040017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Lanning, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitby, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dix, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douhan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hett, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joslyn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niessen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnute, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulce, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteley, L. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayward, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cravatt, B. F.</span><span> </span><span class="NLM_article-title">A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">760</span><span class="NLM_x">â</span> <span class="NLM_lpage">767</span><span class="refDoi">Â DOI: 10.1038/nchembio.1582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1038%2Fnchembio.1582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=25038787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygs7nO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=760-767&issue=9&author=B.+R.+Lanningauthor=L.+R.+Whitbyauthor=M.+M.+Dixauthor=J.+Douhanauthor=A.+M.+Gilbertauthor=E.+C.+Hettauthor=T.+O.+Johnsonauthor=C.+Joslynauthor=J.+C.+Kathauthor=S.+Niessenauthor=L.+R.+Robertsauthor=M.+E.+Schnuteauthor=C.+Wangauthor=J.+J.+Hulceauthor=B.+Weiauthor=L.+O.+Whiteleyauthor=M.+M.+Haywardauthor=B.+F.+Cravatt&title=A+road+map+to+evaluate+the+proteome-wide+selectivity+of+covalent+kinase+inhibitors&doi=10.1038%2Fnchembio.1582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors</span></div><div class="casAuthors">Lanning, Bryan R.; Whitby, Landon R.; Dix, Melissa M.; Douhan, John; Gilbert, Adam M.; Hett, Erik C.; Johnson, Theodore O.; Joslyn, Chris; Kath, John C.; Niessen, Sherry; Roberts, Lee R.; Schnute, Mark E.; Wang, Chu; Hulce, Jonathan J.; Wei, Baoxian; Whiteley, Laurence O.; Hayward, Matthew M.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">760-767</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinases are principal components of signal transduction pathways and the focus of intense basic and drug discovery research.  Irreversible inhibitors that covalently modify non-catalytic cysteines in kinase active sites have emerged as valuable probes and approved drugs.  Many protein classes, however, have functional cysteines, and therefore understanding the proteome-wide selectivity of covalent kinase inhibitors is imperative.  Here, we accomplish this objective using activity-based protein profiling coupled with quant. MS to globally map the targets, both specific and nonspecific, of covalent kinase inhibitors in human cells.  Many of the specific off-targets represent nonkinase proteins that, notably, have conserved active site cysteines.  We define windows of selectivity for covalent kinase inhibitors and show that, when these windows are exceeded, rampant proteome-wide reactivity and kinase target-independent cell death conjointly occur.  Our findings, taken together, provide an exptl. road map to illuminate opportunities and surmount challenges for the development of covalent kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMAiUlEg9R5rVg90H21EOLACvtfcHk0lg0Frb9fVHGtw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygs7nO&md5=6f17b0d1b00e088f37c511eea577d290</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1582%26sid%3Dliteratum%253Aachs%26aulast%3DLanning%26aufirst%3DB.%2BR.%26aulast%3DWhitby%26aufirst%3DL.%2BR.%26aulast%3DDix%26aufirst%3DM.%2BM.%26aulast%3DDouhan%26aufirst%3DJ.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DHett%26aufirst%3DE.%2BC.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DJoslyn%26aufirst%3DC.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DL.%2BR.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHulce%26aufirst%3DJ.%2BJ.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWhiteley%26aufirst%3DL.%2BO.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DA%2520road%2520map%2520to%2520evaluate%2520the%2520proteome-wide%2520selectivity%2520of%2520covalent%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26issue%3D9%26spage%3D760%26epage%3D767%26doi%3D10.1038%2Fnchembio.1582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Eaton, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bammler, T. K.</span><span> </span><span class="NLM_article-title">Consise review of the glutathione S-transferases and their significance to toxicology</span> <span class="citation_source-journal">Toxicol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">156</span><span class="NLM_x">â</span> <span class="NLM_lpage">164</span><span class="refDoi">Â DOI: 10.1093/toxsci/49.2.156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1093%2Ftoxsci%2F49.2.156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10416260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADyaK1MXkt1yqur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1999&pages=156-164&author=D.+L.+Eatonauthor=T.+K.+Bammler&title=Consise+review+of+the+glutathione+S-transferases+and+their+significance+to+toxicology&doi=10.1093%2Ftoxsci%2F49.2.156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Concise review of the glutathione S-transferases and their significance to toxicology</span></div><div class="casAuthors">Eaton, David L.; Bammler, Theo K.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">156-164</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review with â¼50 refs. on the major features of glutathione S-transferase multi-gene family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_nHcHqT7GO7Vg90H21EOLACvtfcHk0lg0Frb9fVHGtw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkt1yqur0%253D&md5=a8a44cf0f2d8cffc5d75cb69cb424246</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2F49.2.156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252F49.2.156%26sid%3Dliteratum%253Aachs%26aulast%3DEaton%26aufirst%3DD.%2BL.%26aulast%3DBammler%26aufirst%3DT.%2BK.%26atitle%3DConsise%2520review%2520of%2520the%2520glutathione%2520S-transferases%2520and%2520their%2520significance%2520to%2520toxicology%26jtitle%3DToxicol.%2520Sci.%26date%3D1999%26volume%3D49%26spage%3D156%26epage%3D164%26doi%3D10.1093%2Ftoxsci%2F49.2.156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Gintant, G.</span><span> </span><span class="NLM_article-title">An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">109</span><span class="NLM_x">â</span> <span class="NLM_lpage">119</span><span class="refDoi">Â DOI: 10.1016/j.pharmthera.2010.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1016%2Fj.pharmthera.2010.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=20807552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvVantA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=109-119&issue=2&author=G.+Gintant&title=An+evaluation+of+hERG+current+assay+performance%3A+Translating+preclinical+safety+studies+to+clinical+QT+prolongation&doi=10.1016%2Fj.pharmthera.2010.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation</span></div><div class="casAuthors">Gintant, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">109-119</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Block of delayed rectifier current (I Kr, Kv11.1 encoding the hERG gene) is assocd. with delayed cardiac repolarization (QTc prolongation), a surrogate marker of proarrhythmia.  Despite its recognized role in assessing QTc prolongation risk, a quant. anal. of the utility and limitations of the hERG current assay has not been reported.  To benchmark hERG assay performance, this retrospective study compared hERG block potency with drug-induced QTc prolongation assessed during rigorous thorough QT (TQT) clin. studies for 39 drugs from multiple classes.  To place block in context, hERG safety margins (IC50 values for block/mean maximal plasma drug concns. during TQT studies) were compared to QTc prolongation (QTc increase â¥ 5 ms).  Most (9/10) drugs eliciting essentially no hERG block at maximal concns. demonstrate no QTc prolongation despite representing a wide hERG safety margin range.  Based on receiver-operator characteristics, a hERG safety margin of 45 provided optimal overall performance linking safety margins to QTc prolongation (sensitivity (true pos. rate) = 0.64, specificity (true neg. rate) = 0.88); the area under the receiver-operator curve (0.72) is indicative of moderate overall concordance.  Likelihood ratios calcd. from multitier contingency tables suggest that QTc prolonging drugs are only 5-7 times as likely to demonstrate low safety margins (1-30 range) compared to drugs that do not prolong QTc.  Paradoxically, higher safety margins demonstrate lesser confidence predicting prolongation.  The overall limitations of hERG safety margins shown using these quant., evidence-based approaches highlight the need for addnl. preclin. assays and adaptive strategies throughout drug discovery to reliably mitigate QTc prolongation risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBSUF3lt6P27Vg90H21EOLACvtfcHk0linEvrGi4j4RQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvVantA%253D%253D&md5=336d014ddc78cc6e790a7248e28a92a3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2010.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2010.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DGintant%26aufirst%3DG.%26atitle%3DAn%2520evaluation%2520of%2520hERG%2520current%2520assay%2520performance%253A%2520Translating%2520preclinical%2520safety%2520studies%2520to%2520clinical%2520QT%2520prolongation%26jtitle%3DPharmacol.%2520Ther.%26date%3D2011%26volume%3D129%26issue%3D2%26spage%3D109%26epage%3D119%26doi%3D10.1016%2Fj.pharmthera.2010.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Schwartz, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzmic, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergqvist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolanos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almaden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">173</span><span class="NLM_x">â</span> <span class="NLM_lpage">178</span><span class="refDoi">Â DOI: 10.1073/pnas.1313733111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1073%2Fpnas.1313733111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=24347635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=173-178&issue=1&author=P.+A.+Schwartzauthor=P.+Kuzmicauthor=J.+Solowiejauthor=S.+Bergqvistauthor=B.+Bolanosauthor=C.+Almadenauthor=A.+Nagataauthor=K.+Ryanauthor=J.+Fengauthor=D.+Dalvieauthor=J.+C.+Kathauthor=M.+Xuauthor=R.+Waniauthor=B.+W.+Murray&title=Covalent+EGFR+inhibitor+analysis+reveals+importance+of+reversible+interactions+to+potency+and+mechanisms+of+drug+resistance&doi=10.1073%2Fpnas.1313733111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span></div><div class="casAuthors">Schwartz, Phillip A.; Kuzmic, Petr; Solowiej, James; Bergqvist, Simon; Bolanos, Ben; Almaden, Chau; Nagata, Asako; Ryan, Kevin; Feng, Junli; Dalvie, Deepak; Kath, John C.; Xu, Meirong; Wani, Revati; Murray, Brion William</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">173-178</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Covalent inhibition is a reemerging paradigm in kinase drug design, but the roles of inhibitor binding affinity and chem. reactivity in overall potency are not well-understood.  To characterize the underlying mol. processes at a microscopic level and det. the appropriate kinetic consts., specialized exptl. design and advanced numerical integration of differential equations are developed.  Previously uncharacterized investigational covalent drugs reported here are shown to be extremely effective epidermal growth factor receptor (EGFR) inhibitors (kinact/Ki in the range 105-107 M-1s-1), despite their low specific reactivity (kinact â¤ 2.1 Ã 10-3 s-1), which is compensated for by high binding affinities (Ki < 1 nM).  For inhibitors relying on reactivity to achieve potency, noncovalent enzyme-inhibitor complex partitioning between inhibitor dissocn. and bond formation is central.  Interestingly, reversible binding affinity of EGFR covalent inhibitors is highly correlated with antitumor cell potency.  Furthermore, cellular potency for a subset of covalent inhibitors can be accounted for solely through reversible interactions.  One reversible interaction is between EGFR-Cys797 nucleophile and the inhibitor's reactive group, which may also contribute to drug resistance.  Because covalent inhibitors target a cysteine residue, the effects of its oxidn. on enzyme catalysis and inhibitor pharmacol. are characterized.  Oxidn. of the EGFR cysteine nucleophile does not alter catalysis but has widely varied effects on inhibitor potency depending on the EGFR context (e.g., oncogenic mutations), type of oxidn. (sulfinylation or glutathiolation), and inhibitor architecture.  These methods, parameters, and insights provide a rational framework for assessing and designing effective covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTpPuRq8MwCLVg90H21EOLACvtfcHk0linEvrGi4j4RQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D&md5=47197c5e7876a238eefb2e8e7de305ea</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1313733111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1313733111%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DP.%2BA.%26aulast%3DKuzmic%26aufirst%3DP.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBolanos%26aufirst%3DB.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWani%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DCovalent%2520EGFR%2520inhibitor%2520analysis%2520reveals%2520importance%2520of%2520reversible%2520interactions%2520to%2520potency%2520and%2520mechanisms%2520of%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26issue%3D1%26spage%3D173%26epage%3D178%26doi%3D10.1073%2Fpnas.1313733111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b','cit2c','cit2d'],'ref3':['cit3a','cit3b'],'ref4':['cit4a','cit4b','cit4c','cit4d'],'ref5':['cit5a','cit5b'],'ref6':['cit6a','cit6b','cit6c','cit6d','cit6e','cit6f','cit6g'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14a','cit14b','cit14c'],'ref15':['cit15'],'ref16':['cit16a','cit16b'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20a','cit20b'],'ref21':['cit21a','cit21b'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 47 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Janina Niggenaber, Leonie Heyden, Tobias Grabe, Matthias P. MÃ¼ller, Jonas Lategahn, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (12)
                                     , 2484-2490. <a href="https://doi.org/10.1021/acsmedchemlett.0c00472" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00472</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00472%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DComplex%252BCrystal%252BStructures%252Bof%252BEGFR%252Bwith%252BThird-Generation%252BKinase%252BInhibitors%252Band%252BSimultaneously%252BBound%252BAllosteric%252BLigands%26aulast%3DNiggenaber%26aufirst%3DJanina%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26082020%26date%3D28092020%26date%3D05112020%26volume%3D11%26issue%3D12%26spage%3D2484%26epage%3D2490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Adi Lahiani, Dikla Haham-Geula, David Lankri, Susan Cornell-Kennon, Erik M. Schaefer, Dmitry Tsvelikhovsky, <span class="NLM_string-name hlFld-ContribAuthor">Philip Lazarovici</span>. </span><span class="cited-content_cbyCitation_article-title">Neurotropic activity and safety of methylene-cycloalkylacetate (MCA) derivative 3-(3-allyl-2-methylenecyclohexyl) propanoic acid. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2020,</strong> <em>11 </em>
                                    (17)
                                     , 2577-2589. <a href="https://doi.org/10.1021/acschemneuro.0c00255" title="DOI URL">https://doi.org/10.1021/acschemneuro.0c00255</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.0c00255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.0c00255%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DNeurotropic%252Bactivity%252Band%252Bsafety%252Bof%252Bmethylene-cycloalkylacetate%252B%252528MCA%252529%252Bderivative%252B3-%2525283-allyl-2-methylenecyclohexyl%252529%252Bpropanoic%252Bacid%26aulast%3DLahiani%26aufirst%3DAdi%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D29042020%26date%3D15072020%26date%3D03082020%26date%3D15072020%26volume%3D11%26issue%3D17%26spage%3D2577%26epage%3D2589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mami Sato, Hirokazu Fuchida, Naoya Shindo, Keiko Kuwata, Keisuke Tokunaga, Guo Xiao-Lin, Ryo Inamori, Keitaro Hosokawa, Kosuke Watari, Tomohiro Shibata, Naoya Matsunaga, Satoru Koyanagi, Shigehiro Ohdo, Mayumi Ono, <span class="NLM_string-name hlFld-ContribAuthor">Akio Ojida</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Covalent Targeting of Mutated EGFR(T790M) with Chlorofluoroacetamide-Pyrimidines. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (6)
                                     , 1137-1144. <a href="https://doi.org/10.1021/acsmedchemlett.9b00574" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00574</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00574%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSelective%252BCovalent%252BTargeting%252Bof%252BMutated%252BEGFR%252528T790M%252529%252Bwith%252BChlorofluoroacetamide-Pyrimidines%26aulast%3DSato%26aufirst%3DMami%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D04122019%26date%3D08042020%26date%3D10042020%26date%3D08042020%26volume%3D11%26issue%3D6%26spage%3D1137%26epage%3D1144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Philipp S. Schmalhorst, <span class="NLM_string-name hlFld-ContribAuthor">Andreas Bergner</span>. </span><span class="cited-content_cbyCitation_article-title">A Grid Map Based Approach to Identify Nonobvious Ligand Design Opportunities in 3D Protein Structure Ensembles. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (4)
                                     , 2178-2188. <a href="https://doi.org/10.1021/acs.jcim.0c00051" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c00051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c00051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c00051%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DA%252BGrid%252BMap%252BBased%252BApproach%252Bto%252BIdentify%252BNonobvious%252BLigand%252BDesign%252BOpportunities%252Bin%252B3D%252BProtein%252BStructure%252BEnsembles%26aulast%3DSchmalhorst%26aufirst%3DPhilipp%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17012020%26date%3D17032020%26date%3D05032020%26volume%3D60%26issue%3D4%26spage%3D2178%26epage%3D2188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Farideh Badichi Akher, Abdolkarim Farrokhzadeh, Neil Ravenscroft, <span class="NLM_string-name hlFld-ContribAuthor">Michelle M. Kuttel</span>. </span><span class="cited-content_cbyCitation_article-title">A Mechanistic Study of a Potent and Selective Epidermal Growth Factor Receptor Inhibitor against the L858R/T790M Resistance Mutation. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2019,</strong> <em>58 </em>
                                    (41)
                                     , 4246-4259. <a href="https://doi.org/10.1021/acs.biochem.9b00710" title="DOI URL">https://doi.org/10.1021/acs.biochem.9b00710</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.9b00710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.9b00710%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DA%252BMechanistic%252BStudy%252Bof%252Ba%252BPotent%252Band%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitor%252Bagainst%252Bthe%252BL858R%25252FT790M%252BResistance%252BMutation%26aulast%3DAkher%26aufirst%3DFarideh%2BBadichi%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D13082019%26date%3D23092019%26date%3D07102019%26volume%3D58%26issue%3D41%26spage%3D4246%26epage%3D4259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Daniel W. Widlicka, Alexander Gontcharov, Ruchi Mehta, Dylan J. Pedro, <span class="NLM_string-name hlFld-ContribAuthor">Robert North</span>. </span><span class="cited-content_cbyCitation_article-title">Enantiospecific Synthesis of (3R,4R)-1-Benzyl-4-fluoropyrrolidin-3-amine Utilizing a Burgess-Type Transformation. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (9)
                                     , 1970-1978. <a href="https://doi.org/10.1021/acs.oprd.9b00245" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00245</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00245%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DEnantiospecific%252BSynthesis%252Bof%252B%2525283R%25252C4R%252529-1-Benzyl-4-fluoropyrrolidin-3-amine%252BUtilizing%252Ba%252BBurgess-Type%252BTransformation%26aulast%3DWidlicka%26aufirst%3DDaniel%2BW.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D24052019%26date%3D31072019%26date%3D16072019%26volume%3D23%26issue%3D9%26spage%3D1970%26epage%3D1978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ruibin Liu, Zhi Yue, Cheng-Chieh Tsai, <span class="NLM_string-name hlFld-ContribAuthor">Jana Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Assessing Lysine and Cysteine Reactivities for Designing Targeted Covalent Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (16)
                                     , 6553-6560. <a href="https://doi.org/10.1021/jacs.8b13248" title="DOI URL">https://doi.org/10.1021/jacs.8b13248</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.8b13248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.8b13248%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DAssessing%252BLysine%252Band%252BCysteine%252BReactivities%252Bfor%252BDesigning%252BTargeted%252BCovalent%252BKinase%252BInhibitors%26aulast%3DLiu%26aufirst%3DRuibin%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D11122018%26date%3D16042019%26date%3D04042019%26volume%3D141%26issue%3D16%26spage%3D6553%26epage%3D6560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas BostrÃ¶m</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ted W. Johnson, Rebecca A. Gallego, <span class="NLM_string-name hlFld-ContribAuthor">Martin P. Edwards</span>. </span><span class="cited-content_cbyCitation_article-title">Lipophilic Efficiency as an Important Metric in Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6401-6420. <a href="https://doi.org/10.1021/acs.jmedchem.8b00077" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00077%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLipophilic%252BEfficiency%252Bas%252Ban%252BImportant%252BMetric%252Bin%252BDrug%252BDesign%26aulast%3DJohnson%26aufirst%3DTed%2BW.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D16012018%26date%3D17042018%26date%3D28032018%26volume%3D61%26issue%3D15%26spage%3D6401%26epage%3D6420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Robert J. Young, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Leeson</span>. </span><span class="cited-content_cbyCitation_article-title">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6421-6467. <a href="https://doi.org/10.1021/acs.jmedchem.8b00180" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00180%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMapping%252Bthe%252BEfficiency%252Band%252BPhysicochemical%252BTrajectories%252Bof%252BSuccessful%252BOptimizations%26aulast%3DYoung%26aufirst%3DRobert%2BJ.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03022018%26date%3D25042018%26date%3D05042018%26volume%3D61%26issue%3D15%26spage%3D6421%26epage%3D6467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lingfeng Chen, Weitao Fu, Lulu Zheng, Zhiguo Liu, <span class="NLM_string-name hlFld-ContribAuthor">Guang Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (10)
                                     , 4290-4300. <a href="https://doi.org/10.1021/acs.jmedchem.7b01310" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01310</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01310%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BProgress%252Bof%252BSmall-Molecule%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%252Bagainst%252BC797S%252BResistance%252Bin%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DChen%26aufirst%3DLingfeng%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D02092017%26date%3D27112017%26date%3D14112017%26volume%3D61%26issue%3D10%26spage%3D4290%26epage%3D4300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ibrahim  Abdelbaky</span>, <span class="hlFld-ContribAuthor ">Hilal  Tayara</span>, <span class="hlFld-ContribAuthor ">Kil To  Chong</span>. </span><span class="cited-content_cbyCitation_article-title">Prediction of kinase inhibitors binding modes with machine learning and reduced descriptor sets. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-80758-4" title="DOI URL">https://doi.org/10.1038/s41598-020-80758-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-80758-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-80758-4%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DPrediction%252Bof%252Bkinase%252Binhibitors%252Bbinding%252Bmodes%252Bwith%252Bmachine%252Blearning%252Band%252Breduced%252Bdescriptor%252Bsets%26aulast%3DAbdelbaky%26aufirst%3DIbrahim%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kamrine E.  Poels</span>, <span class="hlFld-ContribAuthor ">Adam J.  Schoenfeld</span>, <span class="hlFld-ContribAuthor ">Alex  Makhnin</span>, <span class="hlFld-ContribAuthor ">Yosef  Tobi</span>, <span class="hlFld-ContribAuthor ">Yuli  Wang</span>, <span class="hlFld-ContribAuthor ">Heidie  Frisco-Cabanos</span>, <span class="hlFld-ContribAuthor ">Shaon  Chakrabarti</span>, <span class="hlFld-ContribAuthor ">Manli  Shi</span>, <span class="hlFld-ContribAuthor ">Chelsi  Napoli</span>, <span class="hlFld-ContribAuthor ">Thomas O.  McDonald</span>, <span class="hlFld-ContribAuthor ">Weiwei  Tan</span>, <span class="hlFld-ContribAuthor ">Aaron  Hata</span>, <span class="hlFld-ContribAuthor ">Scott L.  Weinrich</span>, <span class="hlFld-ContribAuthor ">Helena A.  Yu</span>, <span class="hlFld-ContribAuthor ">Franziska  Michor</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-021-23912-4" title="DOI URL">https://doi.org/10.1038/s41467-021-23912-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-021-23912-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-021-23912-4%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DIdentification%252Bof%252Boptimal%252Bdosing%252Bschedules%252Bof%252Bdacomitinib%252Band%252Bosimertinib%252Bfor%252Ba%252Bphase%252BI%25252FII%252Btrial%252Bin%252Badvanced%252BEGFR-mutant%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DPoels%26aufirst%3DKamrine%2BE.%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guoxing  Hu</span>, <span class="hlFld-ContribAuthor ">Hanhan  Xu</span>, <span class="hlFld-ContribAuthor ">Wenge  Yang</span>, <span class="hlFld-ContribAuthor ">Aixiang  Hao</span>, <span class="hlFld-ContribAuthor ">Wei  Sun</span>, <span class="hlFld-ContribAuthor ">Weiliang  Shen</span>, <span class="hlFld-ContribAuthor ">Yonghong  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Determination of the solubility of 6-Chloro-7-azapurine in twelve single solvents and four binary mixed solvent systems at tÂ =Â (278.15â323.15)Â K. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Chemical Thermodynamics</span><span> <strong>2021,</strong> <em>160 </em>, 106493. <a href="https://doi.org/10.1016/j.jct.2021.106493" title="DOI URL">https://doi.org/10.1016/j.jct.2021.106493</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jct.2021.106493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jct.2021.106493%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Chemical%2520Thermodynamics%26atitle%3DDetermination%252Bof%252Bthe%252Bsolubility%252Bof%252B6-Chloro-7-azapurine%252Bin%252Btwelve%252Bsingle%252Bsolvents%252Band%252Bfour%252Bbinary%252Bmixed%252Bsolvent%252Bsystems%252Bat%252Bt%2525C2%2525A0%25253D%2525C2%2525A0%252528278.15%2525E2%252580%252593323.15%252529%2525C2%2525A0K%26aulast%3DHu%26aufirst%3DGuoxing%26date%3D2021%26volume%3D160%26spage%3D106493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Levente M.  Mihalovits</span>, <span class="hlFld-ContribAuthor ">GyÃ¶rgy G.  Ferenczy</span>, <span class="hlFld-ContribAuthor ">GyÃ¶rgy M.  KeserÅ±</span>. </span><span class="cited-content_cbyCitation_article-title">The role of quantum chemistry in covalent inhibitor design. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Quantum Chemistry</span><span> <strong>2021,</strong> <em>60 </em><a href="https://doi.org/10.1002/qua.26768" title="DOI URL">https://doi.org/10.1002/qua.26768</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/qua.26768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fqua.26768%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Quantum%2520Chemistry%26atitle%3DThe%252Brole%252Bof%252Bquantum%252Bchemistry%252Bin%252Bcovalent%252Binhibitor%252Bdesign%26aulast%3DMihalovits%26aufirst%3DLevente%2BM.%26date%3D2021%26date%3D2021%26volume%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haixiao  Fang</span>, <span class="hlFld-ContribAuthor ">Bo  Peng</span>, <span class="hlFld-ContribAuthor ">Sing Yee  Ong</span>, <span class="hlFld-ContribAuthor ">Qiong  Wu</span>, <span class="hlFld-ContribAuthor ">Lin  Li</span>, <span class="hlFld-ContribAuthor ">Shao Q.  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in activity-based probes (ABPs) and affinity-based probes (A
              f
              BPs) for profiling of enzymes. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2021,</strong> <em>12 </em>
                                    (24)
                                     , 8288-8310. <a href="https://doi.org/10.1039/D1SC01359A" title="DOI URL">https://doi.org/10.1039/D1SC01359A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1SC01359A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1SC01359A%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DRecent%252Badvances%252Bin%252Bactivity-based%252Bprobes%252B%252528ABPs%252529%252Band%252Baffinity-based%252Bprobes%252B%252528A%252Bf%252BBPs%252529%252Bfor%252Bprofiling%252Bof%252Benzymes%26aulast%3DFang%26aufirst%3DHaixiao%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D24%26spage%3D8288%26epage%3D8310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debasis  Das</span>, <span class="hlFld-ContribAuthor ">Jingbing  Wang</span>, <span class="hlFld-ContribAuthor ">Jian  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">NextâGeneration Kinase Inhibitors Targeting Specific Biomarkers in NonâSmall Cell Lung Cancer (NSCLC): A Recent Overview. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>71 </em><a href="https://doi.org/10.1002/cmdc.202100166" title="DOI URL">https://doi.org/10.1002/cmdc.202100166</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100166%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DNext%2525E2%252580%252590Generation%252BKinase%252BInhibitors%252BTargeting%252BSpecific%252BBiomarkers%252Bin%252BNon%2525E2%252580%252590Small%252BCell%252BLung%252BCancer%252B%252528NSCLC%252529%25253A%252BA%252BRecent%252BOverview%26aulast%3DDas%26aufirst%3DDebasis%26date%3D2021%26date%3D2021%26volume%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Misako  Nagasaka</span>, <span class="hlFld-ContribAuthor ">Viola W.  Zhu</span>, <span class="hlFld-ContribAuthor ">Sun Min  Lim</span>, <span class="hlFld-ContribAuthor ">Michael  Greco</span>, <span class="hlFld-ContribAuthor ">Fengying  Wu</span>, <span class="hlFld-ContribAuthor ">Sai-Hong Ignatius  Ou</span>. </span><span class="cited-content_cbyCitation_article-title">Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase InhibitorsÂ For Advanced EGFR+ NSCLC. </span><span class="cited-content_cbyCitation_journal-name">Journal of Thoracic Oncology</span><span> <strong>2021,</strong> <em>16 </em>
                                    (5)
                                     , 740-763. <a href="https://doi.org/10.1016/j.jtho.2020.11.028" title="DOI URL">https://doi.org/10.1016/j.jtho.2020.11.028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jtho.2020.11.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jtho.2020.11.028%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Thoracic%2520Oncology%26atitle%3DBeyond%252BOsimertinib%25253A%252BThe%252BDevelopment%252Bof%252BThird-Generation%252BEGFR%252BTyrosine%252BKinase%252BInhibitors%2525C2%2525A0For%252BAdvanced%252BEGFR%25252B%252BNSCLC%26aulast%3DNagasaka%26aufirst%3DMisako%26date%3D2021%26volume%3D16%26issue%3D5%26spage%3D740%26epage%3D763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonardo L.G.  Ferreira</span>, <span class="hlFld-ContribAuthor ">Adriano D.  Andricopulo</span>. </span><span class="cited-content_cbyCitation_article-title">StructureâBased Drug Design. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-54. <a href="https://doi.org/10.1002/0471266949.bmc141.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc141.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc141.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc141.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DStructure%2525E2%252580%252590Based%252BDrug%252BDesign%26aulast%3DFerreira%26aufirst%3DLeonardo%2BL.G.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D54%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Isaac  Kyei Barffour</span>, <span class="hlFld-ContribAuthor ">Desmond Omane  Acheampong</span>. </span><span class="cited-content_cbyCitation_article-title">Prospect of reprogramming replication licensing for cancer drug development. </span><span class="cited-content_cbyCitation_journal-name">Biomedicine & Pharmacotherapy</span><span> <strong>2021,</strong> <em>136 </em>, 111190. <a href="https://doi.org/10.1016/j.biopha.2020.111190" title="DOI URL">https://doi.org/10.1016/j.biopha.2020.111190</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biopha.2020.111190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biopha.2020.111190%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicine%2520%2526%2520Pharmacotherapy%26atitle%3DProspect%252Bof%252Breprogramming%252Breplication%252Blicensing%252Bfor%252Bcancer%252Bdrug%252Bdevelopment%26aulast%3DKyei%2BBarffour%26aufirst%3DIsaac%26date%3D2021%26volume%3D136%26spage%3D111190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kavita Kumari  Kakarala</span>, <span class="hlFld-ContribAuthor ">Kaiser  Jamil</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2021,</strong> <em>8 </em>, 1-22. <a href="https://doi.org/10.1080/07391102.2021.1891140" title="DOI URL">https://doi.org/10.1080/07391102.2021.1891140</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2021.1891140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2021.1891140%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DIdentification%252Bof%252Bnovel%252Ballosteric%252Bbinding%252Bsites%252Band%252Bmulti-targeted%252Ballosteric%252Binhibitors%252Bof%252Breceptor%252Band%252Bnon-receptor%252Btyrosine%252Bkinases%252Busing%252Ba%252Bcomputational%252Bapproach%26aulast%3DKakarala%26aufirst%3DKavita%2BKumari%26date%3D2021%26date%3D2021%26volume%3D8%26spage%3D1%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tejas M.  Dhameliya</span>, <span class="hlFld-ContribAuthor ">Kshitij I.  Patel</span>, <span class="hlFld-ContribAuthor ">Rishu  Tiwari</span>, <span class="hlFld-ContribAuthor ">Siva Krishna  Vagolu</span>, <span class="hlFld-ContribAuthor ">Dulal  Panda</span>, <span class="hlFld-ContribAuthor ">Dharmarajan  Sriram</span>, <span class="hlFld-ContribAuthor ">Asit K.  Chakraborti</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of benzo[d]imidazole-2-carboxamides as new anti-TB agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>107 </em>, 104538. <a href="https://doi.org/10.1016/j.bioorg.2020.104538" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104538</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104538%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bbenzo%25255Bd%25255Dimidazole-2-carboxamides%252Bas%252Bnew%252Banti-TB%252Bagents%26aulast%3DDhameliya%26aufirst%3DTejas%2BM.%26date%3D2021%26volume%3D107%26spage%3D104538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Iqrar  Ahmad</span>, <span class="hlFld-ContribAuthor ">Matin  Shaikh</span>, <span class="hlFld-ContribAuthor ">Sanjay  Surana</span>, <span class="hlFld-ContribAuthor ">Arabinda  Ghosh</span>, <span class="hlFld-ContribAuthor ">Harun  Patel</span>. </span><span class="cited-content_cbyCitation_article-title">p38Î± MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2020,</strong> <em>3 </em>, 1-14. <a href="https://doi.org/10.1080/07391102.2020.1844801" title="DOI URL">https://doi.org/10.1080/07391102.2020.1844801</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2020.1844801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2020.1844801%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3Dp38%2525CE%2525B1%252BMAP%252Bkinase%252Binhibitors%252Bto%252Bovercome%252BEGFR%252Btertiary%252BC797S%252Bpoint%252Bmutation%252Bassociated%252Bwith%252Bosimertinib%252Bin%252Bnon-small%252Bcell%252Blung%252Bcancer%252B%252528NSCLC%252529%25253A%252Bemergence%252Bof%252Bfourth-generation%252BEGFR%252Binhibitor%26aulast%3DAhmad%26aufirst%3DIqrar%26date%3D2020%26date%3D2020%26volume%3D3%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhen  Xiao</span>, <span class="hlFld-ContribAuthor ">Cilong  Chu</span>, <span class="hlFld-ContribAuthor ">Lingjia  Zhou</span>, <span class="hlFld-ContribAuthor ">Zhihui  Zhou</span>, <span class="hlFld-ContribAuthor ">Qian  Zhang</span>, <span class="hlFld-ContribAuthor ">Feiyi  Yang</span>, <span class="hlFld-ContribAuthor ">Zunhua  Yang</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (19)
                                     , 115669. <a href="https://doi.org/10.1016/j.bmc.2020.115669" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115669</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115669%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bthiapyran-pyrimidine%252Bderivatives%252Bas%252Bpotential%252BEGFR%252Binhibitors%26aulast%3DXiao%26aufirst%3DZhen%26date%3D2020%26volume%3D28%26issue%3D19%26spage%3D115669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhen  Xiao</span>, <span class="hlFld-ContribAuthor ">Zhihui  Zhou</span>, <span class="hlFld-ContribAuthor ">Cilong  Chu</span>, <span class="hlFld-ContribAuthor ">Qian  Zhang</span>, <span class="hlFld-ContribAuthor ">Lingjia  Zhou</span>, <span class="hlFld-ContribAuthor ">Zunhua  Yang</span>, <span class="hlFld-ContribAuthor ">Xin  Li</span>, <span class="hlFld-ContribAuthor ">Liying  Yu</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>203 </em>, 112511. <a href="https://doi.org/10.1016/j.ejmech.2020.112511" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112511%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bantitumor%252Bactivity%252Bof%252Bnovel%252Bthiophene-pyrimidine%252Bderivatives%252Bas%252BEGFR%252Binhibitors%252Bovercoming%252BT790M%252Band%252BL858R%25252FT790M%252Bmutations%26aulast%3DXiao%26aufirst%3DZhen%26date%3D2020%26volume%3D203%26spage%3D112511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Chen</span>, <span class="hlFld-ContribAuthor ">Linlin  Yang</span>, <span class="hlFld-ContribAuthor ">Hui  Qiao</span>, <span class="hlFld-ContribAuthor ">Zhongyu  Cheng</span>, <span class="hlFld-ContribAuthor ">Jiahao  Xie</span>, <span class="hlFld-ContribAuthor ">Wenjuan  Zhou</span>, <span class="hlFld-ContribAuthor ">Xin  Huang</span>, <span class="hlFld-ContribAuthor ">Yaoxuan  Jiang</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Wen  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFRL858R/T790M NSCLCs by the conformation constrained strategy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>199 </em>, 112388. <a href="https://doi.org/10.1016/j.ejmech.2020.112388" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112388</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112388%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnew%252Bthieno%25255B3%25252C2-d%25255Dpyrimidine%252Bderivatives%252Btargeting%252BEGFRL858R%25252FT790M%252BNSCLCs%252Bby%252Bthe%252Bconformation%252Bconstrained%252Bstrategy%26aulast%3DChen%26aufirst%3DYang%26date%3D2020%26volume%3D199%26spage%3D112388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adileh  Ayati</span>, <span class="hlFld-ContribAuthor ">Setareh  Moghimi</span>, <span class="hlFld-ContribAuthor ">Somayeh  Salarinejad</span>, <span class="hlFld-ContribAuthor ">Maliheh  Safavi</span>, <span class="hlFld-ContribAuthor ">Behjat  Pouramiri</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>. </span><span class="cited-content_cbyCitation_article-title">A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103811. <a href="https://doi.org/10.1016/j.bioorg.2020.103811" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103811</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103811%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DA%252Breview%252Bon%252Bprogression%252Bof%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252B%252528EGFR%252529%252Binhibitors%252Bas%252Ban%252Befficient%252Bapproach%252Bin%252Bcancer%252Btargeted%252Btherapy%26aulast%3DAyati%26aufirst%3DAdileh%26date%3D2020%26volume%3D99%26spage%3D103811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Long  Mao</span>, <span class="hlFld-ContribAuthor ">Wei  Tang</span>, <span class="hlFld-ContribAuthor ">Xiaoying  Zhang</span>, <span class="hlFld-ContribAuthor ">Jia  Liu</span>, <span class="hlFld-ContribAuthor ">Yile  Chen</span>, <span class="hlFld-ContribAuthor ">Yuning  Hua</span>, <span class="hlFld-ContribAuthor ">Bojie  Weng</span>, <span class="hlFld-ContribAuthor ">Xiaopeng  Mo</span>, <span class="hlFld-ContribAuthor ">Yimei  Bao</span>, <span class="hlFld-ContribAuthor ">Li  Teng</span>, <span class="hlFld-ContribAuthor ">Lijun  Xu</span>, <span class="hlFld-ContribAuthor ">Yuren  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Wu</span>, <span class="hlFld-ContribAuthor ">Guanglin  Zhou</span>, <span class="hlFld-ContribAuthor ">Bin  Liang</span>, <span class="hlFld-ContribAuthor ">Changxu  Xu</span>, <span class="hlFld-ContribAuthor ">Biao  Xi</span>, <span class="hlFld-ContribAuthor ">Li  Zhao</span>, <span class="hlFld-ContribAuthor ">Rongda  Xu</span>, <span class="hlFld-ContribAuthor ">Che  Fang</span>, <span class="hlFld-ContribAuthor ">Wanhong  Xu</span>, <span class="hlFld-ContribAuthor ">Xiaobo  Wang</span>, <span class="hlFld-ContribAuthor ">Xiao  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Novel, Selective and Irreversible Inhibitor (Abivertinib) of Mutated EGFR and T790M-induced Resistance for the Treatment of NSCLC. </span><span class="cited-content_cbyCitation_journal-name">Medicine in Drug Discovery</span><span> <strong>2020,</strong> <em>6 </em>, 100035. <a href="https://doi.org/10.1016/j.medidd.2020.100035" title="DOI URL">https://doi.org/10.1016/j.medidd.2020.100035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.medidd.2020.100035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.medidd.2020.100035%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicine%2520in%2520Drug%2520Discovery%26atitle%3DDiscovery%252Bof%252Ba%252BNovel%25252C%252BSelective%252Band%252BIrreversible%252BInhibitor%252B%252528Abivertinib%252529%252Bof%252BMutated%252BEGFR%252Band%252BT790M-induced%252BResistance%252Bfor%252Bthe%252BTreatment%252Bof%252BNSCLC%26aulast%3DMao%26aufirst%3DLong%26date%3D2020%26volume%3D6%26spage%3D100035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haitao  Wang</span>, <span class="hlFld-ContribAuthor ">Yongheng  Wang</span>, <span class="hlFld-ContribAuthor ">Shenghui  Liu</span>, <span class="hlFld-ContribAuthor ">Yudong  Mai</span>, <span class="hlFld-ContribAuthor ">Xiangxin  Zong</span>, <span class="hlFld-ContribAuthor ">Hao  Gao</span>, <span class="hlFld-ContribAuthor ">Rongbin  Hu</span>, <span class="hlFld-ContribAuthor ">Xiaojian  Jiang</span>, <span class="hlFld-ContribAuthor ">YingâYeung  Yeung</span>. </span><span class="cited-content_cbyCitation_article-title">Enantioselective Fluorocyclizations Mediated by AminoâAcidâDerived Phthalazine. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2019,</strong> <em>361 </em>
                                    (23)
                                     , 5334-5339. <a href="https://doi.org/10.1002/adsc.201900814" title="DOI URL">https://doi.org/10.1002/adsc.201900814</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201900814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201900814%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DEnantioselective%252BFluorocyclizations%252BMediated%252Bby%252BAmino%2525E2%252580%252590Acid%2525E2%252580%252590Derived%252BPhthalazine%26aulast%3DWang%26aufirst%3DHaitao%26date%3D2019%26date%3D2019%26volume%3D361%26issue%3D23%26spage%3D5334%26epage%3D5339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana C.Z.  Gelatti</span>, <span class="hlFld-ContribAuthor ">Alexander  Drilon</span>, <span class="hlFld-ContribAuthor ">Fernando C.  Santini</span>. </span><span class="cited-content_cbyCitation_article-title">Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). </span><span class="cited-content_cbyCitation_journal-name">Lung Cancer</span><span> <strong>2019,</strong> <em>137 </em>, 113-122. <a href="https://doi.org/10.1016/j.lungcan.2019.09.017" title="DOI URL">https://doi.org/10.1016/j.lungcan.2019.09.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lungcan.2019.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lungcan.2019.09.017%26sid%3Dliteratum%253Aachs%26jtitle%3DLung%2520Cancer%26atitle%3DOptimizing%252Bthe%252Bsequencing%252Bof%252Btyrosine%252Bkinase%252Binhibitors%252B%252528TKIs%252529%252Bin%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252B%252528EGFR%252529%252Bmutation-positive%252Bnon-small%252Bcell%252Blung%252Bcancer%252B%252528NSCLC%252529%26aulast%3DGelatti%26aufirst%3DAna%2BC.Z.%26date%3D2019%26volume%3D137%26spage%3D113%26epage%3D122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aaron C.  Tan</span>, <span class="hlFld-ContribAuthor ">Yi Lin  Teh</span>, <span class="hlFld-ContribAuthor ">Gillianne G. Y.  Lai</span>, <span class="hlFld-ContribAuthor ">Daniel S. W.  Tan</span>. </span><span class="cited-content_cbyCitation_article-title">Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC). </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Anticancer Therapy</span><span> <strong>2019,</strong> <em>19 </em>
                                    (6)
                                     , 431-435. <a href="https://doi.org/10.1080/14737140.2019.1604228" title="DOI URL">https://doi.org/10.1080/14737140.2019.1604228</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14737140.2019.1604228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14737140.2019.1604228%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Anticancer%2520Therapy%26atitle%3DThird%252Bgeneration%252BEGFR%252BTKI%252Blandscape%252Bfor%252Bmetastatic%252BEGFR%252Bmutant%252Bnon-small%252Bcell%252Blung%252Bcancer%252B%252528NSCLC%252529%26aulast%3DTan%26aufirst%3DAaron%2BC.%26date%3D2019%26date%3D2019%26volume%3D19%26issue%3D6%26spage%3D431%26epage%3D435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tarek S.  Mansour</span>, <span class="hlFld-ContribAuthor ">Vijay  Potluri</span>, <span class="hlFld-ContribAuthor ">Ranga R.  Pallepati</span>, <span class="hlFld-ContribAuthor ">Vishnu  Basetti</span>, <span class="hlFld-ContribAuthor ">Mallaiah  Keesara</span>, <span class="hlFld-ContribAuthor ">Ashok G.  Moghudula</span>, <span class="hlFld-ContribAuthor ">Pranab  Maiti</span>. </span><span class="cited-content_cbyCitation_article-title">Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (12)
                                     , 1435-1439. <a href="https://doi.org/10.1016/j.bmcl.2019.04.029" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.04.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.04.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.04.029%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DLead%252Bgeneration%252Bof%252B1%25252C2-dithiolanes%252Bas%252Bexon%252B19%252Band%252Bexon%252B21%252Bmutant%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DMansour%26aufirst%3DTarek%2BS.%26date%3D2019%26volume%3D29%26issue%3D12%26spage%3D1435%26epage%3D1439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philip J.  Chevis</span>, <span class="hlFld-ContribAuthor ">Sirilak  Wangngae</span>, <span class="hlFld-ContribAuthor ">Thanaphat  Thaima</span>, <span class="hlFld-ContribAuthor ">Anthony W.  Carroll</span>, <span class="hlFld-ContribAuthor ">Anthony C.  Willis</span>, <span class="hlFld-ContribAuthor ">Mookda  Pattarawarapan</span>, <span class="hlFld-ContribAuthor ">Stephen G.  Pyne</span>. </span><span class="cited-content_cbyCitation_article-title">Highly diastereoselective synthesis of enantioenriched
              anti
              -Î±-allyl-Î²-fluoroamines. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2019,</strong> <em>55 </em>
                                    (43)
                                     , 6050-6053. <a href="https://doi.org/10.1039/C9CC02765C" title="DOI URL">https://doi.org/10.1039/C9CC02765C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CC02765C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CC02765C%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DHighly%252Bdiastereoselective%252Bsynthesis%252Bof%252Benantioenriched%252Banti%252B-%2525CE%2525B1-allyl-%2525CE%2525B2-fluoroamines%26aulast%3DChevis%26aufirst%3DPhilip%2BJ.%26date%3D2019%26date%3D2019%26volume%3D55%26issue%3D43%26spage%3D6050%26epage%3D6053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shang-Gin  Wu</span>, <span class="hlFld-ContribAuthor ">Jin-Yuan  Shih</span>. </span><span class="cited-content_cbyCitation_article-title">Management of acquired resistance to EGFR TKIâtargeted therapy in advanced non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer</span><span> <strong>2018,</strong> <em>17 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12943-018-0777-1" title="DOI URL">https://doi.org/10.1186/s12943-018-0777-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12943-018-0777-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12943-018-0777-1%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%26atitle%3DManagement%252Bof%252Bacquired%252Bresistance%252Bto%252BEGFR%252BTKI%2525E2%252580%252593targeted%252Btherapy%252Bin%252Badvanced%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DWu%26aufirst%3DShang-Gin%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chee-Seng  Tan</span>, <span class="hlFld-ContribAuthor ">Nesaretnam Barr  Kumarakulasinghe</span>, <span class="hlFld-ContribAuthor ">Yi-Qing  Huang</span>, <span class="hlFld-ContribAuthor ">Yvonne Li En  Ang</span>, <span class="hlFld-ContribAuthor ">Joan Rou-En  Choo</span>, <span class="hlFld-ContribAuthor ">Boon-Cher  Goh</span>, <span class="hlFld-ContribAuthor ">Ross A.  Soo</span>. </span><span class="cited-content_cbyCitation_article-title">Third generation EGFR TKIs: current data and future directions. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer</span><span> <strong>2018,</strong> <em>17 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12943-018-0778-0" title="DOI URL">https://doi.org/10.1186/s12943-018-0778-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12943-018-0778-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12943-018-0778-0%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%26atitle%3DThird%252Bgeneration%252BEGFR%252BTKIs%25253A%252Bcurrent%252Bdata%252Band%252Bfuture%252Bdirections%26aulast%3DTan%26aufirst%3DChee-Seng%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting EGFR
              L858R/T790M
              and EGFR
              L858R/T790M/C797S
              resistance mutations in NSCLC: Current developments in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2018,</strong> <em>38 </em>
                                    (5)
                                     , 1550-1581. <a href="https://doi.org/10.1002/med.21488" title="DOI URL">https://doi.org/10.1002/med.21488</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21488%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTargeting%252BEGFR%252BL858R%25252FT790M%252Band%252BEGFR%252BL858R%25252FT790M%25252FC797S%252Bresistance%252Bmutations%252Bin%252BNSCLC%25253A%252BCurrent%252Bdevelopments%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D5%26spage%3D1550%26epage%3D1581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jin  Wang</span>, <span class="hlFld-ContribAuthor ">Hong-Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Xue-Yan  Yang</span>, <span class="hlFld-ContribAuthor ">Hao  Lei</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Yong-Xiao  Cao</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (12)
                                     , 3619-3633. <a href="https://doi.org/10.1016/j.bmc.2018.05.039" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.05.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.05.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.05.039%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Birreversible%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%252Bcontaining%252Bpyrido%25255B3%25252C4-d%25255Dpyrimidine%252Bscaffold%26aulast%3DZhang%26aufirst%3DHao%26date%3D2018%26volume%3D26%26issue%3D12%26spage%3D3619%26epage%3D3633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xing  Lu</span>, <span class="hlFld-ContribAuthor ">Yi-Ming  Wu</span>, <span class="hlFld-ContribAuthor ">Jing-Mei  Yang</span>, <span class="hlFld-ContribAuthor ">Feng-E.  Ma</span>, <span class="hlFld-ContribAuthor ">Liang-Ping  Li</span>, <span class="hlFld-ContribAuthor ">Sheng  Chen</span>, <span class="hlFld-ContribAuthor ">Ye  Zhang</span>, <span class="hlFld-ContribAuthor ">Qing-Ling  Ni</span>, <span class="hlFld-ContribAuthor ">Ying-Ming  Pan</span>, <span class="hlFld-ContribAuthor ">Xue  Hong</span>, <span class="hlFld-ContribAuthor ">Yan  Peng</span>. </span><span class="cited-content_cbyCitation_article-title">Preparation of Rhodium(III) complexes with 2(1H)-quinolinone derivatives and evaluation of their inÂ vitro and inÂ vivo antitumor activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>151 </em>, 226-236. <a href="https://doi.org/10.1016/j.ejmech.2018.03.074" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.03.074</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.03.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.03.074%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPreparation%252Bof%252BRhodium%252528III%252529%252Bcomplexes%252Bwith%252B2%2525281H%252529-quinolinone%252Bderivatives%252Band%252Bevaluation%252Bof%252Btheir%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%252Bantitumor%252Bactivity%26aulast%3DLu%26aufirst%3DXing%26date%3D2018%26volume%3D151%26spage%3D226%26epage%3D236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mahaveer  Singh</span>, <span class="hlFld-ContribAuthor ">Hemant R.  Jadhav</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2018,</strong> <em>23 </em>
                                    (3)
                                     , 745-753. <a href="https://doi.org/10.1016/j.drudis.2017.10.004" title="DOI URL">https://doi.org/10.1016/j.drudis.2017.10.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2017.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2017.10.004%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DTargeting%252Bnon-small%252Bcell%252Blung%252Bcancer%252Bwith%252Bsmall-molecule%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DSingh%26aufirst%3DMahaveer%26date%3D2018%26volume%3D23%26issue%3D3%26spage%3D745%26epage%3D753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Zhao</span>, <span class="hlFld-ContribAuthor ">Philip E.  Bourne</span>. </span><span class="cited-content_cbyCitation_article-title">Progress with covalent small-molecule kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2018,</strong> <em>23 </em>
                                    (3)
                                     , 727-735. <a href="https://doi.org/10.1016/j.drudis.2018.01.035" title="DOI URL">https://doi.org/10.1016/j.drudis.2018.01.035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2018.01.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2018.01.035%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DProgress%252Bwith%252Bcovalent%252Bsmall-molecule%252Bkinase%252Binhibitors%26aulast%3DZhao%26aufirst%3DZheng%26date%3D2018%26volume%3D23%26issue%3D3%26spage%3D727%26epage%3D735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jin  Wang</span>, <span class="hlFld-ContribAuthor ">Ying  Shen</span>, <span class="hlFld-ContribAuthor ">Hui-Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Wei-Ming  Duan</span>, <span class="hlFld-ContribAuthor ">Hong-Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Hei</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Yong-Xiao  Cao</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>148 </em>, 221-237. <a href="https://doi.org/10.1016/j.ejmech.2018.02.051" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.02.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.02.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.02.051%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2%25252C4%25252C6-trisubstitued%252Bpyrido%25255B3%25252C4-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bnew%252BEGFR-TKIs%26aulast%3DZhang%26aufirst%3DHao%26date%3D2018%26volume%3D148%26spage%3D221%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deheng  Chen</span>, <span class="hlFld-ContribAuthor ">Dexiang  Guo</span>, <span class="hlFld-ContribAuthor ">Ziqin  Yan</span>, <span class="hlFld-ContribAuthor ">Yujun  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Allenamide as a bioisostere of acrylamide in the design and synthesis of targeted covalent inhibitors. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2018,</strong> <em>9 </em>
                                    (2)
                                     , 244-253. <a href="https://doi.org/10.1039/C7MD00571G" title="DOI URL">https://doi.org/10.1039/C7MD00571G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7MD00571G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7MD00571G%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DAllenamide%252Bas%252Ba%252Bbioisostere%252Bof%252Bacrylamide%252Bin%252Bthe%252Bdesign%252Band%252Bsynthesis%252Bof%252Btargeted%252Bcovalent%252Binhibitors%26aulast%3DChen%26aufirst%3DDeheng%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D2%26spage%3D244%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luhong  Wang</span>, <span class="hlFld-ContribAuthor ">Jingyuan  Zhao</span>, <span class="hlFld-ContribAuthor ">Yao  Yao</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Jianbin  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Xiuli  Sun</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Hong  Yuan</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>142 </em>, 493-505. <a href="https://doi.org/10.1016/j.ejmech.2017.09.024" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.09.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.09.024%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCovalent%252Bbinding%252Bdesign%252Bstrategy%25253A%252BA%252Bprospective%252Bmethod%252Bfor%252Bdiscovery%252Bof%252Bpotent%252Btargeted%252Banticancer%252Bagents%26aulast%3DWang%26aufirst%3DLuhong%26date%3D2017%26volume%3D142%26spage%3D493%26epage%3D505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sherry  Niessen</span>, <span class="hlFld-ContribAuthor ">Melissa M.  Dix</span>, <span class="hlFld-ContribAuthor ">Sabrina  Barbas</span>, <span class="hlFld-ContribAuthor ">Zachary E.  Potter</span>, <span class="hlFld-ContribAuthor ">Shuyan  Lu</span>, <span class="hlFld-ContribAuthor ">Oleg  Brodsky</span>, <span class="hlFld-ContribAuthor ">Simon  Planken</span>, <span class="hlFld-ContribAuthor ">Douglas  Behenna</span>, <span class="hlFld-ContribAuthor ">Chau  Almaden</span>, <span class="hlFld-ContribAuthor ">Ketan S.  Gajiwala</span>, <span class="hlFld-ContribAuthor ">Kevin  Ryan</span>, <span class="hlFld-ContribAuthor ">RoseAnn  Ferre</span>, <span class="hlFld-ContribAuthor ">Michael R.  Lazear</span>, <span class="hlFld-ContribAuthor ">Matthew M.  Hayward</span>, <span class="hlFld-ContribAuthor ">John C.  Kath</span>, <span class="hlFld-ContribAuthor ">Benjamin F.  Cravatt</span>. </span><span class="cited-content_cbyCitation_article-title">Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2017,</strong> <em>24 </em>
                                    (11)
                                     , 1388-1400.e7. <a href="https://doi.org/10.1016/j.chembiol.2017.08.017" title="DOI URL">https://doi.org/10.1016/j.chembiol.2017.08.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2017.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2017.08.017%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DProteome-wide%252BMap%252Bof%252BTargets%252Bof%252BT790M-EGFR-Directed%252BCovalent%252BInhibitors%26aulast%3DNiessen%26aufirst%3DSherry%26date%3D2017%26volume%3D24%26issue%3D11%26spage%3D1388%26epage%3D1400.e7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingfeng  Chen</span>, <span class="hlFld-ContribAuthor ">Weitao  Fu</span>, <span class="hlFld-ContribAuthor ">Chen  Feng</span>, <span class="hlFld-ContribAuthor ">Rong  Qu</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Lulu  Zheng</span>, <span class="hlFld-ContribAuthor ">Bo  Fang</span>, <span class="hlFld-ContribAuthor ">Yinda  Qiu</span>, <span class="hlFld-ContribAuthor ">Jie  Hu</span>, <span class="hlFld-ContribAuthor ">Yuepiao  Cai</span>, <span class="hlFld-ContribAuthor ">Jianpeng  Feng</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Zhiguo  Liu</span>, <span class="hlFld-ContribAuthor ">Guang  Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>140 </em>, 510-527. <a href="https://doi.org/10.1016/j.ejmech.2017.08.061" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.08.061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.08.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.08.061%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bdesign%252Band%252Bsynthesis%252Bof%252B2%25252C4-diaminopyrimidines%252Bas%252BEGFR%252BL858R%25252FT790M%252Bselective%252Binhibitors%252Bfor%252BNSCLC%26aulast%3DChen%26aufirst%3DLingfeng%26date%3D2017%26volume%3D140%26spage%3D510%26epage%3D527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liron  Bar-Peled</span>, <span class="hlFld-ContribAuthor ">Esther K.  Kemper</span>, <span class="hlFld-ContribAuthor ">Radu M.  Suciu</span>, <span class="hlFld-ContribAuthor ">Ekaterina V.  Vinogradova</span>, <span class="hlFld-ContribAuthor ">Keriann M.  Backus</span>, <span class="hlFld-ContribAuthor ">Benjamin D.  Horning</span>, <span class="hlFld-ContribAuthor ">Thomas A.  Paul</span>, <span class="hlFld-ContribAuthor ">Taka-Aki  Ichu</span>, <span class="hlFld-ContribAuthor ">Robert U.  Svensson</span>, <span class="hlFld-ContribAuthor ">Jose  Olucha</span>, <span class="hlFld-ContribAuthor ">Max W.  Chang</span>, <span class="hlFld-ContribAuthor ">Bernard P.  Kok</span>, <span class="hlFld-ContribAuthor ">Zhou  Zhu</span>, <span class="hlFld-ContribAuthor ">Nathan T.  Ihle</span>, <span class="hlFld-ContribAuthor ">Melissa M.  Dix</span>, <span class="hlFld-ContribAuthor ">Ping  Jiang</span>, <span class="hlFld-ContribAuthor ">Matthew M.  Hayward</span>, <span class="hlFld-ContribAuthor ">Enrique  Saez</span>, <span class="hlFld-ContribAuthor ">Reuben J.  Shaw</span>, <span class="hlFld-ContribAuthor ">Benjamin F.  Cravatt</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cell</span><span> <strong>2017,</strong> <em>171 </em>
                                    (3)
                                     , 696-709.e23. <a href="https://doi.org/10.1016/j.cell.2017.08.051" title="DOI URL">https://doi.org/10.1016/j.cell.2017.08.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cell.2017.08.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cell.2017.08.051%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%26atitle%3DChemical%252BProteomics%252BIdentifies%252BDruggable%252BVulnerabilities%252Bin%252Ba%252BGenetically%252BDefined%252BCancer%26aulast%3DBar-Peled%26aufirst%3DLiron%26date%3D2017%26volume%3D171%26issue%3D3%26spage%3D696%26epage%3D709.e23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Bo  Wang</span>, <span class="hlFld-ContribAuthor ">Baichun  Hu</span>, <span class="hlFld-ContribAuthor ">Hailun  Jiang</span>, <span class="hlFld-ContribAuthor ">Bate  Lai</span>, <span class="hlFld-ContribAuthor ">Ning  Li</span>, <span class="hlFld-ContribAuthor ">Maosheng  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">In Silicon Approach for Discovery of Chemopreventive Agents. </span><span class="cited-content_cbyCitation_journal-name">Current Pharmacology Reports</span><span> <strong>2017,</strong> <em>3 </em>
                                    (4)
                                     , 184-195. <a href="https://doi.org/10.1007/s40495-017-0094-1" title="DOI URL">https://doi.org/10.1007/s40495-017-0094-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40495-017-0094-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40495-017-0094-1%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Pharmacology%2520Reports%26atitle%3DIn%252BSilicon%252BApproach%252Bfor%252BDiscovery%252Bof%252BChemopreventive%252BAgents%26aulast%3DWang%26aufirst%3DJian%26date%3D2017%26date%3D2017%26volume%3D3%26issue%3D4%26spage%3D184%26epage%3D195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. <b>1</b> is a previously reported T790M mutant inhibitor that has exceptional selectivity over WT EGFR. The 1.9 Ã cocrystal structure (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG7">5HG7</a>) with EGFR T790M/L858R protein shows the ligand covalently modifying Cys797 of the EGFR protein as designed. The core also forms the classic donorâacceptorâdonor motif to the kinase hinge region. Also highlighted is the gatekeeper residue, Met790. IC<sub>50</sub> data is from cell-based assays.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Modeled docking of screen hit <b>2</b> into the EGFR T790M/L858R protein (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG7">5HG7</a>). Note coreâhinge interactions including polarized C(8) CâH bond. The close proximity of the C(2) vector to target Cys797 indicated the best vector on which to append an electrophile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Modeled docking of simplified compounds containing pyrrolidine-linked warheads into the EGFR T790M/L858R protein (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG7">5HG7</a>). Distance of highlighted CYS797 to the acrylamide is shown. (A and B) Linker from <b>4</b> showing âpseudo-axialâ and âpseudo-equatorialâ warhead conformations, respectively. (C) Isomeric pyrroldine linker from <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. The 1.5 Ã cocrystal structure (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UG8">5UG8</a>) of compound <b>7</b> with EGFR_L858R/T790M mutant (only the ligand binding site is shown). Note <i>anti</i> conformation of fluorine and warhead linker and apparent fluorine interaction with Phe723.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Activating fluorine: Overlap between warhead nitrogen NB-orbital and Ï* orbital of CâF bond of <b>14</b> increases the reactivity of the Michael acceptor. (b) Neutral fluorine: Orthogonal orbitals have minimal interaction which resulted in little effect on intrinsic reactivity of <b>7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Cocrystal structure of <b>16</b> (1.3 Ã, PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UG9">5UG9</a>). The kinase selectivity pocket that is afforded via hinge residue Leu792 is illustrated. Many kinases (59%) have a large Phe or Tyr residue in this position, precluding pyrazole substitution. Filling this pocket with a methoxy group afforded an improved kinase off-target profile without significant detrimental impact on in vitro human microsomal intrinsic clearance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Single mutant vs double mutant potency. Plot showing series potencies against the T790M/L858R double mutant (H1975) and the Del (PC9) single mutant highlighting the superior Del mutant coverage of the purine series (blue) over the previous workâs pyrrolopyrimidine series (yellow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. N(9) <sup>i</sup>Pr rotation on binding to WT EGFR. Cocrystal structures of compound <b>18</b> in EGFR L858R/T790M (left, 1.3 Ã resolution, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UGA">5UGA</a>) and WT EGFR (right, 2.1 Ã resolution, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UGB">5UGB</a>) illustrated the orientation of the <sup>i</sup>Pr group relative to the gatekeeper residue: note the rotation of the N(9) <sup>i</sup>Pr when bound in the WT pocket. *Measured <i>K</i><sub>i</sub> in T790M/L858R double mutant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0009.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Matched pairwise plot by N(9) substituent. Plot illustrated cellular pEGFR WT selectivity seen by varying N(9) substituent size; the larger <i>tert</i>-butyl group consistently afforded the highest selectivity. The methyl substituent examples go against the trend and in many cases <i>improved</i> WT selectivity relative to the corresponding ethyl or isopropyl analogue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0010.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Competitive in situ labeling profiles of 1 Î¼M of each chemical probe, P_1 and P_21, vs a representative aminoquinazoline probe, P_AQ. H1975 cells were treated 1 Î¼M parent inhibitor (<b>26</b>, <b>1</b>, <b>21</b>) or an equal amount of DMSO for 2 h. Next, 1 Î¼M of the corresponding chemical probe was added during 3 h. Representative proteome labeling profiles were also generated with 100 nM of each chemical probe for 3 h. After labeling, cells were harvested, lysed, and separated into particulate (left) and soluble (right) proteomes. Equal amounts of protein lysate were reacted with azide-rhodamine, and covalently labeled proteins were revealed by gel-based fluorescence (gels are shown in grayscale). *Highlights a protein in the particulate proteome predicted to be EGFR by molecular weight that fully competes with parent inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0011.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Initial Route Exemplified by the Synthesis of Compound <b>4</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0012.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Optimized Analoguing Route Exemplified by the Synthesis of Compound <b>5</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/medium/jm-2016-018943_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0013.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Scalable Route to Purine Compounds Exemplified by Clinical Candidate <b>21</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-7/acs.jmedchem.6b01894/20170407/images/large/jm-2016-018943_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01894&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i38">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86036" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86036" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 27 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almaden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behenna, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho-Schultz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferre, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemkens, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson-Fisher, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalaie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kephart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafontaine, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunney, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niessen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ornelas, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planken, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walls, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinrich, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zientek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span> </span><span class="NLM_article-title">Discovery of 1-{(3<i>R</i>,4<i>R</i>)-3-[({5-Chloro-2-[(1-methyl-1<i>H</i>-pyrazol-4-yl)amino]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a potent, WT sparing, irreversible inhibitor of T790M-containing EGFR mutants</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">2005</span><span class="NLM_x">â</span> <span class="NLM_lpage">2024</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01633</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01633" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2005-2024&issue=5&author=H.+Chengauthor=S.+K.+Nairauthor=B.+W.+Murrayauthor=C.+Almadenauthor=S.+Baileyauthor=S.+Baxiauthor=D.+Behennaauthor=S.+Cho-Schultzauthor=D.+Dalvieauthor=D.+M.+Dinhauthor=M.+P.+Edwardsauthor=J.+L.+Fengauthor=R.+A.+Ferreauthor=K.+S.+Gajiwalaauthor=M.+D.+Hemkensauthor=A.+Jackson-Fisherauthor=M.+Jalaieauthor=T.+O.+Johnsonauthor=R.+S.+Kaniaauthor=S.+Kephartauthor=J.+Lafontaineauthor=B.+Lunneyauthor=K.+K.+Liuauthor=Z.+Liuauthor=J.+Matthewsauthor=A.+Nagataauthor=S.+Niessenauthor=M.+A.+Ornelasauthor=S.+T.+Orrauthor=M.+Pairishauthor=S.+Plankenauthor=S.+Renauthor=D.+Richterauthor=K.+Ryanauthor=N.+Sachauthor=H.+Shenauthor=T.+Smealauthor=J.+Solowiejauthor=S.+Suttonauthor=K.+Tranauthor=E.+Tsengauthor=W.+Vernierauthor=M.+Wallsauthor=S.+Wangauthor=S.+L.+Weinrichauthor=S.+Xinauthor=H.+Xuauthor=M.+J.+Yinauthor=M.+Zientekauthor=R.+Zhouauthor=J.+C.+Kath&title=Discovery+of+1-%7B%283R%2C4R%29-3-%5B%28%7B5-Chloro-2-%5B%281-methyl-1H-pyrazol-4-yl%29amino%5D-7H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%7Doxy%29methyl%5D-4-methoxypyrrolidin-1-yl%7Dprop-2-en-1-one+%28PF-06459988%29%2C+a+potent%2C+WT+sparing%2C+irreversible+inhibitor+of+T790M-containing+EGFR+mutants&doi=10.1021%2Facs.jmedchem.5b01633"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01633%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DNair%26aufirst%3DS.%2BK.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBaxi%26aufirst%3DS.%26aulast%3DBehenna%26aufirst%3DD.%26aulast%3DCho-Schultz%26aufirst%3DS.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DFeng%26aufirst%3DJ.%2BL.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DHemkens%26aufirst%3DM.%2BD.%26aulast%3DJackson-Fisher%26aufirst%3DA.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKephart%26aufirst%3DS.%26aulast%3DLafontaine%26aufirst%3DJ.%26aulast%3DLunney%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMatthews%26aufirst%3DJ.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DOrnelas%26aufirst%3DM.%2BA.%26aulast%3DOrr%26aufirst%3DS.%2BT.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DPlanken%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DRichter%26aufirst%3DD.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DSach%26aufirst%3DN.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DSutton%26aufirst%3DS.%26aulast%3DTran%26aufirst%3DK.%26aulast%3DTseng%26aufirst%3DE.%26aulast%3DVernier%26aufirst%3DW.%26aulast%3DWalls%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWeinrich%26aufirst%3DS.%2BL.%26aulast%3DXin%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DM.%2BJ.%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%25201-%257B%25283R%252C4R%2529-3-%255B%2528%257B5-Chloro-2-%255B%25281-methyl-1H-pyrazol-4-yl%2529amino%255D-7H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%257Doxy%2529methyl%255D-4-methoxypyrrolidin-1-yl%257Dprop-2-en-1-one%2520%2528PF-06459988%2529%252C%2520a%2520potent%252C%2520WT%2520sparing%252C%2520irreversible%2520inhibitor%2520of%2520T790M-containing%2520EGFR%2520mutants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D5%26spage%3D2005%26epage%3D2024%26doi%3D10.1021%2Facs.jmedchem.5b01633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">169</span><span class="NLM_x">â</span> <span class="NLM_lpage">181</span><span class="refDoi">Â DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&issue=3&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lhuW80D8TqqbA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26issue%3D3%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bonanno, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jirillo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favaretto, A.</span><span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">922</span><span class="NLM_x">â</span> <span class="NLM_lpage">933</span><span class="refDoi">Â DOI: 10.2174/138945011795528958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.2174%2F138945011795528958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=21443472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlOmsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=922-933&issue=6&author=L.+Bonannoauthor=A.+Jirilloauthor=A.+Favaretto&title=Mechanisms+of+acquired+resistance+to+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+and+new+therapeutic+perspectives+in+non+small+cell+lung+cancer&doi=10.2174%2F138945011795528958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer</span></div><div class="casAuthors">Bonanno, Laura; Jirillo, Antonio; Favaretto, Adolfo</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">922-933</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  EGFR somatic mutations define a subset of NSCLCs that are most likely to benefit from EGFR tyrosine kinase inhibitors (TKIs).  These tumors are dependent on EGFR-signaling for survival.  Recently, tyrosine kinase domain somatic mutations were approved as criterion to decide 1st-line therapy in this group of advanced NSCLCs.  Anyway, all patients ultimately develop resistance to these drugs.  Acquired resistance is linked to a secondary EGFR mutation in about a half of patients.  Uncontrolled activation of MET, another tyrosine kinase receptor, was implicated in neoplastic invasive growth.  MET is overexpressed, activated and sometimes mutated in NSCLC cell lines and tumor tissues.  MET increased gene copy no. was also documented in NSCLC and was studied as neg. prognostic factor.  It was also found in about 20% of patients developing acquired resistance to TKIs inhibitors.  In this group, it seems to display a new mechanism, which is able to mark tumor independence from EGFR signaling.  The study of delayed resistance mechanisms could lead to the development of new therapeutic strategies.  Different mol. alterations could be specifically targeted to extend disease control in this group of NSCLCs with distinct clin. and mol. features.  EGFR irreversible inhibitors, MET inhibitors and dual EGFR/VEGFR inhibitors represent one of the most challenging issues in current clin. research.  Ongoing clin. trials and future perspectives are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1PSQ8xqQ2mbVg90H21EOLACvtfcHk0lhuW80D8TqqbA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlOmsrg%253D&md5=25b1b08011e4aee60673d8dbb8cca222</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.2174%2F138945011795528958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945011795528958%26sid%3Dliteratum%253Aachs%26aulast%3DBonanno%26aufirst%3DL.%26aulast%3DJirillo%26aufirst%3DA.%26aulast%3DFavaretto%26aufirst%3DA.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520and%2520new%2520therapeutic%2520perspectives%2520in%2520non%2520small%2520cell%2520lung%2520cancer%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2011%26volume%3D12%26issue%3D6%26spage%3D922%26epage%3D933%26doi%3D10.2174%2F138945011795528958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruvka, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1070</span><span class="NLM_x">â</span> <span class="NLM_lpage">1080</span><span class="refDoi">Â DOI: 10.1200/JCO.2012.43.3912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1200%2FJCO.2012.43.3912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=23401451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltl2mtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1070-1080&issue=8&author=K.+Ohashiauthor=Y.+E.+Maruvkaauthor=F.+Michorauthor=W.+Pao&title=Epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor-resistant+disease&doi=10.1200%2FJCO.2012.43.3912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease</span></div><div class="casAuthors">Ohashi, Kadoaki; Maruvka, Yosef E.; Michor, Franziska; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1070-1080</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Purpose EGFR-mutant lung cancer was first described as a new clin. entity in 2004.  Here, we present an update on new controversies and conclusions regarding the disease.  Methods This article reviews the clin. implications of EGFR mutations in lung cancer with a focus on epidermal growth factor receptor tyrosine kinase inhibitor resistance.  Results The discovery of EGFR mutations has altered the ways in which we consider and treat non-small-cell lung cancer (NSCLC).  Patients whose metastatic tumors harbor EGFR mutations are expected to live longer than 2 years, more than double the previous survival rates for lung cancer.  Conclusion The information presented in this review can guide practitioners and help them inform their patients about EGFR mutations and their impact on the treatment of NSCLC.  Efforts should now conc. on making EGFR-mutant lung cancer a chronic rather than fatal disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3FJbVyt6ydLVg90H21EOLACvtfcHk0lhuW80D8TqqbA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltl2mtb0%253D&md5=dfda1563a90ce24bc51e55ebbf47d981</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.43.3912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.43.3912%26sid%3Dliteratum%253Aachs%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DMaruvka%26aufirst%3DY.%2BE.%26aulast%3DMichor%26aufirst%3DF.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor-resistant%2520disease%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26issue%3D8%26spage%3D1070%26epage%3D1080%26doi%3D10.1200%2FJCO.2012.43.3912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Chang, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, J. Y.</span><span> </span><span class="NLM_article-title">The role of epidermal growth factor receptor mutations and epidermal growth factor receptor-tyrosine kinase inhibitors in the treatment of lung cancer</span> <span class="citation_source-journal">Cancers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">2667</span><span class="NLM_x">â</span> <span class="NLM_lpage">2678</span><span class="refDoi">Â DOI: 10.3390/cancers3022667</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.3390%2Fcancers3022667" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=2667-2678&issue=2&author=S.+C.+Changauthor=C.+Y.+Changauthor=J.+Y.+Shih&title=The+role+of+epidermal+growth+factor+receptor+mutations+and+epidermal+growth+factor+receptor-tyrosine+kinase+inhibitors+in+the+treatment+of+lung+cancer&doi=10.3390%2Fcancers3022667"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.3390%2Fcancers3022667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers3022667%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%2BC.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DShih%26aufirst%3DJ.%2BY.%26atitle%3DThe%2520role%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520mutations%2520and%2520epidermal%2520growth%2520factor%2520receptor-tyrosine%2520kinase%2520inhibitors%2520in%2520the%2520treatment%2520of%2520lung%2520cancer%26jtitle%3DCancers%26date%3D2011%26volume%3D3%26issue%3D2%26spage%3D2667%26epage%3D2678%26doi%3D10.3390%2Fcancers3022667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abolhoda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span> </span><span class="NLM_article-title">The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">784</span><span class="NLM_x">â</span> <span class="NLM_lpage">791</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-11-0750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1158%2F1535-7163.MCT-11-0750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=22228822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKitr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=784-791&issue=3&author=Y.+Kimauthor=J.+Koauthor=Z.+Cuiauthor=A.+Abolhodaauthor=J.+S.+Ahnauthor=S.+H.+Ouauthor=M.+J.+Ahnauthor=K.+Park&title=The+EGFR+T790M+mutation+in+acquired+resistance+to+an+irreversible+second-generation+EGFR+inhibitor&doi=10.1158%2F1535-7163.MCT-11-0750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor</span></div><div class="casAuthors">Kim, Youngwook; Ko, Jeonghun; Cui, ZhengYun; Abolhoda, Amir; Ahn, Jin Seok; Ou, Sai-Hong; Ahn, Myung-Ju; Park, Keunchil</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">784-791</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mol. target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCLC) who harbor activating mutations in EGFR.  However, these patients eventually develop resistance to the reversible TKIs, and this has led to the development of second-generation, irreversible EGFR inhibitors.  Currently, the mechanism of acquired resistance to irreversible EGFR inhibitors is not clear.  Using an in vitro cell culture system, we modeled the acquired resistance to first-line treatment with second-generation EGFR-TKIs using an EGFR-mutant NSCLC cell line.  Here, we report a mechanism of resistance involving T790M secondary mutation as well as a corresponding clin. case.  The results of these findings suggest that inhibition of EGFR by currently available second-generation EGFR-TKIs may not be sufficient to physiol. prevent the emergence of cells that are still dependent on EGFR signaling.  This finding bears important implications on the limitations of currently available second-generation EGFR-TKIs.  Mol Cancer Ther; 11(3); 784-91.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDhUxzW64OFLVg90H21EOLACvtfcHk0lhrCP6bU9h6qw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKitr4%253D&md5=3cd09bb1dd73f8045b93b054c79480d3</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0750%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%26aulast%3DKo%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DZ.%26aulast%3DAbolhoda%26aufirst%3DA.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DPark%26aufirst%3DK.%26atitle%3DThe%2520EGFR%2520T790M%2520mutation%2520in%2520acquired%2520resistance%2520to%2520an%2520irreversible%2520second-generation%2520EGFR%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D3%26spage%3D784%26epage%3D791%26doi%3D10.1158%2F1535-7163.MCT-11-0750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wheeler, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harari, P. M.</span><span> </span><span class="NLM_article-title">Understanding resistance to EGFR inhibitors-impact on future treatment strategies</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">493</span><span class="NLM_x">â</span> <span class="NLM_lpage">507</span><span class="refDoi">Â DOI: 10.1038/nrclinonc.2010.97</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1038%2Fnrclinonc.2010.97" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=20551942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyjsr7L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=493-507&issue=9&author=D.+L.+Wheelerauthor=E.+F.+Dunnauthor=P.+M.+Harari&title=Understanding+resistance+to+EGFR+inhibitors-impact+on+future+treatment+strategies&doi=10.1038%2Fnrclinonc.2010.97"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding resistance to EGFR inhibitors-impact on future treatment strategies</span></div><div class="casAuthors">Wheeler, Deric L.; Dunn, Emily F.; Harari, Paul M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">493-507</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  EGFR is one of the most studied targets in oncol., and several inhibitors have shown promising results in selected patient populations.  However, intrinsic and acquired resistance to these targeted therapies is increasingly recognized.  The authors of this Review describe the successful translation of EGFR inhibitors to the clinic, and highlight the mechanisms of resistance to these agents that limit their long-term efficacy.  Understanding these processes will allow researchers to develop therapies that overcome resistance and ultimately lead to more successful outcomes.  EGFR is a tyrosine kinase that participates in the regulation of cellular homeostasis.  Following ligand binding, EGFR stimulates downstream cell signaling cascades that influence cell proliferation, apoptosis, migration, survival and complex processes, including angiogenesis and tumorigenesis.  EGFR has been strongly implicated in the biol. of human epithelial malignancies, with therapeutic applications in cancers of the colon, head and neck, lung, and pancreas.  Accordingly, targeting EGFR has been intensely pursued, with the development of a series of promising mol. inhibitors for use in clin. oncol.  As is common in cancer therapy, challenges with respect to treatment resistance emerge over time.  This situation is certainly true of EGFR inhibitor therapies, where intrinsic and acquired resistance is now well recognized.  In this Review, we provide a brief overview regarding the biol. of EGFR, preclin. and clin. development of EGFR inhibitors, and mol. mechanisms that underlie the development of treatment resistance.  A greater understanding of the mechanisms that lead to EGFR resistance may provide valuable insights to help design new strategies that will enhance the impact of this promising class of inhibitors for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw7LepfpXQa7Vg90H21EOLACvtfcHk0lhrCP6bU9h6qw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyjsr7L&md5=2f043ede90d7206e45ec80642302a766</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2010.97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2010.97%26sid%3Dliteratum%253Aachs%26aulast%3DWheeler%26aufirst%3DD.%2BL.%26aulast%3DDunn%26aufirst%3DE.%2BF.%26aulast%3DHarari%26aufirst%3DP.%2BM.%26atitle%3DUnderstanding%2520resistance%2520to%2520EGFR%2520inhibitors-impact%2520on%2520future%2520treatment%2520strategies%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D7%26issue%3D9%26spage%3D493%26epage%3D507%26doi%3D10.1038%2Fnrclinonc.2010.97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span> </span><span class="NLM_article-title">Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Proteins Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1804</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">559</span><span class="NLM_x">â</span> <span class="NLM_lpage">566</span><span class="refDoi">Â DOI: 10.1016/j.bbapap.2009.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1016%2Fj.bbapap.2009.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=20026433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1ymsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1804&publication_year=2010&pages=559-566&issue=3&author=M.+J.+Eckauthor=C.+H.+Yun&title=Structural+and+mechanistic+underpinnings+of+the+differential+drug+sensitivity+of+EGFR+mutations+in+non-small+cell+lung+cancer&doi=10.1016%2Fj.bbapap.2009.12.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer</span></div><div class="casAuthors">Eck, Michael J.; Yun, Cai-Hong</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1804</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">559-566</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  EGFR and other ErbB-family tyrosine kinases are overexpressed in many human tumors, and their aberrant expression and mutational activation is assocd. with the development, progression and aggressiveness of a no. of malignancies.  Thus the EGFR kinase has long been recognized as a potential drug target in oncol., and small-mol. inhibitors have been under development for more than two decades.  As a result of their effectiveness in treating non-small cell lung cancers (NSCLCs) driven by somatic mutations in the EGFR kinase, gefitinib and erlotinib were the first EGFR tyrosine kinase inhibitors (TKIs) approved for clin. use.  Ironically, these drugs found their target against mutant forms of the EGFR kinase, which have altered enzyme active sites, and not against the wild type (WT) kinase against which their potency and selectivity was carefully honed.  Here we review recent structural and enzymol. studies that explore the exquisite sensitivity of a subset of these lung cancer mutants to gefitinib and erlotinib.  We discuss available structural evidence for the mechanisms of activation of the EGFR kinase by these mutants, and compare it to physiol. activation of the kinase by ligand-induced dimerization.  Finally, we consider the mechanisms by which the secondary T790M "gatekeeper" mutation confers resistance to gefitinib and erlotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0KpzCSm4-TbVg90H21EOLACvtfcHk0lhrCP6bU9h6qw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1ymsrs%253D&md5=7717d659eacc3dea0cdb6ae4c85d865c</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2009.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2009.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DYun%26aufirst%3DC.%2BH.%26atitle%3DStructural%2520and%2520mechanistic%2520underpinnings%2520of%2520the%2520differential%2520drug%2520sensitivity%2520of%2520EGFR%2520mutations%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2010%26volume%3D1804%26issue%3D3%26spage%3D559%26epage%3D566%26doi%3D10.1016%2Fj.bbapap.2009.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">307</span><span class="NLM_x">â</span> <span class="NLM_lpage">317</span><span class="refDoi">Â DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&issue=4&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0li9NDy6EIJU0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26issue%3D4%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluge, A. F.</span><span> </span><span class="NLM_article-title">Targeted covalent drugs of the kinase family</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">475</span><span class="NLM_x">â</span> <span class="NLM_lpage">480</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2010.06.168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1016%2Fj.cbpa.2010.06.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=20609616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=475-480&issue=4&author=J.+Singhauthor=R.+C.+Petterauthor=A.+F.+Kluge&title=Targeted+covalent+drugs+of+the+kinase+family&doi=10.1016%2Fj.cbpa.2010.06.168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted covalent drugs of the kinase family</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Kluge, Arthur F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">475-480</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In the past decade tremendous progress has been made toward a new class of therapeutics termed 'targeted covalent drugs', in which structure-based approaches are employed to create small mols. that inactivate their protein target through targeted covalent attachment to a specific cysteine.  In the kinase field, this approach is demonstrating promise in overcoming the potency, selectivity, and efficacy challenges currently faced by reversible kinase inhibitors, with several advancing into late stage clin. testing.  This design paradigm has been successfully applied to making drug candidates for epidermal growth factor receptor (EGFR), Her2, and Bruton's tyrosine kinase (Btk).  Here we review recent pre-clin. and clin. advances with targeted covalent kinase inhibitors, and the potential for broader application of the approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPQb40Eok-vbVg90H21EOLACvtfcHk0li9NDy6EIJU0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtr8%253D&md5=ee3b8b9e0c6ec317f975a426cf08428f</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.06.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.06.168%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DKluge%26aufirst%3DA.%2BF.%26atitle%3DTargeted%2520covalent%2520drugs%2520of%2520the%2520kinase%2520family%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26issue%3D4%26spage%3D475%26epage%3D480%26doi%3D10.1016%2Fj.cbpa.2010.06.168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span> </span><span class="NLM_article-title">Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers</span> <span class="citation_source-journal">J. Natl. Compr. Cancer Network</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">â</span> <span class="NLM_lpage">169</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=23411383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFehurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=161-169&author=H.+A.+Yuauthor=G.+J.+Riely&title=Second-generation+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+in+lung+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4dR"><div class="casContent"><span class="casTitleNuber">4d</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers</span></div><div class="casAuthors">Yu, Helena A.; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Comprehensive Cancer Network</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-169</span>CODEN:
                <span class="NLM_cas:coden">JNCCA4</span>;
        ISSN:<span class="NLM_cas:issn">1540-1405</span>.
    
            (<span class="NLM_cas:orgname">Harborside Press</span>)
        </div><div class="casAbstract">A review.  EGFR mutations identify patients who are more likely to respond to treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) than cytotoxic chemotherapy.  The distinct success of the first-generation EGFR TKIs erlotinib and gefitinib has been accompanied by the observation that acquired resistance to these treatments develops after a median of 1 yr of treatment.  Newer, second-generation EGFR TKIs have been developed with the intent to delay or overcome acquired resistance by the broader inhibition of kinases (eg, HER2 and vascular endothelial growth factor receptor) and/or altering the interactions with EGFR through irreversibly binding to the kinase domain.  This article discusses many of these agents (including afatinib, dacomitinib, XL647, AP26113, and CO-1686) which have the potential for greater efficacy compared with first-generation EGFR TKIs, and may also have clin. activity against other oncogenic mutations within the EGFR family, including HER2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7jw642CNY4LVg90H21EOLACvtfcHk0li9NDy6EIJU0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFehurk%253D&md5=b6c03450a9e9f5835de035a1620875bb</span></div><a href="/servlet/linkout?suffix=cit4d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DSecond-generation%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520lung%2520cancers%26jtitle%3DJ.%2520Natl.%2520Compr.%2520Cancer%2520Network%26date%3D2013%26volume%3D11%26spage%3D161%26epage%3D169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naumov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">PF-00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">11924</span><span class="NLM_x">â</span> <span class="NLM_lpage">11932</span><span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-07-1885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1158%2F0008-5472.CAN-07-1885" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11924-11932&issue=24&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=C.+M.+Galeauthor=E.+Lifshitsauthor=A.+J.+Gonzalesauthor=T.+Shimamuraauthor=F.+Zhaoauthor=P.+W.+Vincentauthor=G.+N.+Naumovauthor=J.+E.+Bradnerauthor=I.+W.+Althausauthor=L.+Gandhiauthor=G.+I.+Shapiroauthor=J.+M.+Nelsonauthor=J.+V.+Heymachauthor=M.+Meyersonauthor=K.+K.+Wongauthor=P.+A.+Janne&title=PF-00299804%2C+an+irreversible+pan-ERBB+inhibitor%2C+is+effective+in+lung+cancer+models+with+EGFR+and+ERBB2+mutations+that+are+resistant+to+gefitinib&doi=10.1158%2F0008-5472.CAN-07-1885"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1885%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DGale%26aufirst%3DC.%2BM.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DNaumov%26aufirst%3DG.%2BN.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DPF-00299804%252C%2520an%2520irreversible%2520pan-ERBB%2520inhibitor%252C%2520is%2520effective%2520in%2520lung%2520cancer%2520models%2520with%2520EGFR%2520and%2520ERBB2%2520mutations%2520that%2520are%2520resistant%2520to%2520gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26issue%3D24%26spage%3D11924%26epage%3D11932%26doi%3D10.1158%2F0008-5472.CAN-07-1885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicer, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fakhoury, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, F. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivault, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlosser, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trachet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tecle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 20. Optimization of substituted quinazoline and pyrido[3,4-<i>d</i>]pyrimidine derivatives as orally active, irreversible inhibitors of the epidermal growth factor receptor family</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">8103</span><span class="NLM_x">â</span> <span class="NLM_lpage">8124</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00883</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00883" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8103-8124&issue=17&author=J.+B.+Smaillauthor=A.+J.+Gonzalesauthor=J.+A.+Spicerauthor=H.+Leeauthor=J.+E.+Reedauthor=K.+Sextonauthor=I.+W.+Althausauthor=T.+Zhuauthor=S.+L.+Blackauthor=A.+Blaserauthor=W.+A.+Dennyauthor=P.+A.+Ellisauthor=S.+Fakhouryauthor=P.+J.+Harveyauthor=K.+Hookauthor=F.+O.+McCarthyauthor=B.+D.+Palmerauthor=F.+Rivaultauthor=K.+Schlosserauthor=T.+Ellisauthor=A.+M.+Thompsonauthor=E.+Trachetauthor=R.+T.+Wintersauthor=H.+Tecleauthor=A.+Bridges&title=Tyrosine+kinase+inhibitors.+20.+Optimization+of+substituted+quinazoline+and+pyrido%5B3%2C4-d%5Dpyrimidine+derivatives+as+orally+active%2C+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor+family&doi=10.1021%2Facs.jmedchem.6b00883"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00883%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DSpicer%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DReed%26aufirst%3DJ.%2BE.%26aulast%3DSexton%26aufirst%3DK.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBlack%26aufirst%3DS.%2BL.%26aulast%3DBlaser%26aufirst%3DA.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DFakhoury%26aufirst%3DS.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DHook%26aufirst%3DK.%26aulast%3DMcCarthy%26aufirst%3DF.%2BO.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DRivault%26aufirst%3DF.%26aulast%3DSchlosser%26aufirst%3DK.%26aulast%3DEllis%26aufirst%3DT.%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DTrachet%26aufirst%3DE.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DBridges%26aufirst%3DA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252020.%2520Optimization%2520of%2520substituted%2520quinazoline%2520and%2520pyrido%255B3%252C4-d%255Dpyrimidine%2520derivatives%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520family%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D17%26spage%3D8103%26epage%3D8124%26doi%3D10.1021%2Facs.jmedchem.6b00883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lelais, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epple, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsilje, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, Y. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNeill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anumolu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badiger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiDonato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juarez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manuia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groessl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasibhatla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isbell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spraggon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P. Y.</span><span> </span><span class="NLM_article-title">Discovery of (<i>R</i>,<i>E</i>)-<i>N</i>-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1<i>H</i>-benzo[<i>d</i>]imid azol-2-yl)-2-methylisonicotinamide (EGF816), a novel, potent, and WT sparing covalent inhibitor of oncogenic (L858R, ex19del) and resistant (T790M) EGFR mutants for the treatment of EGFR mutant non-small-cell lung cancers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">6671</span><span class="NLM_x">â</span> <span class="NLM_lpage">6689</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01985</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01985" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOgu77P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6671-6689&issue=14&author=G.+Lelaisauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=Y.+O.+Longauthor=M.+McNeillauthor=B.+Chenauthor=W.+Luauthor=J.+Anumoluauthor=S.+Badigerauthor=B.+Bursulayaauthor=M.+DiDonatoauthor=R.+Fongauthor=J.+Juarezauthor=J.+Liauthor=M.+Manuiaauthor=D.+E.+Masonauthor=P.+Gordonauthor=T.+Groesslauthor=K.+Johnsonauthor=Y.+Jiaauthor=S.+Kasibhatlaauthor=C.+Liauthor=J.+Isbellauthor=G.+Spraggonauthor=S.+Benderauthor=P.+Y.+Michellys&title=Discovery+of+%28R%2CE%29-N-%287-Chloro-1-%281-%5B4-%28dimethylamino%29but-2-enoyl%5Dazepan-3-yl%29-1H-benzo%5Bd%5Dimid+azol-2-yl%29-2-methylisonicotinamide+%28EGF816%29%2C+a+novel%2C+potent%2C+and+WT+sparing+covalent+inhibitor+of+oncogenic+%28L858R%2C+ex19del%29+and+resistant+%28T790M%29+EGFR+mutants+for+the+treatment+of+EGFR+mutant+non-small-cell+lung+cancers&doi=10.1021%2Facs.jmedchem.5b01985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers</span></div><div class="casAuthors">Lelais, Gerald; Epple, Robert; Marsilje, Thomas H.; Long, Yun O.; McNeill, Matthew; Chen, Bei; Lu, Wenshuo; Anumolu, Jaganmohan; Badiger, Sangamesh; Bursulaya, Badry; DiDonato, Michael; Fong, Rina; Juarez, Jose; Li, Jie; Manuia, Mari; Mason, Daniel E.; Gordon, Perry; Groessl, Todd; Johnson, Kevin; Jia, Yong; Kasibhatla, Shailaja; Li, Chun; Isbell, John; Spraggon, Glen; Bender, Steven; Michellys, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6671-6689</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Over the past decade, first and second generation EGFR inhibitors have significantly improved outcomes for lung cancer patients with activating mutations in EGFR.  However, both resistance through a secondary T790M mutation at the gatekeeper residue and dose-limiting toxicities from wild-type (WT) EGFR inhibition ultimately limit the full potential of these therapies to control mutant EGFR-driven tumors and new therapies are urgently needed.  Herein, we describe our approach toward the discovery of 47 (EGF816, nazartinib), a novel, covalent mutant-selective EGFR inhibitor with equipotent activity on both oncogenic and T790M-resistant EGFR mutations.  Through mol. docking studies we converted a mutant-selective high-throughput screening hit (7) into a no. of targeted covalent EGFR inhibitors with equipotent activity across mutants EGFR and good WT-EGFR selectivity.  We used an abbreviated in vivo efficacy study for prioritizing compds. with good tolerability and efficacy that ultimately led to the selection of 47 as the clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpcKsqbwkyp7Vg90H21EOLACvtfcHk0ljPAizRWF0GTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOgu77P&md5=c106545d878ab3d675644b47099668a0</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01985%26sid%3Dliteratum%253Aachs%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DLong%26aufirst%3DY.%2BO.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DAnumolu%26aufirst%3DJ.%26aulast%3DBadiger%26aufirst%3DS.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DFong%26aufirst%3DR.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DMason%26aufirst%3DD.%2BE.%26aulast%3DGordon%26aufirst%3DP.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DIsbell%26aufirst%3DJ.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26atitle%3DDiscovery%2520of%2520%2528R%252CE%2529-N-%25287-Chloro-1-%25281-%255B4-%2528dimethylamino%2529but-2-enoyl%255Dazepan-3-yl%2529-1H-benzo%255Bd%255Dimid%2520azol-2-yl%2529-2-methylisonicotinamide%2520%2528EGF816%2529%252C%2520a%2520novel%252C%2520potent%252C%2520and%2520WT%2520sparing%2520covalent%2520inhibitor%2520of%2520oncogenic%2520%2528L858R%252C%2520ex19del%2529%2520and%2520resistant%2520%2528T790M%2529%2520EGFR%2520mutants%2520for%2520the%2520treatment%2520of%2520EGFR%2520mutant%2520non-small-cell%2520lung%2520cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D14%26spage%3D6671%26epage%3D6689%26doi%3D10.1021%2Facs.jmedchem.5b01985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine(790) --> methionine(790) mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">2711</span><span class="NLM_x">â</span> <span class="NLM_lpage">2723</span><span class="refDoi">Â DOI: 10.1021/jm201591k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2711-2723&issue=6&author=S.+Changauthor=L.+Zhangauthor=S.+Xuauthor=J.+Luoauthor=X.+Luauthor=Z.+Zhangauthor=T.+Xuauthor=Y.+Liuauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=M.+Gengauthor=J.+Dingauthor=D.+Peiauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+conformationally+constrained+inhibitors+targeting+epidermal+growth+factor+receptor+threonine%28790%29+%2D%2D%3E+methionine%28790%29+mutant&doi=10.1021%2Fjm201591k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1021%2Fjm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520conformationally%2520constrained%2520inhibitors%2520targeting%2520epidermal%2520growth%2520factor%2520receptor%2520threonine%2528790%2529%2520--%253E%2520methionine%2528790%2529%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D6%26spage%3D2711%26epage%3D2723%26doi%3D10.1021%2Fjm201591k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Sogabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cary, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span> </span><span class="NLM_article-title">Structure-based approach for the discovery of pyrrolo[3,2-<i>d</i>]pyrimidine-based EGFR T790M/L858R mutant inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">201</span><span class="NLM_x">â</span> <span class="NLM_lpage">205</span><span class="refDoi">Â DOI: 10.1021/ml300327z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300327z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=201-205&issue=2&author=S.+Sogabeauthor=Y.+Kawakitaauthor=S.+Igakiauthor=H.+Iwataauthor=H.+Mikiauthor=D.+R.+Caryauthor=T.+Takagiauthor=S.+Takagiauthor=Y.+Ohtaauthor=T.+Ishikawa&title=Structure-based+approach+for+the+discovery+of+pyrrolo%5B3%2C2-d%5Dpyrimidine-based+EGFR+T790M%2FL858R+mutant+inhibitors&doi=10.1021%2Fml300327z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1021%2Fml300327z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300327z%26sid%3Dliteratum%253Aachs%26aulast%3DSogabe%26aufirst%3DS.%26aulast%3DKawakita%26aufirst%3DY.%26aulast%3DIgaki%26aufirst%3DS.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DCary%26aufirst%3DD.%2BR.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DTakagi%26aufirst%3DS.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DStructure-based%2520approach%2520for%2520the%2520discovery%2520of%2520pyrrolo%255B3%252C2-d%255Dpyrimidine-based%2520EGFR%2520T790M%252FL858R%2520mutant%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26issue%3D2%26spage%3D201%26epage%3D205%26doi%3D10.1021%2Fml300327z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x"> (</span><span class="NLM_issue">7276</span><span class="NLM_x">) </span> <span class="NLM_fpage">1070</span><span class="NLM_x">â</span> <span class="NLM_lpage">1074</span><span class="refDoi">Â DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&issue=7276&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6dR"><div class="casContent"><span class="casTitleNuber">6d</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0ljIuitn8-x30w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26issue%3D7276%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for EGFR-T790M</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">638</span><span class="NLM_x">â</span> <span class="NLM_lpage">643</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2010.12.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1016%2Fj.bmcl.2010.12.036" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=638-643&issue=2&author=W.+Zhouauthor=D.+Ercanauthor=P.+A.+Janneauthor=N.+S.+Gray&title=Discovery+of+selective+irreversible+inhibitors+for+EGFR-T790M&doi=10.1016%2Fj.bmcl.2010.12.036"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.036%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520EGFR-T790M%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D2%26spage%3D638%26epage%3D643%26doi%3D10.1016%2Fj.bmcl.2010.12.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Finlay, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethel, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grist, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassall, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemmitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waring, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrigley, G. L.</span><span> </span><span class="NLM_article-title">Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">20</span><span class="NLM_x">) </span> <span class="NLM_fpage">8249</span><span class="NLM_x">â</span> <span class="NLM_lpage">8267</span><span class="refDoi">Â DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&issue=20&author=M.+R.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+potent+and+selective+EGFR+inhibitor+%28AZD9291%29+of+both+sensitizing+and+T790M+resistance+mutations+that+spares+the+wild+type+form+of+the+receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6fR"><div class="casContent"><span class="casTitleNuber">6f</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0ljIuitn8-x30w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit6f&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520EGFR%2520inhibitor%2520%2528AZD9291%2529%2520of%2520both%2520sensitizing%2520and%2520T790M%2520resistance%2520mutations%2520that%2520spares%2520the%2520wild%2520type%2520form%2520of%2520the%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D20%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjin, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.,  St</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kalken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1404</span><span class="NLM_x">â</span> <span class="NLM_lpage">1415</span><span class="refDoi">Â DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&issue=12&author=A.+O.+Walterauthor=R.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St.+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M-mediated+resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6gR"><div class="casContent"><span class="casTitleNuber">6g</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lgcwd8mQNQ08g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit6g&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt.%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M-mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26issue%3D12%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Barf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptein, A.</span><span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors: balancing the benefits and risks</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">6243</span><span class="NLM_x">â</span> <span class="NLM_lpage">6262</span><span class="refDoi">Â DOI: 10.1021/jm3003203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&issue=14&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+protein+kinase+inhibitors%3A+balancing+the+benefits+and+risks&doi=10.1021%2Fjm3003203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0lgcwd8mQNQ08g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%253A%2520balancing%2520the%2520benefits%2520and%2520risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D14%26spage%3D6243%26epage%3D6262%26doi%3D10.1021%2Fjm3003203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Mah, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafer, C. M.</span><span> </span><span class="NLM_article-title">Drug discovery considerations in the development of covalent inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">33</span><span class="NLM_x">â</span> <span class="NLM_lpage">39</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2013.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1016%2Fj.bmcl.2013.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=24314671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOlsr3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=33-39&issue=1&author=R.+Mahauthor=J.+R.+Thomasauthor=C.+M.+Shafer&title=Drug+discovery+considerations+in+the+development+of+covalent+inhibitors&doi=10.1016%2Fj.bmcl.2013.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery considerations in the development of covalent inhibitors</span></div><div class="casAuthors">Mah, Robert; Thomas, Jason R.; Shafer, Cynthia M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-39</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In recent years, the no. of drug candidates with a covalent mechanism of action progressing through clin. trials or being approved by the FDA has increased significantly.  And as interest in covalent inhibitors has increased, the tech. challenges for characterizing and optimizing these inhibitors have become evident.  A no. of new tools have been developed to aid this process, but these have not gained wide-spread use.  This review will highlight a no. of methods and tools useful for prosecuting covalent inhibitor drug discovery programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7dY63LHbEhLVg90H21EOLACvtfcHk0lgcwd8mQNQ08g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOlsr3O&md5=9407bcb76e83065f5a56a97b63547ede</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DMah%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DJ.%2BR.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26atitle%3DDrug%2520discovery%2520considerations%2520in%2520the%2520development%2520of%2520covalent%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D1%26spage%3D33%26epage%3D39%26doi%3D10.1016%2Fj.bmcl.2013.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><div class="note"><p class="first last">For a discussion of a purine-derived reversible EGFR inhibitor, see:</p></div><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, X.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.-Y.</span><span> </span><span class="NLM_article-title">Structural optimization and structureâactivity relationships of <i>N</i><sup>2</sup>-(4-(4-Methylpiperazin-1-yl)phenyl)-<i>N</i><sup>8</sup>-phenyl-9<i>H</i>-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">10685</span><span class="NLM_x">â</span> <span class="NLM_lpage">10699</span><span class="refDoi">Â DOI: 10.1021/jm301365e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301365e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10685-10699&issue=23&author=J.+Yangauthor=L.-J.+Wangauthor=J.-J.+Liuauthor=L.+Zhongauthor=R.-L.+Zhengauthor=Y.+Xuauthor=P.+Jiauthor=C.-H.+Zhangauthor=W.-J.+Wangauthor=X.-D.+Linauthor=L.-L.+Liauthor=Y.-Q.+Weiauthor=S.-Y.+Yang&title=Structural+optimization+and+structure%E2%80%93activity+relationships+of+N2-%284-%284-Methylpiperazin-1-yl%29phenyl%29-N8-phenyl-9H-purine-2%2C8-diamine+derivatives%2C+a+new+class+of+reversible+kinase+inhibitors+targeting+both+EGFR-activating+and+resistance+mutations&doi=10.1021%2Fjm301365e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm301365e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301365e%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.-J.%26aulast%3DLiu%26aufirst%3DJ.-J.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DR.-L.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DC.-H.%26aulast%3DWang%26aufirst%3DW.-J.%26aulast%3DLin%26aufirst%3DX.-D.%26aulast%3DLi%26aufirst%3DL.-L.%26aulast%3DWei%26aufirst%3DY.-Q.%26aulast%3DYang%26aufirst%3DS.-Y.%26atitle%3DStructural%2520optimization%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520N2-%25284-%25284-Methylpiperazin-1-yl%2529phenyl%2529-N8-phenyl-9H-purine-2%252C8-diamine%2520derivatives%252C%2520a%2520new%2520class%2520of%2520reversible%2520kinase%2520inhibitors%2520targeting%2520both%2520EGFR-activating%2520and%2520resistance%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D23%26spage%3D10685%26epage%3D10699%26doi%3D10.1021%2Fjm301365e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Schwartz, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzmic, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergqvist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolanos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almaden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">173</span><span class="NLM_x">â</span> <span class="NLM_lpage">178</span><span class="refDoi">Â DOI: 10.1073/pnas.1313733111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1073%2Fpnas.1313733111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=24347635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=173-178&issue=1&author=P.+A.+Schwartzauthor=P.+Kuzmicauthor=J.+Solowiejauthor=S.+Bergqvistauthor=B.+Bolanosauthor=C.+Almadenauthor=A.+Nagataauthor=K.+Ryanauthor=J.+Fengauthor=D.+Dalvieauthor=J.+C.+Kathauthor=M.+Xuauthor=R.+Waniauthor=B.+W.+Murray&title=Covalent+EGFR+inhibitor+analysis+reveals+importance+of+reversible+interactions+to+potency+and+mechanisms+of+drug+resistance&doi=10.1073%2Fpnas.1313733111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span></div><div class="casAuthors">Schwartz, Phillip A.; Kuzmic, Petr; Solowiej, James; Bergqvist, Simon; Bolanos, Ben; Almaden, Chau; Nagata, Asako; Ryan, Kevin; Feng, Junli; Dalvie, Deepak; Kath, John C.; Xu, Meirong; Wani, Revati; Murray, Brion William</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">173-178</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Covalent inhibition is a reemerging paradigm in kinase drug design, but the roles of inhibitor binding affinity and chem. reactivity in overall potency are not well-understood.  To characterize the underlying mol. processes at a microscopic level and det. the appropriate kinetic consts., specialized exptl. design and advanced numerical integration of differential equations are developed.  Previously uncharacterized investigational covalent drugs reported here are shown to be extremely effective epidermal growth factor receptor (EGFR) inhibitors (kinact/Ki in the range 105-107 M-1s-1), despite their low specific reactivity (kinact â¤ 2.1 Ã 10-3 s-1), which is compensated for by high binding affinities (Ki < 1 nM).  For inhibitors relying on reactivity to achieve potency, noncovalent enzyme-inhibitor complex partitioning between inhibitor dissocn. and bond formation is central.  Interestingly, reversible binding affinity of EGFR covalent inhibitors is highly correlated with antitumor cell potency.  Furthermore, cellular potency for a subset of covalent inhibitors can be accounted for solely through reversible interactions.  One reversible interaction is between EGFR-Cys797 nucleophile and the inhibitor's reactive group, which may also contribute to drug resistance.  Because covalent inhibitors target a cysteine residue, the effects of its oxidn. on enzyme catalysis and inhibitor pharmacol. are characterized.  Oxidn. of the EGFR cysteine nucleophile does not alter catalysis but has widely varied effects on inhibitor potency depending on the EGFR context (e.g., oncogenic mutations), type of oxidn. (sulfinylation or glutathiolation), and inhibitor architecture.  These methods, parameters, and insights provide a rational framework for assessing and designing effective covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTpPuRq8MwCLVg90H21EOLACvtfcHk0lh2D_8WSS8gdA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D&md5=47197c5e7876a238eefb2e8e7de305ea</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1313733111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1313733111%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DP.%2BA.%26aulast%3DKuzmic%26aufirst%3DP.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBolanos%26aufirst%3DB.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWani%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DCovalent%2520EGFR%2520inhibitor%2520analysis%2520reveals%2520importance%2520of%2520reversible%2520interactions%2520to%2520potency%2520and%2520mechanisms%2520of%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26issue%3D1%26spage%3D173%26epage%3D178%26doi%3D10.1073%2Fpnas.1313733111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span> </span><span class="NLM_article-title">Should the incorporation of structural alerts be restricted in drug design? An analysis of structure-toxicity trends with aniline-based drugs</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">438</span><span class="NLM_x">â</span> <span class="NLM_lpage">464</span><span class="refDoi">Â DOI: 10.2174/0929867321666141112122118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.2174%2F0929867321666141112122118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=25388012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSrtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=438-464&issue=4&author=A.+S.+Kalgutkar&title=Should+the+incorporation+of+structural+alerts+be+restricted+in+drug+design%3F+An+analysis+of+structure-toxicity+trends+with+aniline-based+drugs&doi=10.2174%2F0929867321666141112122118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Should the Incorporation of Structural Alerts be Restricted in Drug Design? An Analysis of Structure-Toxicity Trends with Aniline-Based Drugs</span></div><div class="casAuthors">Kalgutkar, A. S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">438-464</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Certain idiosyncratic adverse drug reactions (IADRs) can be triggered by electrophilic protein-reactive metabolites that are formed in the process of drug metab.  While methodologies (e.g., structural alert concept in drug design, glutathione (GSH) trapping, and protein covalent binding) for examg. reactive metabolite (RM) formation are available, predicting the IADR potential applying these parameters remains a significant challenge.  The present work examines toxicity trends assocd. with the aniline structural alert in the top 200 prescribed drugs of 2011 and recently approved (2009-2013) small mol. drugs, in relation with 30 aniline-based drugs withdrawn from com. use or assocd. with a black box warning for IADRs.  The aniline sub-structure was found in several drugs from the toxic, mostprescribed, and recently approved category.  RMs resulting from the bioactivation of the aniline alert was also noted in the three categories chosen for comparison.  A major discriminator between the toxic drugs and the majority of drugs in the most-prescribed list, however, was the daily dose - drugs most frequented assocd. with IADRs were the ones with higher daily doses (exceeding hundreds of milligrams).  A greater tolerance for IADRs was also noted with certain drugs intended to treat rare, unmet medical needs (e.g., cancer).  Overall, the anal. suggests that optimization of pharmacol. potency and pharmacokinetics that would lead to a lower daily dose, and therefore, a lower body burden of parent drug/metabolites, should be taken into consideration in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfHSM4D4TO37Vg90H21EOLACvtfcHk0lh2D_8WSS8gdA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSrtbY%253D&md5=c60bd0b64f0020b87e32c07b1dc8a052</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F0929867321666141112122118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867321666141112122118%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DShould%2520the%2520incorporation%2520of%2520structural%2520alerts%2520be%2520restricted%2520in%2520drug%2520design%253F%2520An%2520analysis%2520of%2520structure-toxicity%2520trends%2520with%2520aniline-based%2520drugs%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26issue%3D4%26spage%3D438%26epage%3D464%26doi%3D10.2174%2F0929867321666141112122118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span> </span><span class="NLM_article-title">Role of physiochemical properties and ligand lipophilicity efficiency in addressing drug safety risks</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">380</span><span class="NLM_x">â</span> <span class="NLM_lpage">391</span><span class="refDoi">Â DOI: 10.1016/S0065-7743(10)45023-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1016%2FS0065-7743%2810%2945023-X" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=380-391&author=M.+P.+Edwardsauthor=D.+A.+Price&title=Role+of+physiochemical+properties+and+ligand+lipophilicity+efficiency+in+addressing+drug+safety+risks&doi=10.1016%2FS0065-7743%2810%2945023-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2810%2945023-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-7743%252810%252945023-X%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26atitle%3DRole%2520of%2520physiochemical%2520properties%2520and%2520ligand%2520lipophilicity%2520efficiency%2520in%2520addressing%2520drug%2520safety%2520risks%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D380%26epage%3D391%26doi%3D10.1016%2FS0065-7743%2810%2945023-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Krenske, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houk, K. N.</span><span> </span><span class="NLM_article-title">Transition states and energetics of nucleophilic additions of thiols to substituted alpha,beta-unsaturated ketones: substituent effects involve enone stabilization, product branching, and solvation</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">5074</span><span class="NLM_x">â</span> <span class="NLM_lpage">5081</span><span class="refDoi">Â DOI: 10.1021/jo200761w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo200761w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2011&pages=5074-5081&issue=12&author=E.+H.+Krenskeauthor=R.+C.+Petterauthor=Z.+Zhuauthor=K.+N.+Houk&title=Transition+states+and+energetics+of+nucleophilic+additions+of+thiols+to+substituted+alpha%2Cbeta-unsaturated+ketones%3A+substituent+effects+involve+enone+stabilization%2C+product+branching%2C+and+solvation&doi=10.1021%2Fjo200761w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjo200761w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo200761w%26sid%3Dliteratum%253Aachs%26aulast%3DKrenske%26aufirst%3DE.%2BH.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DHouk%26aufirst%3DK.%2BN.%26atitle%3DTransition%2520states%2520and%2520energetics%2520of%2520nucleophilic%2520additions%2520of%2520thiols%2520to%2520substituted%2520alpha%252Cbeta-unsaturated%2520ketones%253A%2520substituent%2520effects%2520involve%2520enone%2520stabilization%252C%2520product%2520branching%252C%2520and%2520solvation%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2011%26volume%3D76%26issue%3D12%26spage%3D5074%26epage%3D5081%26doi%3D10.1021%2Fjo200761w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hunter, L.</span><span> </span><span class="NLM_article-title">The C-F bond as a conformational tool in organic and biological chemistry</span>.  <span class="citation_source-journal">Beilstein J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span>, No. 38. doi: <span class="refDoi">Â DOI: 10.3762/bjoc.6.38</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.3762%2Fbjoc.6.38" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=20502650" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&author=L.+Hunter&title=The+C-F+bond+as+a+conformational+tool+in+organic+and+biological+chemistry&doi=10.3762%2Fbjoc.6.38"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.3762%2Fbjoc.6.38&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3762%252Fbjoc.6.38%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DL.%26atitle%3DThe%2520C-F%2520bond%2520as%2520a%2520conformational%2520tool%2520in%2520organic%2520and%2520biological%2520chemistry%26jtitle%3DBeilstein%2520J.%2520Org.%2520Chem.%26date%3D2010%26volume%3D6%26doi%3D10.3762%2Fbjoc.6.38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rablen, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hrovat, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borden, W. T.</span><span> </span><span class="NLM_article-title">Is hyperconjugation responsible for the gauche effect in 1-fluoropropane and other 2-substituted-1-fluoroethanes?</span> <span class="citation_source-journal">J. Chem. Soc., Perkin Trans. 2</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_fpage">1719</span><span class="NLM_x">â</span> <span class="NLM_lpage">1726</span><span class="refDoi">Â DOI: 10.1039/A901974J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1039%2FA901974J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADyaK1MXks1GgtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&pages=1719-1726&author=P.+R.+Rablenauthor=R.+W.+Hoffmannauthor=D.+A.+Hrovatauthor=W.+T.+Borden&title=Is+hyperconjugation+responsible+for+the+gauche+effect+in+1-fluoropropane+and+other+2-substituted-1-fluoroethanes%3F&doi=10.1039%2FA901974J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Is hyperconjugation responsible for the "gauche effect" in 1-fluoropropane and other 2-substituted-1-fluoroethanes?</span></div><div class="casAuthors">Rablen, Paul R.; Hoffmann, Reinhard W.; Hrovat, David A.; Borden, Weston Thatcher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1719-1726</span>CODEN:
                <span class="NLM_cas:coden">JCPKBH</span>;
        ISSN:<span class="NLM_cas:issn">0300-9580</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The energies and geometries of a series of 2-substituted-1-fluoroethanes were computed at the MP2/6-311++G**(6D)//MP2/6-31+G* level of theory for both the maxima and min. of the rotation about the C-C bond.  The results did not support the predictions of a hyperconjugative model, that both 1,2-difluoroethane and 1-chloro-2-fluoroethane would strongly prefer a gauche conformation, and that 1-fluoro-2-silylethane would strongly prefer an anti conformation.  The existence of competing electrostatic interactions between the fluorine and the substituents at C-2 was indicated by the detailed geometries of the gauche conformers and by the calcd. sensitivity of the gauche-anti energy differences to the presence of a polar solvent.  However, Fourier analyses of the torsional potential energies were wholly consistent with hyperconjugative electron donation into the C-F Ï* orbital contributing to the conformational preferences of these 1-fluoroethanes.  Fourier analyses also showed that hyperconjugation contributes to the small variations in C-C and C-F bond lengths and in fluorine at. charges that were computed.  The torsional potential energies, variations in geometry and at. charge, and sensitivity to solvent were all in accord with the expected ranking of hyperconjugative electron donating ability of bonds to carbon, C-Si > C-H > C-C > C-Cl > C-F.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ6jY2idjLdbVg90H21EOLACvtfcHk0liwm42SvG7CFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXks1GgtbY%253D&md5=35c634a19b21a591229978e51125ff11</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1039%2FA901974J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FA901974J%26sid%3Dliteratum%253Aachs%26aulast%3DRablen%26aufirst%3DP.%2BR.%26aulast%3DHoffmann%26aufirst%3DR.%2BW.%26aulast%3DHrovat%26aufirst%3DD.%2BA.%26aulast%3DBorden%26aufirst%3DW.%2BT.%26atitle%3DIs%2520hyperconjugation%2520responsible%2520for%2520the%2520gauche%2520effect%2520in%25201-fluoropropane%2520and%2520other%25202-substituted-1-fluoroethanes%253F%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25202%26date%3D1999%26spage%3D1719%26epage%3D1726%26doi%3D10.1039%2FA901974J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">OâHagan, D.</span><span> </span><span class="NLM_article-title">Understanding organofluorine chemistry. An introduction to the C-F bond</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">308</span><span class="NLM_x">â</span> <span class="NLM_lpage">319</span><span class="refDoi">Â DOI: 10.1039/B711844A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1039%2FB711844A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=18197347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVGnsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2008&pages=308-319&author=D.+O%E2%80%99Hagan&title=Understanding+organofluorine+chemistry.+An+introduction+to+the+C-F+bond&doi=10.1039%2FB711844A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14cR"><div class="casContent"><span class="casTitleNuber">14c</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding organofluorine chemistry. An introduction to the C-F bond</span></div><div class="casAuthors">O'Hagan, David</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">308-319</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Fluorine is the most electroneg. element in the periodic table.  When bound to carbon it forms the strongest bonds in org. chem. and this makes fluorine substitution attractive for the development of pharmaceuticals and a wide range of specialty materials.  Although highly polarized, the C-F bond gains stability from the resultant electrostatic attraction between the polarized CÎ´+ and FÎ´- atoms.  This polarity suppresses lone pair donation from fluorine and in general fluorine is a weak coordinator.  However, the C-F bond has interesting properties which can be understood either in terms of electrostatic/dipole interactions or by considering stereoelectronic interactions with neighboring bonds or lone pairs.  In this tutorial review these fundamental aspects of the C-F bond are explored to rationalize the geometry, conformation and reactivity of individual organofluorine compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKbJH2EG40obVg90H21EOLACvtfcHk0liwm42SvG7CFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVGnsw%253D%253D&md5=7d4111d3b05c22c8e6df282cf051fccb</span></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1039%2FB711844A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB711844A%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hagan%26aufirst%3DD.%26atitle%3DUnderstanding%2520organofluorine%2520chemistry.%2520An%2520introduction%2520to%2520the%2520C-F%2520bond%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2008%26volume%3D37%26spage%3D308%26epage%3D319%26doi%3D10.1039%2FB711844A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferre, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodsky, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinrich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A.</span><span> </span><span class="NLM_article-title">Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">209</span><span class="NLM_x">â</span> <span class="NLM_lpage">219</span><span class="refDoi">Â DOI: 10.1016/j.str.2012.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1016%2Fj.str.2012.11.014" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=209-219&issue=2&author=K.+S.+Gajiwalaauthor=J.+Fengauthor=R.+Ferreauthor=K.+Ryanauthor=O.+Brodskyauthor=S.+Weinrichauthor=J.+C.+Kathauthor=A.+Stewart&title=Insights+into+the+aberrant+activity+of+mutant+EGFR+kinase+domain+and+drug+recognition&doi=10.1016%2Fj.str.2012.11.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2012.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2012.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DFerre%26aufirst%3DR.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DBrodsky%26aufirst%3DO.%26aulast%3DWeinrich%26aufirst%3DS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DStewart%26aufirst%3DA.%26atitle%3DInsights%2520into%2520the%2520aberrant%2520activity%2520of%2520mutant%2520EGFR%2520kinase%2520domain%2520and%2520drug%2520recognition%26jtitle%3DStructure%26date%3D2013%26volume%3D21%26issue%3D2%26spage%3D209%26epage%3D219%26doi%3D10.1016%2Fj.str.2012.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bissantz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, M.</span><span> </span><span class="NLM_article-title">A medicinal chemistâs guide to molecular interactions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">5061</span><span class="NLM_x">â</span> <span class="NLM_lpage">5084</span><span class="refDoi">Â DOI: 10.1021/jm100112j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100112j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKjtbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5061-5084&issue=14&author=C.+Bissantzauthor=B.+Kuhnauthor=M.+Stahl&title=A+medicinal+chemist%E2%80%99s+guide+to+molecular+interactions&doi=10.1021%2Fjm100112j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">A Medicinal Chemist's Guide to Molecular Interactions</span></div><div class="casAuthors">Bissantz, Caterina; Kuhn, Bernd; Stahl, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5061-5084</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraV8HPbwsihbVg90H21EOLACvtfcHk0lh-8ahmrE_7dg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKjtbs%253D&md5=f39cf8700267cdc311c73de4d433bab0</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1021%2Fjm100112j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100112j%26sid%3Dliteratum%253Aachs%26aulast%3DBissantz%26aufirst%3DC.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DA%2520medicinal%2520chemist%25E2%2580%2599s%2520guide%2520to%2520molecular%2520interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D14%26spage%3D5061%26epage%3D5084%26doi%3D10.1021%2Fjm100112j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhou, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang, Z.</span><span> </span><span class="NLM_article-title">Fluorine bonding--how does it work in protein-ligand interactions?</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">2344</span><span class="NLM_x">â</span> <span class="NLM_lpage">2355</span><span class="refDoi">Â DOI: 10.1021/ci9002393</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci9002393" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2lur7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=2344-2355&issue=10&author=P.+Zhouauthor=J.+Zouauthor=F.+Tianauthor=Z.+Shang&title=Fluorine+bonding%2D%2Dhow+does+it+work+in+protein-ligand+interactions%3F&doi=10.1021%2Fci9002393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine Bonding - How Does It Work In Protein-Ligand Interactions?</span></div><div class="casAuthors">Zhou, Peng; Zou, Jianwei; Tian, Feifei; Shang, Zhicai</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2344-2355</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although fluorination of pharmacol. active compds. has long been a common strategy to increase their metabolic stability and membrane permeation, the functionality of protein-ligand interactions involving fluorine atoms (fluorine bonding) was only recently recognized in the chem. and biol. communities.  In this study, the geometric characteristics and the energetic behaviors of fluorine bonding were systematically investigated by combining two quite disparate but complementary approaches: X-ray structural anal. and theor. calcns.  We found that the short contacts involving fluorine atoms (generalized fluorine bonding) between proteins and fluorinated ligands are very frequent, and these contacts, compared to those routine hydrogen/halogen bonding, are more similar to sulfur-involved hydrogen bonding obsd. in proteins.  ONIOM-based quantum mechanics/mol. mechanics anal. further revealed that fluorine bonding does play an essential role in protein-ligand binding, albeit the strength of isolated fluorine bonding is quite modest.  Furthermore, 14 quantum mechanics (QM) and mol. mechanics (MM) methods were performed to reproduce fluorine bonding energies obtained at the rigorous MP2/aug-cc-pVDZ level of theory, and the results showed that most QM and very few MM methods perform well in the reproducibility; the MPWLYP functional and MMFF94 force field are recommended to study moderate and large fluorine bonding systems, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsf6h3MdRaPLVg90H21EOLACvtfcHk0lh-8ahmrE_7dg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2lur7E&md5=3c4539b546dcf207f4bf44a500be1d71</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1021%2Fci9002393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci9002393%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DZou%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DF.%26aulast%3DShang%26aufirst%3DZ.%26atitle%3DFluorine%2520bonding--how%2520does%2520it%2520work%2520in%2520protein-ligand%2520interactions%253F%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26issue%3D10%26spage%3D2344%26epage%3D2355%26doi%3D10.1021%2Fci9002393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Ryckmans, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correia, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, T.</span><span> </span><span class="NLM_article-title">Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A lipophilic efficiency (LipE) analysis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">4406</span><span class="NLM_x">â</span> <span class="NLM_lpage">4409</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.05.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1016%2Fj.bmcl.2009.05.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=19500981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4406-4409&issue=15&author=T.+Ryckmansauthor=M.+P.+Edwardsauthor=V.+A.+Horneauthor=A.+M.+Correiaauthor=D.+R.+Owenauthor=L.+R.+Thompsonauthor=I.+Tranauthor=M.+F.+Tuttauthor=T.+Young&title=Rapid+assessment+of+a+novel+series+of+selective+CB%282%29+agonists+using+parallel+synthesis+protocols%3A+A+lipophilic+efficiency+%28LipE%29+analysis&doi=10.1016%2Fj.bmcl.2009.05.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis</span></div><div class="casAuthors">Ryckmans, Thomas; Edwards, Martin P.; Horne, Val A.; Correia, Ana Monica; Owen, Dafydd R.; Thompson, Lisa R.; Tran, Isabelle; Tutt, Michelle F.; Young, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4406-4409</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of libraries were designed using the 1-(cyclopropylmethyl)-2-alkyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-5-ium templates 2a-b, and Sulfonamide derivs. 11a-n proved to be potent agonists of the CB2 receptor.  Anal. of the Lipophilic Efficiency (LipE) of potent compds. provided new insight for the design of potent, metabolically stable CB2 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1cihq9YHuO7Vg90H21EOLACvtfcHk0lh-8ahmrE_7dg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D&md5=b62d97e5f52a594cfdd510f32d2e566f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.05.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.05.062%26sid%3Dliteratum%253Aachs%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DHorne%26aufirst%3DV.%2BA.%26aulast%3DCorreia%26aufirst%3DA.%2BM.%26aulast%3DOwen%26aufirst%3DD.%2BR.%26aulast%3DThompson%26aufirst%3DL.%2BR.%26aulast%3DTran%26aufirst%3DI.%26aulast%3DTutt%26aufirst%3DM.%2BF.%26aulast%3DYoung%26aufirst%3DT.%26atitle%3DRapid%2520assessment%2520of%2520a%2520novel%2520series%2520of%2520selective%2520CB%25282%2529%2520agonists%2520using%2520parallel%2520synthesis%2520protocols%253A%2520A%2520lipophilic%2520efficiency%2520%2528LipE%2529%2520analysis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D15%26spage%3D4406%26epage%3D4409%26doi%3D10.1016%2Fj.bmcl.2009.05.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deal, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lingardo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Discovery of (10<i>R</i>)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2<i>H</i>-8,4-(metheno)pyrazolo[4,3-<i>h</i>][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">4720</span><span class="NLM_x">â</span> <span class="NLM_lpage">4744</span><span class="refDoi">Â DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&issue=11&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.+L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28metheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+macrocyclic+inhibitor+of+anaplastic+lymphoma+kinase+%28ALK%29+and+c-ros+oncogene+1+%28ROS1%29+with+preclinical+brain+exposure+and+broad-spectrum+potency+against+ALK-resistant+mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0lgXaR3EALbeog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-2H-8%252C4-%2528metheno%2529pyrazolo%255B4%252C3-h%255D%255B2%252C5%252C11%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520macrocyclic%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520and%2520c-ros%2520oncogene%25201%2520%2528ROS1%2529%2520with%2520preclinical%2520brain%2520exposure%2520and%2520broad-spectrum%2520potency%2520against%2520ALK-resistant%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D11%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Innocenti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodward, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solanki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwood, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faisal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Haven Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâFee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saville, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matijssen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Montfort, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linardopoulos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoelder, S.</span><span> </span><span class="NLM_article-title">Rapid discovery of pyrido[3,4-<i>d</i>]pyrimidine inhibitors of monopolar spindle kinase 1 (MPS1) using a structure-based hybridization approach</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">3671</span><span class="NLM_x">â</span> <span class="NLM_lpage">3688</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01811</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01811" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3671-3688&issue=8&author=P.+Innocentiauthor=H.+L.+Woodwardauthor=S.+Solankiauthor=S.+Naudauthor=I.+M.+Westwoodauthor=N.+Croninauthor=A.+Hayesauthor=J.+Robertsauthor=A.+T.+Henleyauthor=R.+Bakerauthor=A.+Faisalauthor=G.+W.+Makauthor=G.+Boxauthor=M.+Valentiauthor=A.+De+Haven+Brandonauthor=L.+O%E2%80%99Feeauthor=H.+Savilleauthor=J.+Schmittauthor=B.+Matijssenauthor=R.+Burkeauthor=R.+L.+van+Montfortauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=S.+Linardopoulosauthor=J.+Blaggauthor=S.+Hoelder&title=Rapid+discovery+of+pyrido%5B3%2C4-d%5Dpyrimidine+inhibitors+of+monopolar+spindle+kinase+1+%28MPS1%29+using+a+structure-based+hybridization+approach&doi=10.1021%2Facs.jmedchem.5b01811"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01811%26sid%3Dliteratum%253Aachs%26aulast%3DInnocenti%26aufirst%3DP.%26aulast%3DWoodward%26aufirst%3DH.%2BL.%26aulast%3DSolanki%26aufirst%3DS.%26aulast%3DNaud%26aufirst%3DS.%26aulast%3DWestwood%26aufirst%3DI.%2BM.%26aulast%3DCronin%26aufirst%3DN.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DRoberts%26aufirst%3DJ.%26aulast%3DHenley%26aufirst%3DA.%2BT.%26aulast%3DBaker%26aufirst%3DR.%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3DMak%26aufirst%3DG.%2BW.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DDe%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Fee%26aufirst%3DL.%26aulast%3DSaville%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DJ.%26aulast%3DMatijssen%26aufirst%3DB.%26aulast%3DBurke%26aufirst%3DR.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DLinardopoulos%26aufirst%3DS.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DHoelder%26aufirst%3DS.%26atitle%3DRapid%2520discovery%2520of%2520pyrido%255B3%252C4-d%255Dpyrimidine%2520inhibitors%2520of%2520monopolar%2520spindle%2520kinase%25201%2520%2528MPS1%2529%2520using%2520a%2520structure-based%2520hybridization%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D8%26spage%3D3671%26epage%3D3688%26doi%3D10.1021%2Facs.jmedchem.5b01811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Greshock, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanders, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drolet, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajapakse, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rada, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiscia, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sur, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilodeau, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renger, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kern, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span> </span><span class="NLM_article-title">Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">2631</span><span class="NLM_x">â</span> <span class="NLM_lpage">2635</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.04.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1016%2Fj.bmcl.2016.04.021" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2631-2635&issue=11&author=T.+J.+Greshockauthor=J.+M.+Sandersauthor=R.+E.+Droletauthor=H.+A.+Rajapakseauthor=R.+K.+Changauthor=B.+Kimauthor=V.+L.+Radaauthor=H.+E.+Tisciaauthor=H.+Suauthor=M.+T.+Laiauthor=S.+M.+Surauthor=R.+I.+Sanchezauthor=M.+T.+Bilodeauauthor=J.+J.+Rengerauthor=J.+T.+Kernauthor=J.+A.+McCauley&title=Potent%2C+selective+and+orally+bioavailable+leucine-rich+repeat+kinase+2+%28LRRK2%29+inhibitors&doi=10.1016%2Fj.bmcl.2016.04.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.04.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.04.021%26sid%3Dliteratum%253Aachs%26aulast%3DGreshock%26aufirst%3DT.%2BJ.%26aulast%3DSanders%26aufirst%3DJ.%2BM.%26aulast%3DDrolet%26aufirst%3DR.%2BE.%26aulast%3DRajapakse%26aufirst%3DH.%2BA.%26aulast%3DChang%26aufirst%3DR.%2BK.%26aulast%3DKim%26aufirst%3DB.%26aulast%3DRada%26aufirst%3DV.%2BL.%26aulast%3DTiscia%26aufirst%3DH.%2BE.%26aulast%3DSu%26aufirst%3DH.%26aulast%3DLai%26aufirst%3DM.%2BT.%26aulast%3DSur%26aufirst%3DS.%2BM.%26aulast%3DSanchez%26aufirst%3DR.%2BI.%26aulast%3DBilodeau%26aufirst%3DM.%2BT.%26aulast%3DRenger%26aufirst%3DJ.%2BJ.%26aulast%3DKern%26aufirst%3DJ.%2BT.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26atitle%3DPotent%252C%2520selective%2520and%2520orally%2520bioavailable%2520leucine-rich%2520repeat%2520kinase%25202%2520%2528LRRK2%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D11%26spage%3D2631%26epage%3D2635%26doi%3D10.1016%2Fj.bmcl.2016.04.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Estrada, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker-Glenn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beresford, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominguez, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drummond, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuji, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinheinz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Pichon, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyssikatos, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medhurst, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scearce-Levie, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shore, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, Z. K.</span><span> </span><span class="NLM_article-title">Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">921</span><span class="NLM_x">â</span> <span class="NLM_lpage">936</span><span class="refDoi">Â DOI: 10.1021/jm401654j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401654j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=921-936&issue=3&author=A.+A.+Estradaauthor=B.+K.+Chanauthor=C.+Baker-Glennauthor=A.+Beresfordauthor=D.+J.+Burdickauthor=M.+Chambersauthor=H.+Chenauthor=S.+L.+Dominguezauthor=J.+Dotsonauthor=J.+Drummondauthor=M.+Flagellaauthor=R.+Fujiauthor=A.+Gillauthor=J.+Halladayauthor=S.+F.+Harrisauthor=T.+P.+Heffronauthor=T.+Kleinheinzauthor=D.+W.+Leeauthor=C.+E.+Le+Pichonauthor=X.+Liuauthor=J.+P.+Lyssikatosauthor=A.+D.+Medhurstauthor=J.+G.+Moffatauthor=K.+Nashauthor=K.+Scearce-Levieauthor=Z.+Shengauthor=D.+G.+Shoreauthor=S.+Wongauthor=S.+Zhangauthor=X.+Zhangauthor=H.+Zhuauthor=Z.+K.+Sweeney&title=Discovery+of+highly+potent%2C+selective%2C+and+brain-penetrant+aminopyrazole+leucine-rich+repeat+kinase+2+%28LRRK2%29+small+molecule+inhibitors&doi=10.1021%2Fjm401654j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1021%2Fjm401654j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401654j%26sid%3Dliteratum%253Aachs%26aulast%3DEstrada%26aufirst%3DA.%2BA.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DBaker-Glenn%26aufirst%3DC.%26aulast%3DBeresford%26aufirst%3DA.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DChambers%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DDominguez%26aufirst%3DS.%2BL.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DDrummond%26aufirst%3DJ.%26aulast%3DFlagella%26aufirst%3DM.%26aulast%3DFuji%26aufirst%3DR.%26aulast%3DGill%26aufirst%3DA.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DHarris%26aufirst%3DS.%2BF.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DD.%2BW.%26aulast%3DLe%2BPichon%26aufirst%3DC.%2BE.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26aulast%3DMedhurst%26aufirst%3DA.%2BD.%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26aulast%3DNash%26aufirst%3DK.%26aulast%3DScearce-Levie%26aufirst%3DK.%26aulast%3DSheng%26aufirst%3DZ.%26aulast%3DShore%26aufirst%3DD.%2BG.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26atitle%3DDiscovery%2520of%2520highly%2520potent%252C%2520selective%252C%2520and%2520brain-penetrant%2520aminopyrazole%2520leucine-rich%2520repeat%2520kinase%25202%2520%2528LRRK2%2529%2520small%2520molecule%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D3%26spage%3D921%26epage%3D936%26doi%3D10.1021%2Fjm401654j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney-Pickett, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umland, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gebhard, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Federico, J. J.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varma, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kempshall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Kattan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liston, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troutman, M. D.</span><span> </span><span class="NLM_article-title">Development of a new permeability assay using low-efflux MDCKII cells</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">4974</span><span class="NLM_x">â</span> <span class="NLM_lpage">4985</span><span class="refDoi">Â DOI: 10.1002/jps.22674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1002%2Fjps.22674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=21766308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=4974-4985&issue=11&author=L.+Diauthor=C.+Whitney-Pickettauthor=J.+P.+Umlandauthor=H.+Zhangauthor=X.+Zhangauthor=D.+F.+Gebhardauthor=Y.+Laiauthor=J.+J.+Federicoauthor=R.+E.+Davidsonauthor=R.+Smithauthor=E.+L.+Reynerauthor=C.+Leeauthor=B.+Fengauthor=C.+Rotterauthor=M.+V.+Varmaauthor=S.+Kempshallauthor=K.+Fennerauthor=A.+F.+El-Kattanauthor=T.+E.+Listonauthor=M.+D.+Troutman&title=Development+of+a+new+permeability+assay+using+low-efflux+MDCKII+cells&doi=10.1002%2Fjps.22674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a new permeability assay using low-efflux MDCKII cells</span></div><div class="casAuthors">Di, Li; Whitney-Pickett, Carrie; Umland, John P.; Zhang, Hui; Zhang, Xun; Gebhard, David F.; Lai, Yurong; Federico, James J.; Davidson, Ralph E.; Smith, Russ; Reyner, Eric L.; Lee, Caroline; Feng, Bo; Rotter, Charles; Varma, Manthena V.; Kempshall, Sarah; Fenner, Katherine; El-kattan, Ayman F.; Liston, Theodore E.; Troutman, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4974-4985</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Permeability is an important property of drug candidates.  The Madin-Darby canine kidney cell line (MDCK) permeability assay is widely used and the primary concern of using MDCK cells is the presence of endogenous transporters of nonhuman origin.  The canine P-glycoprotein (Pgp) can interfere with permeability and transporter studies, leading to less reliable data.  A new cell line, MDCKII-LE (low efflux), has been developed by selecting a subpopulation of low-efflux cells from MDCKII-WT using an iterative fluorescence-activated cell sorting technique with calcein-AM as a Pgp and efflux substrate.  MDCKII-LE cells are a subpopulation of MDCKII cells with over 200-fold lower canine Pgp mRNA level and fivefold lower protein level than MDCKII-WT.  MDCKII-LE cells showed less functional efflux activity than MDCKII-WT based on efflux ratios.  Notably, MDCKII-MDR1 showed about 1.5-fold decreased expression of endogenous canine Pgp, suggesting that using the net flux ratio might not completely cancel out the background endogenous transporter activities.  MDCKII-LE cells offer clear advantages over the MDCKII-WT by providing less efflux transporter background signals and minimizing interference from canine Pgp.  The MDCKII-LE apparent permeability values well differentiates compds. from high to medium/low human intestinal absorption and can be used for Biopharmaceutical Classification System.  The MDCKII-LE permeability assay (4-in-1 cassette dosing) is high throughput with good precision, reproducibility, robustness, and cost-effective. Â© 2011 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTVtRmYnbF17Vg90H21EOLACvtfcHk0lhmPbskn2OB9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D&md5=97f647fc215ea6d04882351ffc912a1e</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1002%2Fjps.22674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22674%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DUmland%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGebhard%26aufirst%3DD.%2BF.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DFederico%26aufirst%3DJ.%2BJ.%26aulast%3DDavidson%26aufirst%3DR.%2BE.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DRotter%26aufirst%3DC.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26atitle%3DDevelopment%2520of%2520a%2520new%2520permeability%2520assay%2520using%2520low-efflux%2520MDCKII%2520cells%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26issue%3D11%26spage%3D4974%26epage%3D4985%26doi%3D10.1002%2Fjps.22674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Varma, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyn, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nkansah, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotter, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney-Pickett, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenner, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Kattan, A. F.</span><span> </span><span class="NLM_article-title">pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1199</span><span class="NLM_x">â</span> <span class="NLM_lpage">1212</span><span class="refDoi">Â DOI: 10.1021/mp2004912</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp2004912" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=1199-1212&issue=5&author=M.+V.+Varmaauthor=I.+Gardnerauthor=S.+J.+Steynauthor=P.+Nkansahauthor=C.+J.+Rotterauthor=C.+Whitney-Pickettauthor=H.+Zhangauthor=L.+Diauthor=M.+Cramauthor=K.+S.+Fennerauthor=A.+F.+El-Kattan&title=pH-Dependent+solubility+and+permeability+criteria+for+provisional+biopharmaceutics+classification+%28BCS+and+BDDCS%29+in+early+drug+discovery&doi=10.1021%2Fmp2004912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery</span></div><div class="casAuthors">Varma, Manthena V.; Gardner, Iain; Steyn, Stefanus J.; Nkansah, Paul; Rotter, Charles J.; Whitney-Pickett, Carrie; Zhang, Hui; Di, Li; Cram, Michael; Fenner, Katherine S.; El-Kattan, Ayman F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1199-1212</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Biopharmaceutics Classification System (BCS) is a scientific framework that provides a basis for predicting the oral absorption of drugs.  These concepts have been extended in the Biopharmaceutics Drug Disposition Classification System (BDDCS) to explain the potential mechanism of drug clearance and understand the effects of uptake and efflux transporters on absorption, distribution, metab., and elimination.  The objective of present work is to establish criteria for provisional biopharmaceutics classification using pH-dependent passive permeability and aq. soly. data generated from high throughput screening methodologies in drug discovery settings.  The apparent permeability across monolayers of clonal cell line of Madin-Darby canine kidney cells, selected for low endogenous efflux transporter expression, was measured for a set of 105 drugs, with known BCS and BDDCS class.  The permeability at apical pH 6.5 for acidic drugs and at pH 7.4 for nonacidic drugs showed a good correlation with the fraction absorbed in human (Fa).  Receiver operating characteristic (ROC) curve anal. was utilized to define the permeability class boundary.  At permeability â¥5 Ã 10-6 cm/s, the accuracy of predicting Fa of â¥0.90 was 87%.  Also, this cutoff showed more than 80% sensitivity and specificity in predicting the literature permeability classes (BCS), and the metab. classes (BDDCS).  The equil. soly. of a subset of 49 drugs was measured in pH 1.2 medium, pH 6.5 phosphate buffer, and in FaSSIF medium (pH 6.5).  Although dose was not considered, good concordance of the measured soly. with BCS and BDDCS soly. class was achieved, when soly. at pH 1.2 was used for acidic compds. and FaSSIF soly. was used for basic, neutral, and zwitterionic compds.  Using a cutoff of 200 Î¼g/mL, the data set suggested a 93% sensitivity and 86% specificity in predicting both the BCS and BDDCS soly. classes.  In conclusion, this study identified pH-dependent permeability and soly. criteria that can be used to assign provisional biopharmaceutics class at early stage of the drug discovery process.  Addnl., such a classification system will enable discovery scientists to assess the potential limiting factors to oral absorption, as well as help predict the drug disposition mechanisms and potential drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr84irw4TD15rVg90H21EOLACvtfcHk0likTi3nKMVYNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D&md5=2bcb29ea512d2e0665973292e4a4a0a3</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1021%2Fmp2004912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp2004912%26sid%3Dliteratum%253Aachs%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DNkansah%26aufirst%3DP.%26aulast%3DRotter%26aufirst%3DC.%2BJ.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DCram%26aufirst%3DM.%26aulast%3DFenner%26aufirst%3DK.%2BS.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26atitle%3DpH-Dependent%2520solubility%2520and%2520permeability%2520criteria%2520for%2520provisional%2520biopharmaceutics%2520classification%2520%2528BCS%2520and%2520BDDCS%2529%2520in%2520early%2520drug%2520discovery%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26issue%3D5%26spage%3D1199%26epage%3D1212%26doi%3D10.1021%2Fmp2004912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Behenna, D. C.; Cheng, H.; Cho-Schultz, S.; Johnson, T. O.; Kath, J. C.; Nagata, A.; Nair, S. K.; Planken, S.</span><span> </span><span class="NLM_article-title">Purine derivatives</span>. Pfizer Patent US 2015/0141402,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=D.+C.+Behenna&author=H.+Cheng&author=S.+Cho-Schultz&author=T.+O.+Johnson&author=J.+C.+Kath&author=A.+Nagata&author=S.+K.+Nair&author=S.+Planken&title=Purine+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBehenna%26aufirst%3DD.%2BC.%26atitle%3DPurine%2520derivatives%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Perez-Soler, R.</span><span> </span><span class="NLM_article-title">The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">12-2</span><span class="NLM_x">) </span> <span class="NLM_fpage">4238s</span><span class="NLM_x">â</span> <span class="NLM_lpage">4240s</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-040017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1158%2F1078-0432.CCR-040017" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=4238s-4240s&issue=12-2&author=R.+Perez-Soler&title=The+role+of+erlotinib+%28Tarceva%2C+OSI+774%29+in+the+treatment+of+non-small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-040017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-040017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-040017%26sid%3Dliteratum%253Aachs%26aulast%3DPerez-Soler%26aufirst%3DR.%26atitle%3DThe%2520role%2520of%2520erlotinib%2520%2528Tarceva%252C%2520OSI%2520774%2529%2520in%2520the%2520treatment%2520of%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26issue%3D12-2%26spage%3D4238s%26epage%3D4240s%26doi%3D10.1158%2F1078-0432.CCR-040017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Lanning, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitby, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dix, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douhan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hett, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joslyn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niessen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnute, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulce, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteley, L. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayward, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cravatt, B. F.</span><span> </span><span class="NLM_article-title">A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">760</span><span class="NLM_x">â</span> <span class="NLM_lpage">767</span><span class="refDoi">Â DOI: 10.1038/nchembio.1582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1038%2Fnchembio.1582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=25038787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygs7nO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=760-767&issue=9&author=B.+R.+Lanningauthor=L.+R.+Whitbyauthor=M.+M.+Dixauthor=J.+Douhanauthor=A.+M.+Gilbertauthor=E.+C.+Hettauthor=T.+O.+Johnsonauthor=C.+Joslynauthor=J.+C.+Kathauthor=S.+Niessenauthor=L.+R.+Robertsauthor=M.+E.+Schnuteauthor=C.+Wangauthor=J.+J.+Hulceauthor=B.+Weiauthor=L.+O.+Whiteleyauthor=M.+M.+Haywardauthor=B.+F.+Cravatt&title=A+road+map+to+evaluate+the+proteome-wide+selectivity+of+covalent+kinase+inhibitors&doi=10.1038%2Fnchembio.1582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors</span></div><div class="casAuthors">Lanning, Bryan R.; Whitby, Landon R.; Dix, Melissa M.; Douhan, John; Gilbert, Adam M.; Hett, Erik C.; Johnson, Theodore O.; Joslyn, Chris; Kath, John C.; Niessen, Sherry; Roberts, Lee R.; Schnute, Mark E.; Wang, Chu; Hulce, Jonathan J.; Wei, Baoxian; Whiteley, Laurence O.; Hayward, Matthew M.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">760-767</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinases are principal components of signal transduction pathways and the focus of intense basic and drug discovery research.  Irreversible inhibitors that covalently modify non-catalytic cysteines in kinase active sites have emerged as valuable probes and approved drugs.  Many protein classes, however, have functional cysteines, and therefore understanding the proteome-wide selectivity of covalent kinase inhibitors is imperative.  Here, we accomplish this objective using activity-based protein profiling coupled with quant. MS to globally map the targets, both specific and nonspecific, of covalent kinase inhibitors in human cells.  Many of the specific off-targets represent nonkinase proteins that, notably, have conserved active site cysteines.  We define windows of selectivity for covalent kinase inhibitors and show that, when these windows are exceeded, rampant proteome-wide reactivity and kinase target-independent cell death conjointly occur.  Our findings, taken together, provide an exptl. road map to illuminate opportunities and surmount challenges for the development of covalent kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMAiUlEg9R5rVg90H21EOLACvtfcHk0lhlyl8p3e46uw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygs7nO&md5=6f17b0d1b00e088f37c511eea577d290</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1582%26sid%3Dliteratum%253Aachs%26aulast%3DLanning%26aufirst%3DB.%2BR.%26aulast%3DWhitby%26aufirst%3DL.%2BR.%26aulast%3DDix%26aufirst%3DM.%2BM.%26aulast%3DDouhan%26aufirst%3DJ.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DHett%26aufirst%3DE.%2BC.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DJoslyn%26aufirst%3DC.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DL.%2BR.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHulce%26aufirst%3DJ.%2BJ.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWhiteley%26aufirst%3DL.%2BO.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DA%2520road%2520map%2520to%2520evaluate%2520the%2520proteome-wide%2520selectivity%2520of%2520covalent%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26issue%3D9%26spage%3D760%26epage%3D767%26doi%3D10.1038%2Fnchembio.1582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Eaton, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bammler, T. K.</span><span> </span><span class="NLM_article-title">Consise review of the glutathione S-transferases and their significance to toxicology</span> <span class="citation_source-journal">Toxicol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">156</span><span class="NLM_x">â</span> <span class="NLM_lpage">164</span><span class="refDoi">Â DOI: 10.1093/toxsci/49.2.156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1093%2Ftoxsci%2F49.2.156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10416260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADyaK1MXkt1yqur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1999&pages=156-164&author=D.+L.+Eatonauthor=T.+K.+Bammler&title=Consise+review+of+the+glutathione+S-transferases+and+their+significance+to+toxicology&doi=10.1093%2Ftoxsci%2F49.2.156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Concise review of the glutathione S-transferases and their significance to toxicology</span></div><div class="casAuthors">Eaton, David L.; Bammler, Theo K.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">156-164</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review with â¼50 refs. on the major features of glutathione S-transferase multi-gene family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_nHcHqT7GO7Vg90H21EOLACvtfcHk0ljImS7SeXAEBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkt1yqur0%253D&md5=a8a44cf0f2d8cffc5d75cb69cb424246</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2F49.2.156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252F49.2.156%26sid%3Dliteratum%253Aachs%26aulast%3DEaton%26aufirst%3DD.%2BL.%26aulast%3DBammler%26aufirst%3DT.%2BK.%26atitle%3DConsise%2520review%2520of%2520the%2520glutathione%2520S-transferases%2520and%2520their%2520significance%2520to%2520toxicology%26jtitle%3DToxicol.%2520Sci.%26date%3D1999%26volume%3D49%26spage%3D156%26epage%3D164%26doi%3D10.1093%2Ftoxsci%2F49.2.156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Gintant, G.</span><span> </span><span class="NLM_article-title">An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">109</span><span class="NLM_x">â</span> <span class="NLM_lpage">119</span><span class="refDoi">Â DOI: 10.1016/j.pharmthera.2010.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1016%2Fj.pharmthera.2010.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=20807552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvVantA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=109-119&issue=2&author=G.+Gintant&title=An+evaluation+of+hERG+current+assay+performance%3A+Translating+preclinical+safety+studies+to+clinical+QT+prolongation&doi=10.1016%2Fj.pharmthera.2010.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation</span></div><div class="casAuthors">Gintant, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">109-119</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Block of delayed rectifier current (I Kr, Kv11.1 encoding the hERG gene) is assocd. with delayed cardiac repolarization (QTc prolongation), a surrogate marker of proarrhythmia.  Despite its recognized role in assessing QTc prolongation risk, a quant. anal. of the utility and limitations of the hERG current assay has not been reported.  To benchmark hERG assay performance, this retrospective study compared hERG block potency with drug-induced QTc prolongation assessed during rigorous thorough QT (TQT) clin. studies for 39 drugs from multiple classes.  To place block in context, hERG safety margins (IC50 values for block/mean maximal plasma drug concns. during TQT studies) were compared to QTc prolongation (QTc increase â¥ 5 ms).  Most (9/10) drugs eliciting essentially no hERG block at maximal concns. demonstrate no QTc prolongation despite representing a wide hERG safety margin range.  Based on receiver-operator characteristics, a hERG safety margin of 45 provided optimal overall performance linking safety margins to QTc prolongation (sensitivity (true pos. rate) = 0.64, specificity (true neg. rate) = 0.88); the area under the receiver-operator curve (0.72) is indicative of moderate overall concordance.  Likelihood ratios calcd. from multitier contingency tables suggest that QTc prolonging drugs are only 5-7 times as likely to demonstrate low safety margins (1-30 range) compared to drugs that do not prolong QTc.  Paradoxically, higher safety margins demonstrate lesser confidence predicting prolongation.  The overall limitations of hERG safety margins shown using these quant., evidence-based approaches highlight the need for addnl. preclin. assays and adaptive strategies throughout drug discovery to reliably mitigate QTc prolongation risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBSUF3lt6P27Vg90H21EOLACvtfcHk0ljImS7SeXAEBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvVantA%253D%253D&md5=336d014ddc78cc6e790a7248e28a92a3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2010.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2010.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DGintant%26aufirst%3DG.%26atitle%3DAn%2520evaluation%2520of%2520hERG%2520current%2520assay%2520performance%253A%2520Translating%2520preclinical%2520safety%2520studies%2520to%2520clinical%2520QT%2520prolongation%26jtitle%3DPharmacol.%2520Ther.%26date%3D2011%26volume%3D129%26issue%3D2%26spage%3D109%26epage%3D119%26doi%3D10.1016%2Fj.pharmthera.2010.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Schwartz, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzmic, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergqvist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolanos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almaden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">173</span><span class="NLM_x">â</span> <span class="NLM_lpage">178</span><span class="refDoi">Â DOI: 10.1073/pnas.1313733111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=10.1073%2Fpnas.1313733111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=24347635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=173-178&issue=1&author=P.+A.+Schwartzauthor=P.+Kuzmicauthor=J.+Solowiejauthor=S.+Bergqvistauthor=B.+Bolanosauthor=C.+Almadenauthor=A.+Nagataauthor=K.+Ryanauthor=J.+Fengauthor=D.+Dalvieauthor=J.+C.+Kathauthor=M.+Xuauthor=R.+Waniauthor=B.+W.+Murray&title=Covalent+EGFR+inhibitor+analysis+reveals+importance+of+reversible+interactions+to+potency+and+mechanisms+of+drug+resistance&doi=10.1073%2Fpnas.1313733111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span></div><div class="casAuthors">Schwartz, Phillip A.; Kuzmic, Petr; Solowiej, James; Bergqvist, Simon; Bolanos, Ben; Almaden, Chau; Nagata, Asako; Ryan, Kevin; Feng, Junli; Dalvie, Deepak; Kath, John C.; Xu, Meirong; Wani, Revati; Murray, Brion William</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">173-178</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Covalent inhibition is a reemerging paradigm in kinase drug design, but the roles of inhibitor binding affinity and chem. reactivity in overall potency are not well-understood.  To characterize the underlying mol. processes at a microscopic level and det. the appropriate kinetic consts., specialized exptl. design and advanced numerical integration of differential equations are developed.  Previously uncharacterized investigational covalent drugs reported here are shown to be extremely effective epidermal growth factor receptor (EGFR) inhibitors (kinact/Ki in the range 105-107 M-1s-1), despite their low specific reactivity (kinact â¤ 2.1 Ã 10-3 s-1), which is compensated for by high binding affinities (Ki < 1 nM).  For inhibitors relying on reactivity to achieve potency, noncovalent enzyme-inhibitor complex partitioning between inhibitor dissocn. and bond formation is central.  Interestingly, reversible binding affinity of EGFR covalent inhibitors is highly correlated with antitumor cell potency.  Furthermore, cellular potency for a subset of covalent inhibitors can be accounted for solely through reversible interactions.  One reversible interaction is between EGFR-Cys797 nucleophile and the inhibitor's reactive group, which may also contribute to drug resistance.  Because covalent inhibitors target a cysteine residue, the effects of its oxidn. on enzyme catalysis and inhibitor pharmacol. are characterized.  Oxidn. of the EGFR cysteine nucleophile does not alter catalysis but has widely varied effects on inhibitor potency depending on the EGFR context (e.g., oncogenic mutations), type of oxidn. (sulfinylation or glutathiolation), and inhibitor architecture.  These methods, parameters, and insights provide a rational framework for assessing and designing effective covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTpPuRq8MwCLVg90H21EOLACvtfcHk0ljPoLBMhrPI0w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D&md5=47197c5e7876a238eefb2e8e7de305ea</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1313733111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1313733111%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DP.%2BA.%26aulast%3DKuzmic%26aufirst%3DP.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBolanos%26aufirst%3DB.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWani%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DCovalent%2520EGFR%2520inhibitor%2520analysis%2520reveals%2520importance%2520of%2520reversible%2520interactions%2520to%2520potency%2520and%2520mechanisms%2520of%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26issue%3D1%26spage%3D173%26epage%3D178%26doi%3D10.1073%2Fpnas.1313733111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG7','PDB','5HG7'); return false;">PDB: 5HG7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UG8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UG8','PDB','5UG8'); return false;">PDB: 5UG8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UG9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UG9','PDB','5UG9'); return false;">PDB: 5UG9</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UGA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UGA','PDB','5UGA'); return false;">PDB: 5UGA</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UGB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UGB','PDB','5UGB'); return false;">PDB: 5UGB</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UGC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UGC','PDB','5UGC'); return false;">PDB: 5UGC</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i34"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01894">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_50281"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b01894">10.1021/acs.jmedchem.6b01894</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">SMILES data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01894/suppl_file/jm6b01894_si_001.csv">CSV</a>)</p></li><li><p class="inline">Focused kinase activity data for select compounds within, full kinase profiling for <b>21</b>, off-target in vitro assessment of <b>21</b> in a safety panel, EGFR kinetic parameters for <b>21</b>, small molecule X-ray data for <b>21</b>, proteomic compound probes (their key activity and physiochemical data and commassie gels), <b>21</b> metabolite ID and profiling, details of ADME assays, synthetic experimental details, and molecular formula strings for key compounds contained within (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01894/suppl_file/jm6b01894_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01894/suppl_file/jm6b01894_si_001.csv">jm6b01894_si_001.csv (1.89 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01894/suppl_file/jm6b01894_si_002.pdf">jm6b01894_si_002.pdf (1.9 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01894%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-7" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01894" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                9MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a5f4acd37d1bf","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
